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The United Kingdom Focal Point on Drugs
The United Kingdom (UK) Focal Point on Drugs is based at Public Health England (PHE). It is the national 
partner of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and provides 
comprehensive information to the Centre on the drug situation in England, Northern Ireland, Scotland 
and Wales.
The Focal Point works closely with the Home Office, other government departments and the devolved 
administrations (DAs). In addition to this annual report, it collates an extensive range of data in the form 
of standard tables (STs) and responses to structured questionnaires (SQs), which are submitted regularly 
to the EMCDDA. It also contributes to other elements of the EMCDDA’s work such as the development 
and implementation of its five key epidemiological indicators, the Exchange on Drug Demand Reduction 
Action (EDDRA) and the implementation of the Council Decision on New Psychoactive Substances (NPS).
Further information about the UK Focal Point, including previous annual reports can be found on the Focal 
Point website at http://www.nta.nhs.uk/focalpoint.aspx 
The EMCDDA’s website is www.emcdda.europa.eu
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Technical Notes
Standard Tables
References in the text to Standard Tables (sometimes abbreviated to ST01, ST02 etc.) are to standardised 
reporting formats specified by the EMCDDA. All National Focal Points provide data using these Standard 
Tables in order to facilitate the collection of information in a consistent and comparable format across 
Europe. Information from the standard tables referred to in this report is published alongside the report on 
the Focal Point webpage. A list of standard tables is included in Part C of this document. The standard tables 
usually include the source of the data and details of methodology. 
References to Specific Drugs
Cocaine. Where appropriate, this report distinguishes between ‘cocaine powder’ and ‘crack cocaine’. 
When the word ‘cocaine’ is used it should be interpreted as meaning both forms of the drug.
Amphetamine(s). The term used in the text is the same as that used in the survey or study being 
described. In the UK methyl amphetamine is the term used in legislation for what is more generally 
known as methamphetamine.
Ecstasy. The term refers to MDMA in any form.
Use of term ‘significant’
When the word significant is used it should be interpreted as meaning statistically significant at the 
5% level or better.
Reference to latest/most recent data
Where the terms latest or most recent are used they should be interpreted as meaning the most recent 
data with respect to the drafting of this report. Due to delays between writing and publishing this 
document, it is possible that newer data is released prior to publication which is not referred to in this 
year’s report. Where data are being compared between each country of the UK, data from the most 
recent year where available for all four will be used. In some cases individual countries of the UK may 
have released information relating to more recent years; this may also be referred to.
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The UK population was estimated to be 64.6 million according to the 2014 mid-year estimate. Eighty-four 
per cent (54.3 million) live in England, eight per cent (5.3 million) in Scotland, five per cent (3.1 million) in 
Wales and three per cent (1.8 million) in Northern Ireland.
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Summary
Chapter 1. Drug policy
National Action Plans and Strategies
In its annual review of the drug strategy, the Home Office highlighted the continued focus on all three 
strands of the strategy: reducing demand, restricting supply and building recovery. It also emphasised 
key advances since 2010 and outlined priorities for the year ahead. 
In Scotland, the 2015/16 Updated Guidance for Alcohol and Drug Partnerships (ADPs) on Planning 
and Reporting Arrangements were published. In addition a new Recovery Outcomes Web (ROW) tool 
has been developed, which will form part of the new national Drug and Alcohol Information System 
(DAISy) expected to be operational in autumn 2016.
The Welsh Government published Working together to reduce harm: Substance misuse strategy 
annual report – 2015, which reviewed progress made towards the objectives cited in their substance 
misuse strategy. Priorities for the year ahead include the publication of the new 2016-2018 delivery plan 
and the commencement of work on the new substance misuse strategy for Wales 2018-2028.
In Northern Ireland, the third annual report of progress towards outcomes contained within the drug 
strategy, New Strategic Direction (NSD) for Alcohol and Drugs Phase 2, 2011-2016, was published. 
A final evaluation of NSD Phase 2 will be conducted in 2016/17 with consideration being given to a new 
strategy after this. 
The Scottish Government and the National Assembly for Wales each commissioned and published 
their own expert reviews on new psychoactive substances (NPS) in 2015. Both reviews made a series 
of recommendations to their respective governments for tackling the harms caused by NPS, including 
working with the Home Office to create new legislation for a blanket ban of NPS across the entire United 
Kingdom (UK). 
In July 2015 the Prime Minister commissioned a review into how best to support those suffering 
from long-term yet treatable conditions, such as drug and alcohol addiction, back into work or to remain 
in work.
Treatment funding
Expenditure on drug misuse services for adults in England in 2013/14 was £581.1 million, with a 
further £74.9 million being spent on services for young people. 
Local authorities received a ring-fenced Public Health Grant of £2.79 billion for public health services 
in the 2015/16 financial year. A new condition was added to the grant to encourage local authorities 
to improve the take up of, and outcomes from, their drug and alcohol misuse treatment services.
At present there is a consultation on the proposed allocation formula which will be used to calculate 
funds for 2016/17. New funding allocations will be announced in due course.
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Chapter 2. Legal framework and drug law offences
Changes to drug misuse legislation
The Government has set out the limits for the maximum blood concentrations for 16 specific substances 
under the new drug driving legislation the Drug Driving (Specified Limits) (England and Wales) 
Regulations 2014. Limits are specified for eight illicit drugs such as cannabis, heroin and cocaine, and 
eight medicines, which are sometimes abused. The new regulations came into force in England and 
Wales in March 2015.
Amendments to the Misuse of Drugs Act 1971 have been made so that the following substances have 
been classified as Class A under the Act: 
•	 the NPS known as MT-45 and 4,4’-DMAR; 
•	 the synthetic opioid AH-7921; 
•	 the LSD-related compounds commonly known as ALD-52, AL-LAD, ETH-LAD, PRO-LAD and LSZ; and 
•	 the compounds captured by the extended definition of tryptamines
On 30 November 2015, ketamine became a Schedule II controlled drug under the Misuse of Drugs 
Regulations 2001.
The following compounds and their simple derivatives were put under a Temporary Class Drug Order (TCDO):
•	 ethylphenidate;
•	 3,4-dichloromethylphenidate (‘3,4-DCMP’);
•	 methylnaphthidate (‘HDMP-28’);
•	 isopropylphenidate (‘IPP’ or ‘IPPD’); 
•	 propylphenidate; 
•	 4-methylmethylphenidate (‘4-Me-TMP’); and
•	 ethylnaphthidate (‘HDEP-28’)
There have been also a number of changes in legislation over the last year which aim to restrict the 
supply of illicit substances, including the introduction of the Serious Crime Act 2015 to tackle the trade in 
cutting agents; making it an offence to throw any article or substance into a prison; and the strengthening 
of the Proceeds of Crime Act 2002, which has enabled assets held by defendants and others to be 
frozen and recovered, and traffickers prosecuted more quickly.
Legislative changes aimed at increasing the availability of naloxone came into force in October 2015.
Legislation designed to control new psychoactive substances
The Psychoactive Substances Bill has been introduced in Parliament and, subject to Parliamentary 
approval, this legislation will ban the sale, supply, production and distribution of psychoactive substances 
for human consumption. Other initiatives at a local level have also been introduced to control the use of 
NPS, such as the banning of consumption of intoxicating substances in public spaces. 
With the Criminal Justice and Courts Act 2015, additional powers have been given to prison governors 
to stop the use of drugs in prison. These powers include testing for non-controlled drugs, such as NPS, 
and stiffer penalties on those suspected of being involved in smuggling NPS into prisons. 
United Kingdom Drug Situation 2015 editionPage 14
Chapter 3. Prevalence, availability and relative importance of different drugs
Cannabis
The long-term declining trend in the prevalence of cannabis use seen in surveys conducted on the general 
population as well as in results from school surveys shows signs of levelling out. The proportion of cannabis 
users who report having used cannabis in the last month has continued to reduce in recent years.
Stimulants
Cocaine (in powder form) remains the most prevalent stimulant in the UK followed by ecstasy (MDMA). 
While overall prevalence of cocaine is lower than a few years ago, the proportion of users aged 35-44 
has been rising. There is a long-term downward trend in the proportion of last year users reporting having 
used in the last month for both cocaine and ecstasy.
Opioids
UK Focal Point estimates there are about 370,000 problem drug users in the UK who are mainly opioid 
users. There is an increasing practice of prescribing opioids for pain-relief. The Crime Survey for England 
and Wales reported that 5.4% of adults aged 16 to 59 had misused a prescription-only painkiller not 
prescribed to them in the last year.
Injecting drug use
There are current concerns about increased injection of amphetamine-type stimulants including NPS 
and synthetic cathinones. In Edinburgh, injecting of ethylphenidate-based NPS with brand names such 
as Burst and Blue Stuff has been associated with the spread of infection. There is an ongoing decline in 
the numbers of drug users injecting opioids and crack–cocaine in England.
Chapter 4. Prevention
Environmental prevention
In England and Wales a new legislation regulating the maximum blood concentration allowed for a 
selection of legal and illicit drugs for drivers came into force in March 2015.
In Scotland the legal blood alcohol limit for drivers has been lowered to 50mg in every 100ml of blood. 
The Northern Ireland Assembly is considering introducing a similar measure from mid–2016.
In March 2015 the UK Parliament approved the introduction of standardised packaging for tobacco 
products. The regulation will take effect in May 2016. 
Smoking in private vehicles carrying children became illegal in October 2015 in England and Wales.
Universal prevention
In 2015 the Advisory Council on the Misuse of Drugs (ACMD) Recovery Committee published a 
document aimed at supporting policy-makers and practitioners working in prevention as well as 
providing recommendations.
In November 2014 Public Health England (PHE) lunched Rise Above, an interactive online resource for 
young people; the service was activated in February 2015. The website not only provides information but 
also supports a range of situational tools and skills-based resources aimed at helping young people to 
make positive choices for their health.
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Chapter 5. Drug-related treatment: treatment demand and availability
Treatment Demand Indicator
There were 100,456 treatment presentations in the UK in 2014 (those starting a new treatment episode). 
Just over half (52.1%) of all treatment presentations in the UK were for primary opioid use. However, 
these were disproportionately distributed, accounting for over two-thirds (68.0%) of presentations of 
previously treated clients in comparison to just under one-quarter (23.2%) of those who had never 
previously received treatment. 
Just over one-quarter (26.0%) of all treatment presentations were for primary cannabis use. Despite 
recent rises in the percentage of first ever treatment presentations for cannabis, between 2013 and 2014 
the proportion fell from 48.6% to 46.6%. 
The proportion of all treatment entrants presenting for primary cocaine remained stable at 9.4%, the 
same level seen in 2013. 
In England, between 2011/12 and 2012/13 there was a steep increase in the number of clients aged 18 
or over presenting to treatment for any club drug, from 2,675 to 3,536, which has stabilised in 2013/14 
(n= 3,543). This represents five per cent of those presenting to treatment in 2013/14.
The number of young people (aged 17 years and under) attending specialist misuse services for drugs 
or alcohol in England decreased by 4.5%, from 20,032 in 2012/13 to 19,126 in 2013/14.
Treatment Outcomes
In England, amongst clients who received a review in 2013/14, users of crack cocaine only and 
cocaine powder were most likely to be abstinent at treatment review (60% and 65% respectively). 
Forty-eight per cent of opioid only users in 2013/14 were abstinent at the time of treatment review. In 
2013/14 the number of successful completions in England remained stable at 15% of the total number 
of people in treatment.
Analysis of treatment outcomes data in Wales showed that on exit from treatment in 2014, the average 
number of days of using for primary heroin users had decreased by 61.8%. Furthermore, 59.1% of 
primary heroin users had been abstinent from heroin use in the 28 days prior to treatment exit.
New developments
In 2014 PHE, on behalf of the departments of health in England, Scotland, Wales and Northern Ireland, 
held a consultation regarding whether the 2007 Drug Misuse and Dependence: UK Guidelines on 
Clinical Management could benefit from being updated. The majority of responses received by the 
consultation were in favour of an update and consequently a review of the evidence is currently being 
conducted. Updated guidelines are expected to be published in early 2016. 
In November 2014, PHE published a toolkit to help local authorities and National Health Service (NHS) 
England respond to the use, and associated problems, of NPS in their area. The toolkit provided advice, 
resources and points for consideration across multiple factors including: tackling supply and use; 
prevention; NPS interventions and treatment; NPS in prisons; and competence in working with NPS users. 
In March 2015, project NEPTUNE (Novel Psychoactive Treatment UK Network) also published new 
guidance designed to increase the confidence and skills of clinicians in: the detection and identification 
of club drugs and NPS being used; assessment of the associated harms; clinical management of acute 
and chronic harms; and delivering harm reduction interventions.
United Kingdom Drug Situation 2015 editionPage 16
Chapter 6. Drug-related infectious diseases and other drug-related harms
The prevalence of HIV infection amongst people who inject drugs (PWID) remains fairly stable. In 2014, 
it was one per cent in England, Wales and Northern Ireland amongst PWID taking part in the Unlinked 
Anonymous Monitoring (UAM) survey. Similarly, the prevalence of hepatitis C amongst PWID has 
remained relatively stable over the last decade and in 2014 it was 49% amongst those participating in 
the UAM survey. The prevalence of hepatitis B has remained stable in recent years and is half the level 
that was recorded a decade ago (14% in 2014 compared to 28% in 2004). This decrease is possibly due 
to the increased uptake of the hepatitis B vaccine amongst injecting drug users.
There have been increasing concerns related to the harms associated with the practice of chemsex, 
especially among men who have sex with men (MSM). The use and injection of crystal methamphetamine 
and mephedrone and the consumption of GHB/GBL before or during planned sexual activities are 
thought to be a factor in the increased transmission of a number of sexually transmitted infections, HIV 
and viral hepatitis among this population sub-group.
Prevalence of hepatitis C among people who inject image and performance enhancing drugs (IPEDs) 
was lower than that found among participants in the main UAM survey targeted at PWID; however, it was 
still higher than observed in the general population, whilst prevalence of HIV was similar in both groups. 
This raises concerns regarding the risks and harms associated with the transmission of drug-related 
infectious diseases among IPED injectors.
New developments
In Northern Ireland a new pilot project is being undertaken in 2015 to survey the blood-borne virus 
(BBV) status of people using IPEDs who are accessing pharmacy needle exchange sites. Health 
Improvement Scotland and NHS Scotland have published new guidelines for cost-effective treatment 
of hepatitis C. In Wales, in May 2015 the new Together for Health – Liver Disease Plan was published, 
which sets out key service issues, priorities and assurance measures in preventing disease and 
improving treatment services.
Chapter 7. Drug-related deaths
Changes to methodology
UK figures under the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) definition 
are, from 2015 reporting year onwards, counting deaths from England and Wales according to year 
of occurrence. As such, 2013 is the latest available reporting year by this definition, as this is the most 
recent year where it can be assumed the large majority of relevant deaths in England and Wales have 
now been registered. For the Office for National Statistics (ONS) and Drug Misuse definitions, the figures 
continue to represent registrations in the most recent year (2014).
A further methodological change in this year’s reporting is that deaths with an underlying cause of death 
of X44, X64 and Y14 alongside relevant T-codes have been incorporated into UK figures reported using 
the EMCDDA definition. Due to historical coding practice in England and Wales, this has substantially 
increased the number of deaths counted under this definition. Also, due to changes in reporting, a small 
number of deaths registered in England and Wales where the person was not resident in either country 
are no longer included.
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Drug-related deaths
Using the EMCDDA definition, the total number of drug-related deaths registered in the UK during 
2013 was 2,449, a 12% increase from 2012 and the highest number reported to date. Numbers of 
deaths using the Drug Misuse definition and the much wider ONS definition showed increases in 2014 
compared to 2013. However, Wales is an exception to the UK trend, with a reported 16% fall in deaths 
registered using DMD.
Combined England and Wales figures for 2013 using the EMCDDA definition saw an 18% increase in the 
number of drug-related deaths compared to 2012, while Scotland experienced a fall of 6%, and Northern 
Ireland a rise of 48%.
In 2013, the average age of those dying was 41.6 years, with males tending to be about five years 
younger than females (40.5 years and 45.1 years respectively). The average age at death has increased 
from 37.6 years in 2004.
Overall, the largest proportion of deaths occurring in the UK in 2013 occurred in the 40 to 44 years age-
group (433, or 18% of deaths) and deaths in this age group increased by 21% from the previous year 
(n= 358). Compared to 2008, the number of drug-related deaths decreased for all age-groups below 
the age of 40 and increased for all age-groups above this point. An increase was seen in all age-groups 
in 2013 compared to 2012, with the exception of the 20-24 age-group.
Across England and Wales under the EMCDDA definition for 2013, there were 1,624 deaths counted 
which featured an opioid (87% of the total). As in previous years, the substance with the largest number 
of associated deaths was heroin (n= 792). This represented a 30% increase compared to the 2012 
figure but also a return to a level similar to that seen in 2008 (n= 798). In 2013, the number of methadone 
deaths registered fell to 366, continuing the decrease observed since 2011 (n= 490). Deaths mentioning 
cocaine increased again in 2013 (up 26% from the previous year). Deaths mentioning tramadol continued 
to increase greatly, by nine per cent between 2011 and 2012, and 33% between 2012 and 2013.
New developments
There has been growing concern regarding the harmful effects of new psychoactive substances 
across the UK. In March 2015 the synthetic stimulant 4,4’-DMAR became controlled as a class A 
drug after it was associated with 37 deaths across the UK. The Prisons and Probation Ombudsman 
also reported on an increased number of deaths in prison related to NPS between April 2012 and 
September 2014. 
Chapter 8. Drug users in prison
The Offender Rehabilitation Act 2014 (Her Majesty’s Government, 2014) came into force on 1 February 
2015. The former Probation Trusts were dissolved and their responsibilities were transferred to either 
the newly established National Probation Service, which is responsible for providing supervision to the 
highest risk offenders in the community, or the Community Rehabilitation Companies (CRCs), which 
supervise lower to medium risk offenders. 
Data from the 2014/15 survey by Her Majesty’s Inspectorate of Prisons (HMIP) show that 28% of male 
and 41% of female new arrivals at prison in England and Wales stated they had substance misuse 
needs. The HMIP Report also found that 32% of adult male respondents stated that illicit drugs were 
“easy” or “very easy” to obtain in their prison. 
In England and Wales during 2014/15 the rate of drug misuse as reflected by those testing positive in 
mandatory drug tests was 6.9%. This was a decrease from the rate for the previous year of 7.4%.
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Drug-related health responses 
In April 2014 a new opt-out testing programme for blood-borne viruses was introduced in 11 prisons 
across England. In the first six months there was a near doubling of BBV testing, though the proportion of 
those testing positive remained stable, with 0.3% testing positive for HIV, 0.2% positive for hepatitis B and 
nine per cent testing positive for hepatitis C. It is hoped that opt-out BBV testing will be fully implemented 
across all prisons in England by 2016/17. 
There were 872 Take Home Naloxone (THN) kits issued by prisons in Scotland in 2014/15 to persons 
at risk of opioid overdose. The total number of kits issued in Scottish prisons decreased by 18% in 
comparison to 2013/14.
In Wales one-fifth of male unique individuals issued with THN between 1 April 2013 and 31 March 2014 
were issued with THN upon release from prison. When compared to national Area Planning Board (APB) 
provision, prisons are amongst the highest distributors of THN within Wales.
The availability of naloxone to prisoners in England has so far been limited. Naloxone has been made 
available to a limited extent in some prisons and there are proposals to pilot its use as part of the end-
to-end approach to tackling addiction from custody into the community currently being tested in the 
north-west area.
New developments
The increasing presence of NPS within prison establishments is a growing concern. They have been 
linked to mental health problems and disturbed behaviour by prisoners and as such their use is having a 
dangerous impact on the security and order in prisons. In response to this, two new legislative changes 
have been enacted, the Serious Crime Act 2015 and the Criminal Justice and Courts Act 2015. In addition, 
a new toolkit to support prison healthcare and custody staff to tackle NPS has been developed by PHE.
On 1 November 2014 two new licence conditions and supervision requirements, the Drug Appointment 
Condition and the Drug Testing Condition, became available to manage offenders in the community 
following their release.
Chapter 9. Drug markets
Seizures
In 2013/14 there was an increase in the number of seizures for all drugs, except cannabis and mephedrone. 
Despite the decline in the number of seizures, cannabis remained the most commonly seized drug by 
far, involved in around nine times as many seizures as cocaine powder, the next most commonly seized 
drug. The quantity of cannabis resin seized fell steeply by 91.6% driven by a substantial decrease in the 
quantity seized in England and Wales. Ketamine saw the largest increase in the quantity seized, rising 
46% between 2012/13 and 2013/14. 
Price/purity
Street-level price data from law enforcement sources suggest that the price of most drugs remained 
stable in 2014, although the retail price of both cannabis resin and sinsemilla rose by over 55%. The price 
of ecstasy per tablet also rose, despite a decline in the typical MDMA content per pill. 
Having been low during both 2011 and 2012, heroin purity has risen over the last two years and is now 
higher than in 2010. The price per gram at street-level has also increased. However, the purity-adjusted 
price has fallen considerably from a peak of around £74 per gram in 2011 to around £45 in 2014 as a 
result of the increased quality of the substance typically being sold at street-level.
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Cocaine powder purity in the domestic market has fallen slightly for the first time in five years, though it 
remains one and half times higher than the level seen in 2009. Conversely, the purity-adjusted price of 
cocaine has risen for the first time in five years. 
Supply reduction activities
There have been a number of changes in legislation over the last year which aim to restrict the supply of 
illicit substances, including the introduction of the Serious Crime Act 2015 to tackle the trade in cutting 
agents; strengthening of the Proceeds of Crime Act 2002, and a number of NPS and prescription 
medicines were permanently controlled under the Misuse of Drugs Act 1971.
New developments
British Organised Crime Groups (OCGs) are importing liquid amphetamine oil and wet base into the UK 
to be converted into amphetamine sulphate. This requires much less expertise than production from 
precursors and provides more diverse opportunities to conceal trafficking into the UK.
The Psychoactive Substances Bill has been introduced in Parliament and, subject to Parliamentary 
approval, this legislation will ban the sale, supply, production and distribution of psychoactive substances 
for human consumption.

Part A: 
New Developments 
and Trends
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1. Drug policy
1.1 Introduction
The United Kingdom (UK) consists of England, Wales, Scotland and Northern Ireland. Eighty-four per cent 
(54.3 million) live in England, eight per cent (5.3 million) in Scotland, five per cent (3.1 million) in Wales 
and three per cent (1.8 million) in Northern Ireland. A number of powers have been devolved from the UK 
Parliament to Wales, Scotland, and Northern Ireland, but each has different levels of devolved responsibilities.
The UK Government is responsible for setting the overall strategic approach to reducing drug harms 
and for its delivery in the devolved administrations only in matters where it has reserved power. The 
Drug Strategy 2010: Reducing demand, restricting supply, building recovery: supporting people to 
live a drug free life (Her Majesty’s Government, 2010) places a much greater emphasis than preceding 
strategies on supporting those who are drug dependent to achieve recovery, and also widens the focus 
of dependence to prescription and over the counter medicines and tackling emerging new psychoactive 
substances (NPS). Within the strategy, policies concerning health, education, housing and social care 
are confined to England; those for policing and the criminal justice system cover England and Wales; 
and the work of the Department for Work and Pensions (DWP) applies to England, Scotland and Wales.
The Scottish Government and Welsh Government’s national drug strategies were published in 2008 
(Scottish Government, 2008c; Welsh Assembly Government, 2008a), the latter combining drugs, alcohol 
and addiction to prescription drugs and over the counter medicines. Each strategy aims to make further 
progress on reducing harm and helping individuals recover from their drug problems. The Scottish and 
Welsh strategy documents are also accompanied by an action or implementation plan, providing a 
detailed set of objectives; actions and responsibilities; expected outcomes; and a corresponding 
timescale for delivery (Scottish Government, 2008c; Welsh Assembly Government, 2008b). Each plan 
reflects the devolution of responsibilities to the national government. 
In Scotland, the 2015/16 Updated Guidance for Alcohol and Drug Partnerships (ADPs) on Planning 
and Reporting Arrangements (Scottish Government, 2015e) aims to continue to support the embedding 
of outcomes-based planning and reporting at the local level. This guidance identified nationally agreed 
core outcomes and indicators that all ADPs are expected to deliver against.
Northern Ireland’s strategy for reducing the harm related to alcohol and drug misuse, the New Strategic 
Direction for Alcohol and Drugs, was launched in 2006 (Department of Health Social Services and 
Public Safety Northern Ireland, 2006). The strategy contained actions and outcomes, at both the regional 
and local level, to achieve its overarching aims. A review of the strategy was conducted in 2010, and, 
after consultation, a revised strategy, the New Strategic Direction for Alcohol and Drugs Phase 2, 
2011-2016, was launched in December 2011 (Department of Health Social Services and Public Safety 
Northern Ireland, 2011b). 
The drug strategies in Wales and Northern Ireland are underpinned by performance management 
frameworks, including Public Service Agreements (PSAs) and associated sets of performance indicators, 
against which progress is measured. 
1.2 National action plan, strategy, evaluation and co-ordination
1.2.1 Current national drug strategy
The UK Government is responsible for setting the overall strategic approach to reducing drug harms and it 
retains some reserved powers. The legal framework relating to the misuse of drugs, including the Misuse 
of Drugs Act 1971 (Her Majesty’s Government, 1971), is reserved to the UK Government, however some 
areas of policy including health, education, housing and social care only apply to England. Similarly, the 
role of the police and criminal justice system apply to England and Wales and the work of the DWP to 
England, Scotland and Wales. Each of the devolved administrations has produced their own drug strategy, 
which reflects their ideology and the devolution of responsibilities to the national government. 
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The UK Government continues to build on the Drug Strategy 2010, Reducing demand, restricting 
supply, building recovery: supporting people to live a drug free life (Her Majesty’s Government, 
2010), which was published in December 2010. The strategy places greater emphasis than preceding 
strategies on supporting those who are drug dependent to achieve recovery, and on the provision of the 
integrated support necessary to enable this, such as housing and employment. The strategy is divided 
into the three broad themes of reducing demand, restricting supply and building recovery, each with a 
number of objectives and proposed actions. 
The two overarching aims of the strategy are to: 
•	 reduce illicit and other harmful drug use; and
•	 increase the numbers recovering from their dependence
For the first time, the strategy widened its focus to include dependence on all drugs, including prescription 
and over the counter drugs, as well as tackling the emergence of NPS. It emphasised a shift in responsibility 
away from central government to locally led treatment plans, highlighting the creation of Public Health 
England (PHE) (see section 1.3.1). The strategy sets out the function of roles including Directors of Public 
Health and Police and Crime Commissioners, to support the shift of responsibility for health improvement 
to a local level. Furthermore, the strategy introduced new legal powers aimed at restricting the supply of 
drugs, including the introduction of Temporary Class Drug Orders (TCDOs) for NPS (see section 2.2.3) and 
new powers to seize cutting agents and precursor chemicals (see section 2.2.1).
The Home Office leads on the implementation of the strategy within England, and with regard to reserved 
matters elsewhere, and is supported by various departments and organisations including the DWP, 
the Department of Health (DH), the Department for Communities and Local Government (DCLG), the 
Department for Education (DfE), the National Crime Agency (NCA) and the Ministry of Justice (MoJ).
Scotland
The Scottish Government’s national long-term drug strategy, The Road to Recovery: A new approach to 
tackling Scotland’s drug problem, was published in 2008 (Scottish Government, 2008c). Central to the 
strategy is the concept of recovery and supporting people to live a drug-free life as active and engaged 
members of society. It continues to receive cross-party support from the Scottish Parliament. The 
strategy included multiple objectives across five principal action areas: promoting recovery; delivering 
the recovery model; prevention; enforcement; and children affected by substance misusing families. 
The key priorities of the strategy are:
•	 better prevention of drug problems, with improved life chances for children and young people, 
especially those at particular risk of developing a drug problem, allowing them to realise their full 
potential in all areas of life;
•	 to see more people recover from problem drug use so that they can live longer, healthier lives, 
realising their potential and making a positive contribution to society and the economy; 
•	 having communities that are safer and stronger places to live and work because crime, disorder and 
danger related to drug use have been reduced; 
•	 ensuring that children affected by parental drug problems are safer and more able to achieve their 
potential; and 
•	 improving the effectiveness of delivery at a national and local level
In Scotland, the 2015/16 Updated Guidance for Alcohol and Drug Partnerships (ADPs) on Planning 
and Reporting Arrangements (Scottish Government, 2015e) aims to continue to support the embedding 
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of outcomes-based planning and reporting at the local level. This guidance identifies nationally agreed 
core outcomes and indicators that all ADPs are expected to deliver against. The Scottish Government 
has developed a Recovery Outcomes Web (ROW) tool, which will form part of the new national Drug and 
Alcohol Information System (DAISy), which aims to support the tracking of progress towards recovery for 
individuals in drug (and alcohol) services. DAISy is expected to be operational in autumn 2016. 
Wales
The Welsh Government also published its long-term substance misuse strategy in 2008, Working 
together to reduce harms 2008-2018 (Welsh Assembly Government, 2008a). The strategy combines 
drugs, alcohol and addiction to prescription drugs and over the counter medications. It has a clear focus 
on reducing the harms associated with substance misuse, citing its four aims as:
•	 reducing the harm to individuals (particularly young people), their families and wider communities 
from the misuse of drugs and alcohol, whilst not stigmatising substance misuse; 
•	 improving the availability and quality of education, prevention and treatment services and related 
support, with a greater priority given than under the previous strategy to those related to alcohol; 
•	 making better use of resources - supporting evidence-based decision making, improving treatment 
outcomes, developing the skills base of partners and service providers by giving a greater focus to 
workforce development and joining up agencies and services more effectively; and 
•	 embedding the core Welsh Assembly Government values of sustainability, equality and diversity, 
support for the Welsh Language and developing user-focused services and a rights base for children 
and young people in both the development and delivery of the strategy
Since the launch of the strategy several accompanying shorter term delivery plans have also been 
published, the current version being Substance misuse delivery plan 2013-2015 (Welsh Government, 
2013). These delivery plans set out performance measures for each of the strategy’s key action areas: 
preventing harm; supporting substance misusers to improve their health and aid and maintain recovery; 
supporting and protecting families; and tackling availability and protecting individuals and communities 
via enforcement activity. Progress of the delivery plan is monitored through an internal cross-Government 
Substance Misuse Programme Board, and an external Substance Misuse National Partnership Board 
(SMNPB) which meets three times a year. The final three year delivery plan 2016-18 is currently in 
development and consultation stakeholder workshops have been held. In August 2015, the National 
Assembly for Wales published the results of an inquiry into alcohol and substance misuse in Wales 
(National Assembly for Wales, 2015a). The report made a series of 21 recommendations to the Welsh 
Government, including suggested items for inclusion in the 2016-2018 substance misuse delivery plan. 
The new plan in expected to be subject to formal consultation in autumn 2015. 
Northern Ireland
Northern Ireland’s strategy, New Strategic Direction for Alcohol and Drugs (NSD), was launched in 2006 
with a focus on reducing the harms related to alcohol and drug misuse (Department of Health Social 
Services and Public Safety Northern Ireland, 2006).
The NSD emphasised five supporting pillars for the strategy: prevention and early intervention; treatment 
and support; law and criminal justice; harm reduction and monitoring; and evaluation and research. 
It identified two themes: children, young people and families; and adults, carers and the general 
public, to be addressed across the five pillars as well as the three cross-sectional threads of workforce 
development, stakeholder involvement and vulnerable groups to run throughout the strategy.
The strategy contained actions and outcomes, at both the regional and local level, to achieve its 
overarching aims. A review of the strategy was conducted in 2010 and, after consultation, it was decided 
that rather than design an entire new strategy, a review, revision and extension of the strategy would 
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be more appropriate and would allow for the embedding of key principles. As such the New Strategic 
Direction for Alcohol and Drugs Phase 2, 2011-2016, was launched in December 2011 (Department of 
Health Social Services and Public Safety Northern Ireland, 2011b). 
A number of key priorities were identified including: 
•	 developing a regional commissioning framework for treatment; 
•	 targeting those at risk and vulnerable;
•	 alcohol- and drug-related crime including anti-social behaviour and tackling underage drinking; 
•	 reduced availability of illicit drugs; 
•	 addressing community issues; 
•	 promoting good practice in respect of alcohol- and drug-related education and prevention;
•	 developing harm reduction approaches; and 
•	 workforce development
The ongoing development and implementation of the drug strategy are overseen by the NSD Steering 
Group and the NSD Liaison Group (see section 1.3.1).
1.2.2 Drug strategy evaluations/reviews
At present none of the current UK or devolved administration (DA) drug strategies have been formally 
evaluated, though there have been a number of strategy reviews published (see details below). Each 
review reports on progress made towards the objectives of the respective drug strategy and outlines 
proposed actions for future developments. 
Following the publication of the Drug Strategy Evaluation Framework (Home Office, 2013) the 
Government continues to assess the effectiveness and, where possible, the value for money of the 2010 
drug strategy, drawing on expert advice as appropriate. The evaluation is considering evidence for the 
effectiveness of the interventions which fall under the following five activity strands: (i) early interventions; 
(ii) media and information; (iii) treatment; (iv) non-treatment rehabilitative activity; and (v) enforcement. 
Drug strategy annual review 
In February 2015, the Home Office published the Drug Strategy annual review: A balanced approach 
(Home Office, 2015g). The review highlighted key achievements made in the last year towards the 
objectives on all three strands of the Drug Strategy 2010 and outlined priorities for the year ahead. 
Main findings/key achievements
There are a number of achievements which build on the work of previous years, including a refresh of 
the ‘Reducing Demand’ strand of the strategy, the expansion of the Troubled Families programme and 
ongoing work to understand and tackle NPS. One of the new developments was the spring 2015 launch 
of “Rise Above”: an online resource which aims to help build the resilience and empowerment of 11-16 
year olds to enable them to make positive healthy choices (see section 4.3.1 and (UK Focal Point, 2014)).
Progress towards restricting supply included several pieces of new legislation; the Serious Crime Act (Her 
Majesty’s Government, 2015b), which introduced powers for law enforcement to tackle the trade in cutting 
agents; the permanent control of a number of NPS and prescription medicines under the Misuse of Drugs 
Act 1971 (Her Majesty’s Government, 1971); and the introduction of the drug-driving offence (see section 
2.2.1). Further, a guidance document was published for local authorities (LAs) to advise them of their 
powers to reduce the supply of NPS through “head shops” (Home Office, 2015h) (see section 2.2.3). 
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Under the ‘Building Recovery’ strand, a new condition was added to the Public Health Grant to encourage 
LAs to invest in the provision of high quality drug and alcohol treatment services. Similarly, a budget of £5 
million was provided for the Health Premium Incentive Scheme for 2015/16, to be distributed to LAs who can 
show a two per cent improvement in the number of successful completions for treatment. The review also 
included progress made towards meeting other potential needs of those in treatment for substance misuse 
such as statutory guidance on social housing and improvement of training packages at Jobcentre Plus.
Recommendations/Priorities for the next year
As well as highlighting some of the key achievements, the review also presented priorities across each 
of the three strands for the year ahead. 
There are a number of objectives which focus on reducing the demand for drugs amongst young 
people. This includes the promotion of evidence-based practice in schools, the continuation of funding 
for the Alcohol and Drug Education and Prevention Information Service (ADEPIS) (see section 4.3.1) and 
addressing wider aspects associated with potential substance misuse such as reducing the number of 
youths who are not in education, employment or training (NEET). 
Other activities under the ‘Reducing Demand’ strand of the strategy include: increased collaboration 
between police, festival organisers, night time economy stakeholders and LAs; the implementation of 
the National Institute for Health and Care Excellence (NICE) Needle and Syringe Programme (NSP) 
guidance; and the continued roll-out of Liaison and Diversion schemes (see section 2.4.3).
In order to restrict the supply of illicit drugs, future work will include: a crackdown on UK-based websites 
in violation of the Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971); an evaluation of the five 
new Joint Border Intelligence Units and, if successful, the roll out of further units; and increased access 
to centralised data on drug testing on arrest to enable the identification of local trends.
The future priorities for the ‘Building Recovery’ strand of the strategy cover public health, the criminal 
justice system, employment and housing as well as recovery and rehabilitation. Two of these goals which 
have now been realised are: the introduction of provisions for the wider distribution of naloxone through 
alterations to medical regulations, which came into effect in October 2015 (see section 2.2.1); and the 
introduction of new licence conditions in November 2014 for newly released prisoners to attend drug 
appointments in the community (see section 8.7.3). 
A continued desire to reduce the harms caused by NPS is reflected by its representation in goals across 
all three strands of the strategy and underpinned by a wide-ranging action plan specifically looking at 
prevention, treatment and information sharing following recommendations made by an expert panel 
review published in October 2014 (Home Office, 2014a). For example, increasing training for frontline 
National Health Service (NHS) workers to recognise the harms of NPS and how to treat those who have 
used them, and developing an alert system for clinicians and outreach workers to identify and reduce 
potential harms. Restricting the supply of NPS is captured through the investigation of the viability of a 
“blanket ban” on NPS and focusing legislation on the effect a substance has on the brain rather than its 
chemical structure (see section 2.2.3). 
Scotland
In 2011 the Drug Strategy Delivery Commission (DSDC) (see section 1.3.1) published a review of the 
progress made in the first three years of the drug strategy and made recommendations for the prioritisation 
of actions moving forward (Drug Strategy Delivery Commission, 2011). These recommendations have 
been progressed considerably since 2011 and the Scottish Government continues to work with partners 
and experts, including members of the former DSDC, to implement them. The DSDC itself was concluded 
in November 2014 and a new Scottish Drugs Collaborative has been developed which will include an 
evaluator function in its new role. 
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Wales
In October 2015 the Welsh Government published Working together to reduce harm: Substance 
misuse strategy annual report – 2015 (Welsh Government, 2015b), reviewing progress made towards 
the objectives cited in their substance misuse strategy. The report highlights key developments from 
throughout the previous year including the publication of a number of new treatment frameworks, revised 
commissioning guidance and the continued investment of over £32 million from the substance misuse 
fund. Harm reduction and recovery remain core elements of the Wales strategy. 
Priorities for the year ahead include the publication of the new delivery plan 2016-2018; commencement 
of work on the new substance misuse strategy for Wales 2018 to 2028; an enhanced focus on NPS 
including continued expansion of the Welsh Emerging Drugs and Identification of Novel Substances 
(WEDINOS) project; and a number of new initiatives to address and prevent alcohol-related harm. 
Northern Ireland
In July 2015 the third annual report of progress towards outcomes contained within the drug strategy 
was published (Department of Health Social Services and Public Safety Northern Ireland, 2015b). An 
assessment of the progress achieved towards short-, medium- and long-term outcomes showed that 
the majority of the 141 outcomes are on track for achievement within the timescale expected.1 Fifteen 
(11%) of the outcomes have been completed, 99 (70%) of the outcomes are classified as being on track 
for achievement, and for 26 (18%) of the outcomes progress is being made but with some delay. At this 
stage, only one outcome, relating to research in respect of prescription drug misuse, is classified as not 
being on track for achievement. All outcomes are monitored and reported on annually. 
A final evaluation of NSD Phase 2 will be conducted in 2016/17 with consideration being given to a new 
strategy after this. 
1.2.3 Commentary on drug policy
New psychoactive substances
Following the UK government NPS expert review, published in October 2014, both the Scottish 
Government and the National Assembly for Wales Health and Social Care Committee commissioned 
and published their own expert reviews (National Assembly for Wales, 2015b; Scottish Government, 
2015c). Both reviews made a number of recommendations to their respective governments for tackling 
the harms caused by NPS within their own country. Both reviews also recommended working with the 
Home Office to create new legislation for a blanket ban of NPS across the entire UK. In May 2015 the 
newly elected Conservative government announced the proposal of a Psychoactive Substances Bill to 
legislate against the production, distribution, import and export of all psychoactive substances except 
for stated exemptions (to include alcohol, tobacco and food) (see section 2.2.3). The proposed Bill has 
passed through the House of Lords and is continuing to proceed through Parliament. 
Carol Black Review
The Prime Minister has asked Professor Dame Carol Black to consider how best to support those 
suffering from long-term yet treatable conditions back into work or to remain in work. The review will 
focus on drug and alcohol addiction, and obesity, and will consider the holistic needs of these individuals 
including the effects of multiple health conditions and other barriers to work. The review will also consider 
the case for linking benefit entitlements to take up of appropriate treatment or support. The review is 
ongoing and the findings are due to be published in early 2016.
1 These include outcomes relating to both drugs and alcohol.
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1.3 Drug policy co-ordination 
1.3.1 Co-ordination bodies
England
See Figure 1.1 for an accompanying summary graphic of drug treatment commissioning bodies in England. 
Inter-Ministerial Group on Drugs
The Inter-Ministerial Group on Drugs, chaired by the Home Office, includes ministerial representation 
from across several key Government departments and oversees the delivery of the Drug Strategy.
Home Office 
The Home Office is the department with lead responsibility for the co-ordination of the delivery of the 
Drug Strategy on behalf of the Government, and publishing annual reviews detailing the progress made 
towards the strategy’s objectives. The DH leads on the ‘Building Recovery’ strand of the strategy and 
jointly leads on the ‘Reducing Demand’ strand together with the Home Office. The delivery of the strategy 
involves close working with a number of key departments including the MoJ, DWP, DCLG and DfE.
Advisory Council on the Misuse of Drugs 
The Advisory Council on the Misuse of Drugs (ACMD) is an independent expert body responsible for 
advising the Home Office on drug-related matters, and was established under the Misuse of Drugs Act 
1971 (Her Majesty’s Government, 1971). The ACMD is responsible for, amongst other things, making 
recommendations on the control of dangerous or otherwise harmful drugs, including classifications and 
scheduling under the Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971), and carrying out 
in-depth inquiries which focus on emerging threats and challenges that are causing concern. 
National Crime Agency
The National Crime Agency (NCA), formerly the Serious Organised Crime Agency (SOCA), became 
operational in October 2013. They are a non-ministerial government department, accountable to the 
Home Secretary, and work with the police, Border Force and international collaborators to lead the UK 
law enforcement’s fight to cut serious and organised crime. This includes restricting the supply of drugs 
trafficked into the UK. 
Local Authorities
In April 2013, under the Health and Social Care Act 2012 (Her Majesty’s Government, 2012b), LAs 
became accountable for meeting the needs of their local drug using population. LAs are now responsible 
for tendering and commissioning the drug and alcohol treatment services they feel will provide the most 
suitable support for the needs of their constituents.
The Director of Public Health (DPH) is appointed jointly by PHE and the LA, and as officer champion 
for health within each upper tier and unitary authority has the responsibility of delivering public health 
outcomes in their local area. Other LA roles which are statutory members of the Health and Wellbeing 
boards include: the Director for Adult Social Services; the Director for Children’s Services; and an elected 
representative. 
Health and Wellbeing Boards 
Health and Wellbeing Boards (HWB) were established under the Health and Social Care Act 2012 (Her 
Majesty’s Government, 2012b) and assumed responsibility for providing the overall strategic direction 
for improving well-being in their area. 
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Each HWB must contain the following statutory members:
•	 at least one local elected representative;
•	 a representative of the local Healthwatch organisation;
•	 a representative of each local clinical commissioning group;
•	 the LA Director for Adult Social Services;
•	 the LA Director for Children’s Services; and 
•	 the Director of Public Health for the LA
Each HWB is required to produce a Joint Strategic Needs Assessment (JSNA) which outlines the current 
and future health and social care needs of their area and a plan to meet these needs in the Joint Health 
and Wellbeing Strategy (JHWS).
Healthwatch
There are 152 local Healthwatch organisations which were established under the Health and Social 
Care Act 2012 (Her Majesty’s Government, 2012b). They are commissioned directly by LAs and, 
together with the nationally-focused Healthwatch England, form the Healthwatch network. Their role is to 
represent the users of health and care services at the HWB, providing feedback to service providers and 
commissioners on how and why people use local services and their experience when doing so. 
Department of Health
The DH is the government department responsible for developing the statute and policy underpinning 
the health and care system. It leads on the ‘Building Recovery’ strand and jointly manages the ‘Reducing 
Demand’ strand of the 2010 strategy with the Home Office. It is supported by key agencies such as NHS 
England, the Care Quality Commission (CQC) and PHE. 
NHS England
Since April 2013 NHS England has been the functioning name of the NHS Commissioning Board which 
was established in October 2012 as an executive non-departmental public body. Even though the 
responsibility for the management of public health shifted away from the NHS and on to LAs in April 
2013, NHS England still plays a significant role in the treatment of substance misuse. It is involved in the 
provision of pharmacological treatments including opioid substitution therapy (OST); the implementation 
of Liaison and Diversion Programmes;2 and is responsible for commissioning health services within 
prisons, including drug and alcohol treatment services. NHS England also oversees the Clinical 
Commissioning Groups (CCGs) which are clinically led groups that commission local healthcare services 
within their geographical boundaries. This includes general practitioners, urgent and emergency care, 
and mental health and learning disability services. CCGs do not commission drug and alcohol treatment 
services directly, although it is mandatory that a representative from the local CCG sits on each HWB. 
Public Health England 
In April 2013 a number of functions of the National Treatment Agency were absorbed by PHE, a newly 
launched executive agency of DH whose role is to protect and improve the nation’s health and well-
being, and reduce health inequalities. PHE supports LAs to commission and deliver alcohol and drug 
services by providing evidence-based guidance and advice, and by collating and analysing alcohol 
2 Liaison and Diversion schemes are designed to identify, assess, screen and refer offenders who have mental health, 
learning disability, substance misuse or other vulnerabilities to an appropriate treatment or support service. 
See: https://www.england.nhs.uk/commissioning/health-just/liaison-and-diversion/ld-about/
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and drug treatment performance data (from the National Drug Treatment Monitoring System) for LAs. 
PHE uses this data to generate reports, which in turn can be fed back to LAs. PHE works with the DH 
which leads on the ‘Building Recovery’ section of the UK Drug Strategy and is also involved in the 
implementation of prevention activities, working towards the ‘Reducing Demand’ objectives.
Care Quality Commission 
The CQC is an independent body charged with monitoring, inspecting and regulating health and social 
care services in England. Services must be registered with the CQC which then ensures that they are 
meeting core standards of care based on five core questions: Are they safe?; Are they effective?; Are 
they caring?; Are they responsive to people’s needs?; and Are they well-led? 
Following an inspection, the CQC will rate a service provider either Inadequate, Requires improvement, 
Good or Outstanding for each of the five questions. By law the organisation must clearly display these 
ratings in an area where service users can easily see them. The CQC will also publish a report of their 
findings, which will include any actions taken against the provider such as the implementation of special 
measures or the issuing of requirement or warning notices. 
National Institute for Health and Care Excellence 
NICE is an executive non-departmental public body of the DH. Their role is to develop guidance, 
standards and information to improve health and social care. NICE directions are used by the NHS, 
LAs and anyone else involved in the delivering of care. NICE products are based on the best available 
evidence and are developed by multi-disciplinary teams of healthcare professionals and consumers or 
guideline development groups with particular expertise or experience in the topic. This is to ensure that 
all NHS patients have the same access to treatment, and that the treatment available is cost-effective.
Ministry of Justice 
Charged with protecting the public, reducing offending and overseeing courts, prisons, probation 
services and the secure youth estate; the MoJ are therefore involved in the hearing of criminal cases 
concerning drug-related offences and the rehabilitation of offenders. 
National Offender Management Service
The National Offender Management Service (NOMS) is an executive agency sponsored by the Ministry of 
Justice. Through Her Majesty’s Prison Service and the National Probation Service, NOMS is accountable 
for ensuring that both prison and community sentences in England and Wales are carried out. 
Whilst the responsibility for prison healthcare services ultimately rests with NHS England, a National 
Partnership Agreement was created in October 2013 with NOMS and PHE for the co-commissioning and 
delivery of services in England until April 2016 (National Health Service England, Public Health England, 
& National Offender Management Service, 2015) (see section 8.3.2). 
Department for Work and Pensions
Given the emphasis placed in the Drug Strategy on integrated working, the DWP plays an important 
role in ensuring that those accessing treatment are receiving the full range of benefits to which they 
are entitled, and supporting those recovering from addiction back into work. Universal Credit3 is a new 
single payment for people who are looking for work or on a low income, which brings together a range 
of working-age benefits, replacing the employment benefits, income support benefit, tax credits and 
housing benefit. It is currently being rolled out across the UK. 
3 As part of Universal Credit, the Department for Work and Pensions introduced ‘tailored conditionality’ whereby work 
search and work availability requirements can be suspended for a period of up to six months in any 12 month period for 
claimants actively participating in structured recovery-orientated treatment. This is to give claimants the time and space 
to engage in treatment, and begin their recovery journey. After the end of the period of ‘tailored conditionality’, on-going 
treatment commitments are still taken into account when an individual is looking for employment. This is recognised as a 
critical step in enabling people with dependencies to become ready for sustainable employment.
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Department for Communities and Local Government
The DCLG supports local governments to help ensure that their areas are working efficiently and 
effectively. They publish annual reports based on fiscal data provided by LAs on their revenue expenditure 
and financing, including that spent under the Public Health Grant. 
Department for Education 
DfE is responsible for education and children’s services in England. In 2013 drug education became a 
statutory part of the science curriculum for schools in England (see section 4.3.1). 
Figure 1.1: Commissioning structure for drug treatment in England
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See Figure 1.2 for an accompanying summary structure graphic.
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Scottish Government 
The Scottish Government has devolved powers for policies concerning health, education, housing, social 
care, policing and the criminal justice system. It provides annual funding, in the region of £70 million across 
drugs and alcohol, to the ADPs, via NHS Boards, to enable them to implement their local delivery plans 
(LDPs). LDPs are guided by ministerial priorities and ADP core outcomes, informed by a robust assessment 
of local need and developed and delivered in line with the recognised evidence base.
Convention of Scottish Local Authorities
The Convention of Scottish Local Authorities (CoSLA) represents local governments in Scotland and was 
involved, along with NHS Scotland and the Scottish Government, in producing the updated guidance 
for ADPs.
Alcohol and Drug Partnerships
There are 30 ADPs in Scotland, and each is responsible for designing and implementing a comprehensive 
and evidence-based local alcohol and drugs strategy and commissioning treatment services most suitable 
for their local resident population. The partnerships include representatives from local NHS Boards, LAs 
and other key partners such as Police Scotland, the Scottish Prison Service, Housing and Social Services.
Community Planning Partnerships 
The Community Planning Partnerships (CPP) hold the ADPs to account, and are involved in the 
generation of Single Outcome Agreements (SOA). 
NHS Boards 
NHS Boards develop annual LDPs which contain designated Health improvement, Efficiency and Access 
Treatment (HEAT) targets, including those relating to drugs and alcohol, and strategies for how they will 
be achieved. For 2015/16 the HEAT targets for drugs and alcohol (around reducing waiting times to 
treatment and delivery of Alcohol Brief Interventions (ABIs)) have evolved to become LDP Standard to 
support sustained performance. 
Information Services Division 
The Information Services Division (ISD) is part of NHS Scotland and provides health data, information 
and advice services which support the NHS to enable them to make informed decisions regarding health 
and care facilities. The Scottish Government has commissioned ISD to lead on the development of the 
new national combined drugs and alcohol data system, DAISy, which will eventually replace the current 
Scottish Drug Misuse Database (SDMD).
Scottish Drug Strategy Delivery Commission 
The DSDC was established by the Scottish government in 2009 to independently monitor and assess the 
implementation and success of the national drugs strategy. This has now achieved its initial goals and 
was formally concluded by the then Minister for Community Safety in November 2014. Arrangements 
are currently being finalised for a new Scottish Drugs Collaborative structure which will replace the work 
of the former DSDC and lead the sector going forward. The new structure will advise, lead, and directly 
deliver on areas of work including: harm reduction and drug deaths; quality of standards; prevention; 
communities and stigma; and research.
Wales 
See Figures 1.3 for an accompanying summary structure graphic.
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Figure 1.2: Overview of planning and reporting arrangements for Alcohol and Drug Partnerships in Scotland
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Welsh Government 
The Welsh Government has devolved powers for policies concerning health, education, housing and 
social care.
Substance Misuse National Partnership Board
The role of the SMNPB is to guide and monitor progress and to facilitate co-ordination between the 
Welsh Government, statutory agencies and the third and independent sectors. 
Community Safety Partnerships 
Established in each of the 22 LA areas, Community Safety Partnerships (CSPs) have representatives 
from local stakeholders including the police, LAs, the NHS, fire and rescue services and voluntary 
organisations.
Area Planning Boards 
Seven Area Planning Boards (APBs) were introduced in 2010 to support the planning, commissioning 
and performance management of substance misuse services at a regional level. The Boards include 
representatives from local health boards, LAs and other key partners such as police, prison, probation, 
housing, social services, service providers and service users.
Local Health Boards 
The Local Health Boards (LHBs) commission healthcare services in public sector prisons, including drug 
treatment services. 
Advisory Panel on Substance Misuse
The Advisory Panel on Substance Misuse (APoSM) is a Welsh Government-sponsored body established 
under general executive powers of the Welsh Ministers. The Panel is an independent expert advisory 
body whose remit is to advise the Minister on measures to prevent or reduce substance misuse and the 
associated health and social harms.
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Figure 1.3: Commissioning and reporting structure of substance misuse services in Wales 
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Northern Ireland
See Figure 1.4 for an accompanying summary structure graphic. 
Department of Health, Social Services, and Public Safety 
The Department of Health, Social Services, and Public Safety (DHSSPS) was responsible for the 
development and launch of the Drug Strategy in 2006 and its review and extension in 2011. DHSSPS will 
be responsible for the evaluation of the strategy and it is anticipated that they will retain responsibility for 
a successor strategy. 
Public Health Agency 
The Public Health Agency (PHA) provides expert advice and commissions a range of alcohol and drug 
services under the NSD Phase 2. They also support the work of the Drug and Alcohol Co-ordination 
Teams (DACTs). 
New Strategic Direction Steering Group 
Established in 2006, the NSD Steering group is chaired by the Chief Medical Officer. Its primary role is 
to oversee the ongoing policy development, delivery of the strategy and the achievement of outcomes. 
The Steering group includes all key government departments, including the Department of Justice and 
the Department for Social Development, and ensures a cross-sectoral approach to developing policy 
and implementing the strategy. 
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Figure 1.4: Commissioning and reporting structure of substance misuse services in Northern Ireland 
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The group members include representatives from various branches of the DHSSPS including the Public 
Health Information and Research branch, the Health Development Policy branch and the chairs of four 
DHSSPS advisory groups: children, young people and families; treatment and support; alcohol advisory 
group; and law and criminal justice. The group monitors progress towards NSD targets and outcomes. 
Drug and Alcohol Coordination Teams 
DACTs generate local action plans and priorities to implement the Drug Strategy and guide the 
expenditure of PHA funding, including the commissioning of drug treatment services. They work closely 
with other local groups and partnerships, including Policing and Community Safety Partnerships.
1.4 Funding for drug treatment
England
Public Health Grant
LAs in England received a ring-fenced Public Health Grant of £2.79 billion for public health services in the 
2015/16 financial year.4 Funding for drug and alcohol treatment is not ring-fenced within the Public Health 
Grant, and expenditure on services is determined by an assessment of the local populations’ needs by 
local HWBs. LAs are required to report their annual forecasted and actual expenditure on each public 
health intervention making up the Grant. The categories for reporting this data include: adult drugs; adult 
alcohol; and young people’s drug and alcohol spend. 
4 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/388172/final_PH_grant_
determination_and_conditions_2015_16.pdf
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Expenditure on drug misuse services for adults in England in 2013/14 was £581.1 million, with a further 
£74.9 million being spent on services for young people.5 These two elements of expenditure accounted 
for almost one quarter (24%) of public health spend by LAs. It is important to note that the data collection 
is a new exercise and there may be differences with how LAs report their public health spend.
At present there is a consultation on the proposed allocation formula which will be used to calculate 
funds for 2016/17.6 This consultation closed on 6 November 2015, and new funding allocations will be 
announced in due course. 
Wales
The Welsh Government invests almost £50 million annually to deliver the commitments within the 
substance misuse strategy, Working Together to Reduce Harm 2008-2018, and its associated delivery 
plan. Alongside the £17.134 million ring-fenced funding within the Health Board budget for substance 
misuse services, the Substance Misuse Action Fund (SMAF) budget for 2014/15 stands at £32.047 
million. Over £22 million of this funding goes directly to the seven APBs in Wales, which supports a 
number of projects ranging from education and prevention to treatment services.
Scotland
In 2015/16, £30.4 million was allocated to ADPs to support the delivery of improved outcomes for 
drugs, the same as the figure for 2014/15 and a slight increase on 2012/13 (£30.3 million). The Scottish 
Government is in the process of developing National Recovery Indicators to measure outcomes. These 
indicators will form part of a national Drug and Alcohol Information System (DAISy) planned for 2015/16.
Northern Ireland
Expenditure on alcohol and drugs services has remained broadly consistent in Northern Ireland – around 
£8 million per year is allocated to the implementation of the NSD Phase 2, 2011-2016 (Department of 
Health Social Services and Public Safety Northern Ireland, 2011b) and a further £8 million is allocated to 
statutory addiction services through the mental health budget.
5 See: https://www.gov.uk/government/statistics/local-authority-revenue-expenditure-and-financing-england-2013-to-2014-
individual-local-authority-data-outturn 
6 See: https://www.gov.uk/government/consultations/public-health-formula-for-local-authorities-from-april-2016 
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2. Legal framework and drug law offences
2.1 Introduction
The Misuse of Drugs Act 1971 is the principal legislation in the UK for the control and supply of 
psychoactive substances that are considered dangerous or otherwise harmful when misused (Her 
Majesty’s Government, 1971). Drug use is not a crime in the UK, but possession, production and 
dealing, as well as trafficking (including importation and exportation) are specific offences under the 
Misuse of Drugs Act 1971.7 
The Misuse of Drugs Act 1971 divides drugs into three classes (A, B and C) and sets maximum criminal 
penalties for illegal production, possession and supply in relation to each class. Drugs in Class A include 
cocaine, ecstasy, heroin, tryptamines (such as LSD), magic mushrooms, methadone, methylamphetamine 
and injectable amphetamines, as well as NBOMe8 compounds. Class B drugs include amphetamines, 
benzofuran compounds, cannabis and synthetic cannabinoids, synthetic cathinone derivatives including 
mephedrone, ketamine and analogue compounds including methoxetamine, and pipradrol-related 
compounds including desoxypipradrol (2-DPMP) and diphenylprolinol (D2PM). Class C drugs include 
anabolic steroids, benzodiazepines, GBL/GHB, khat, piperazines (such as BZP) and tranquilisers. 
The Police Reform and Social Responsibility Act 2011 (Her Majesty’s Government, 2011b) added 
provisions for 12-month Temporary Class Drug Orders (TCDOs) enabling law enforcement activity 
against those trafficking and supplying new psychoactive substances (NPS) (see section 2.2.3). There 
are no possession offences associated with TCDOs.
Most drugs controlled under the Act are also placed in one of five schedules to the Misuse of Drugs 
Regulations 2001 based on an assessment of their medicinal or therapeutic usefulness, the need for 
legitimate access and their potential harms when misused (Her Majesty’s Government, 2001b).9 The 
schedules determine the circumstances in which controlled substances can be lawfully manufactured, 
possessed and distributed. Schedule I is for substances deemed to have no therapeutic value so 
cannot be prescribed. Research can be conducted on these substances but this requires a license 
to be obtained from the Home Office. At the other end, Schedule V drugs can be legally supplied and 
possessed without prescription.
Under the Misuse of Drugs Act 1971, police have special powers to stop, detain and search people on 
‘reasonable suspicion’ that they are in possession of a controlled drug. Police may also enter and search 
premises with a warrant if there are reasonable grounds to suspect an offence against the Act has been 
committed. A prison sentence is the most common outcome when found guilty at court of import/export 
and trafficking offences but a fine, community sentence or conditional discharge are the most common 
disposals for possession offences. The range of possible penalties is covered in section 2.3.2.
The Drugs Act 2005 amended the Police and Criminal Evidence Act 1984, introducing mandatory drug 
testing of detainees following arrest in certain circumstances (Her Majesty’s Government, 1984). The Act 
also introduced a new offence of failing to attend a Required Assessment with a drug worker for those 
testing positive (see section 2.4.2). These amendments provided a legally enforceable lever through 
which to identify drug using offenders on arrest and to engage them with treatment.
7 Possession: In the UK it is unlawful to possess any quantity of a controlled drug, unless the individual is in possession of 
an authorisation in the form of a licence (for example a prescription), or the person can prove that they were unaware that 
the substance was a controlled drug.
 Supply and possession with the intent of supply: Supply defined as the simple act of passing a controlled drug 
from one person to another. According to the law, it is irrelevant if the act is done for profit or not. The financial gain has 
influences only on the sentence given.
 Production: In the UK it is illegal to produce any controlled drug, unless the individual is in possession of an authorisation 
in the form of a licence. Production is defined as ‘manufacturing, cultivating or production by any other method’.
8  NBOMe refers to a family of hallucinogenic drugs.
9 See: https://www.gov.uk/government/policies/reducing-drugs-misuse-and-dependence/supporting-pages/classifying-
and-controlling-drugs.
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To protect young people, the Drugs Act 2005 sets out aggravating factors which must be taken into 
account by courts when considering the seriousness of an offence of supply of a controlled drug by 
a person aged 18 or over. These include when the offence was committed in the vicinity of school 
premises at a relevant time and when the offender engaged someone under the age of 18 as a courier.
2.2 Legal Framework
2.2.1 Recent changes to drug misuse legislation
Drug driving legislation
England and Wales
The Crime and Courts Act 2013 (Her Majesty’s Government, 2013a) makes it an offence to drive or be in 
charge of a motor vehicle with a blood concentration of specified controlled drugs above certain limits. 
In 2014, following an expert panel report (which offered suggestions about the best course of action on 
specified drugs and limits for each drug under the legislation) (UK Focal Point, 2012; Wolff et al., 2013) 
and a public consultation, the Government announced that they accepted the panel’s recommendations 
on the blood concentration limits suggested for eight illegal drugs and eight drugs mostly associated 
with medical uses. The new regulations came into force in England and Wales in March with the setting of 
blood concentration limits for 16 substances specified in The Drug Driving (Specified Limits) (England 
and Wales) Regulations 2014 (Her Majesty’s Government, 2014). There is a ‘zero tolerance’ approach to 
eight drugs most associated with illegal use (i.e. at a level designed only to exclude accidental exposure) 
and a road safety risk-based approach to eight drugs most associated with medicinal use.
Table 2.1: Threshold limits for blood drug concentrations
‘ILLEGAL’ DRUGS (‘ACCIDENTAL 
ExPOSURE’ – zERO TOLERANCE 
APPROACH)
THRESHOLD LIMIT IN 
BLOOD FOR ‘ILLEGAL’ 
DRUGS
‘MEDICINAL’ DRUGS 
(RISk BASED 
APPROACH)
THRESHOLD LIMIT 
IN BLOOD FOR 
‘MEDICINAL’ DRUGS
Benzoylecgonine (cocaine metabolite) 50µg/L Amphetamine 250µg/L
Cocaine 10µg/L Clonazepam 50µg/L
Delta-9-tetrahydrocannabinol (cannabis) 2µg/L Diazepam 550µg/L
Ketamine 20µg/L Flunitrazepam 300µg/L
LSD 1µg/L Lorazepam 100µg/L
Methylamphetamine 10µg/L Methadone 500µg/L
MDMA 10µg/L Morphine 80µg/L
6-monoacetylmorphine (heroin) 5µg/L Oxazepam 300µg/L
Source: (Her Majesty’s Government, 2014)
Scotland
Drug driving is reserved to the UK Government, but two aspects of the new offence: the power to specify 
the controlled drugs that will trigger the new offence; and the applicable limits that will trigger the new 
offence, are devolved to Scottish Ministers.
The UK Government launched a consultation paper on the new drug driving offence on 9 July 2013 and, 
at the request of the Scottish Government, this consultation covered Scotland as well. An analysis report 
on the consultation responses in relation to Scotland were published on 3 July 2015. The views offered in 
the consultation will help to inform decisions on whether a new drug driving offence for Scotland should 
be introduced (Scottish Government, 2015b).
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Northern Ireland
Legislation in relation to drug driving is devolved to Northern Ireland and the work undertaken by the UK 
Government will inform any final policy proposals for Northern Ireland.
Stop and search 
In March a revised version of the Police and Criminal Evidence Act, Code A (Home Office, 2015d), came 
into force. It included amendments to the meaning of ‘reasonable grounds for suspicion’. It stipulates 
that an officer must have an objective basis for suspicion (fact, information and/or intelligence) and 
that personal factors can never support reasonable grounds for suspicion. It also emphasises that the 
misuse of stop and search powers will lead to formal performance or disciplinary proceedings.
A change to the Misuse of Drugs Act 1971: control of MT-45 and 4,4’-DMAR
In February 2015 Parliament approved the recommendation of the Advisory Council on the Misuse of 
Drugs (ACMD) to control NPS known as MT-45 (a synthetic opioid) and 4,4’-DMAR (a chemical stimulant) 
due to their potential to cause serious harm including deaths. Amendments to the Misuse of Drugs Act 
1971 and its subordinate legislation to permanently control such compounds as Class A came into force 
on 11 March 2015 (Home Office, 2015c).
A change to the Misuse of Drugs Act 1971: control of AH-7921, LSD–related compounds, tryptamines, 
and rescheduling of GHB
In January 2015 the Home Office controlled the following compounds (or class of compound) as Class 
A drugs under the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 (001/2015): 
•	 the synthetic opioid AH-7921; 
•	 the LSD-related compounds commonly known as ALD-52, AL-LAD, ETH-LAD, PRO-LAD and LSZ; and 
•	 the compounds captured by the extended definition of tryptamines, including compounds commonly 
known as AMT and 5-MeO-DALT
These changes came into effect on 7 January 2015 (Home Office, 2015b).
Availability of naloxone
In October 2015 legislative changes came into force to increase the availability of naloxone. These 
changes made naloxone exempt from prescription-only medicine requirements when it is supplied by 
a drug service commissioned by a local authority (LA) or the National Health Service (NHS). This will 
make naloxone easier to access not only by individuals who are using or have previously used opioids 
and are at potential risk of overdose, but also by their carers, a family member or friend, and/or a named 
individual in a hostel or other facility where drug users gather.
Serious Crime Act 2015
The Serious Crime Act 2015 (Her Majesty’s Government, 2015b), enacted in March 2015, gives effect to 
a number of legislative proposals suggested by the Serious and organised crime strategy (Her Majesty’s 
Government, 2013b). It builds on current criminal and civil law to ensure that law enforcement agencies 
have the powers to continue to disrupt the activities and bring to justice serious and organised criminals. 
It introduced powers for law enforcement officers to tackle the trade in cutting agents, allowing them to 
enter premises, with a warrant, where there are reasonable grounds to suspect chemicals are being used 
for unlawful conduct, as well as to seize, detain and destroy certain substances. The Act strengthened the 
Proceeds of Crime Act 2002 (Her Majesty’s Government, 2002) enabling assets held by defendants and 
others to be frozen and recovered, and traffickers prosecuted more quickly. The Serious Crime Act 2015 
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also made it an offence to throw any article or substance into a prison. Those found guilty could face up 
to 12 months in jail or a fine or both for a summary conviction, or up to two years in jail or a fine or both for 
an indicted conviction.
2.2.2 Advisory Council on the Misuse of Drugs (ACMD)
Ketamine: Rescheduling and Patient Group Directions
In June 2014, the Government accepted the recommendation of the ACMD and reclassified ketamine 
as Class B. They also held a public consultation on the impact of listing ketamine in Schedule II of the 
2001 Regulations (UK Focal Point, 2012). In February 2015, the ACMD informed the Government that if 
ketamine was listed in Schedule II, as they recommended, this would place it outside the remit of Patient 
Group Directions (PGD). Consequently, certain healthcare providers would not be able to supply or 
offer to supply the drug for immediate treatment to patients, when not under the direct supervision of 
a medical practitioner.10 Therefore, the ACMD recommended that specific exceptions should be put in 
to place to ensure that ketamine continues to be available under PGDs when it is rescheduled. In her 
reply the then Minister of State informed the ACMD that in light of the consultation outcomes11 and their 
further recommendation, she had approved the rescheduling of ketamine from Part 1 of Schedule IV to 
Schedule II of the 2001 Regulations, including the legislative changes needed to ensure its continued 
use under PGDs. On 30 November 2015, ketamine become a Schedule II controlled drug under the 
Misuse of Drugs Regulations 2001.
Misuse of Drugs (Amendment)(No.2)(England, Wales and Scotland) Regulation 2015
The ACMD has approved12 the Home Office’s suggestion to review specific provisions under the 
Misuse of Drugs Regulations 2001 (Her Majesty’s Government, 2001b), with the aim of increasing the 
flexibility and access to controlled drugs by removing unnecessary barriers whilst implementing better 
monitoring of the ordering of controlled drugs stocks by healthcare professionals within the community. 
The Government13 acknowledged the ACMD’s support for these changes and they were implemented 
on 1 June 2015 (except for changes relating to ketamine and mandatory requisition forms, which came 
into force on 30 November).
Electronic Prescribing Service (EPS) for Schedules II and III Controlled Drugs
In July 2014 the Government launched a consultation on the joint proposal by the Department of Health 
and Home Office to enable the Electronic Prescribing Service (EPS) for Schedules II and III controlled 
drugs for NHS and private prescribers. As a result of a positive response to the consultation14 and 
support from the ACMD (which also recommended that the implementation of such changes should be 
contingent on compliance with the ‘Advanced Electronic Signature’ standard and other security standards 
required of NHS prescribers), the Government has made the necessary legislative amendments to 
enable the electronic prescribing of Schedules II and III controlled drugs, and the legislation came into 
force in July 2015.
10 Subject to some specific exceptions, the use of controlled drugs under PGDs is limited to drugs listed in Schedule IV and 
V to the 2001 Regulations.
11 A summary of the consultation responses included in the letter to the ACMD reported that the vast majority of the 
responses to the consultation supported the rescheduling of ketamine to Schedule II of the Misuse of Drugs Regulations 
2001, but they also agreed that such rescheduling should not be a burden to the veterinary practices and healthcare 
organisations that already treat ketamine as a Schedule II drug. https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/417601/Ketamine_Consultation_-_Summary_of_Responses.pdf 
12 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/416670/25_03_2015_ACMD_
Advice_-_Proposals_to_review__amend_specific_provisions_under_MDR_2001.pdf 
13 See : https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418399/2015-03-25-LF-LI-Misuse_
of_Drugs_Regulations.pdf 
14 See; https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/415885/consultation_response.pdf 
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New Temporary Class Drug Order for compounds related to methylphenidate
In April 2015, the Government accepted the ACMD’s recommendation to put under a TCDO 
five compounds related to methylphenidate.15,16 Consequently, the substances ethylphenidate, 
3,4-dichloromethylphenidate (‘3,4-DCMP’), methylnaphthidate (‘HDMP-28’), isopropylphenidate (‘IPP’ or 
‘IPPD’) and propylphenidate became subject to a TCDO pursuant to section 2A of the Misuse of Drugs 
Act 1971. In June 2015 a further TCDO was introduced to cover 4-methylmethylphenidate (‘4-Me-TMP’) 
and ethylnaphthidate (‘HDEP-28’) alongside the original five substances.17
2.2.3 Legislation designed to control new psychoactive substances
Temporary Class Drug Order 
Since November 2011, with the amendment to the Misuse of Drugs Act 1971 made by the Police Reform 
and Social Responsibility Act 2011 (Her Majesty’s Government, 2011b), the Home Secretary has had the 
power to make a TCDO where, following consultation with or a recommendation from the ACMD, there 
is sufficient concern about the potential harms of a NPS. The importation, exportation, production and 
supply of a drug which is subject to a TCDO are unlawful. While the personal possession of a temporary 
class drug is not an offence, the police have the power to seize and destroy any drug suspected of being 
subject to a TCDO. The order can last for a maximum of 12 months. 
The Forensic Early Warning System (FEWS) was set up in January 2011 to forensically identify NPS in a 
prompt manner, in order to assist the ACMD and the Government to tackle the threat posed by emerging 
substances (UK Focal Point, 2012). It forms part of the Government’s wider action on NPS, as set out in 
the NPS Action Plan (Home Office, 2012). FEWS collected samples from the internet and head shops, 
music festivals, the police and border control to identify which NPS are present in the UK or being offered 
for sale in the UK market.
New Psychoactive Substances Bill
Following a six-month review of the UK’s response to NPS undertaken by an independent expert 
panel, 31 recommendations on new and bespoke measures ranging from legislation to prevention, 
education, information sharing, treatment and interventions were put to the Government (Home Office, 
2014a). Among the recommendations was a proposal for a blanket ban on supply of NPS, similar to 
that introduced in Ireland in 2010. The prospective ban has been welcomed in a report on NPS by an 
Expert Review Group established by the Scottish Government (Scottish Government, 2015b), as well as 
in a report by the National Assembly for Wales’ Health and Social Care Committee (National Assembly 
for Wales, 2015b). In May 2015 the newly elected majority Conservative Government announced the 
proposal of a Psychoactive Substances Bill to legislate against the supply, production, distribution, import 
and export of all psychoactive substances except for stated exemptions (to include alcohol, tobacco and 
food). The Bill will proceed through Parliament over the autumn with anticipated Royal Assent by the end 
of 2015 and commencement in spring 2016.
New psychoactive substances in prison 
In January 2015 the Criminal Justice and Courts Act (Her Majesty’s Government, 2015a) provided 
additional powers to prison governors to test for non-controlled drugs, such as NPS, in mandatory 
drug testing and to impose stiffer penalties on those suspected of being involved in smuggling NPS 
into prisons. New sanctions include ‘closed visits’ (no contact with partners or children), extended or 
further sentences, solitary confinement, forfeiture of prison wages and/or privileges and being moved to 
a higher security prison.
15 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420983/TCDO_methylphenidate_NPS.pdf 
16 Methylphenidate in the UK, it is controlled as a Class B material and as a Schedule II substance under the Misuse of 
Drugs Regulations 1971 
17 See: https://www.gov.uk/government/news/two-new-legal-highs-to-be-banned-under-temporary-order 
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Local Government powers to tackle new psychoactive substances
England
In January 2015 a councillors’ guide was published by the Local Government Association (LGA) which 
aimed to provide LAs with information on how they can protect their community from the harms of NPS 
use under the existing legal framework. The guidance contains an introduction to NPS, suggestions on 
how they can raise awareness of the harm of NPS use and information on what LAs can do to tackle 
sales of NPS in their areas (Local Government Association, 2015). Guidance to LAs was also published 
by the Home Office with the aim of highlighting the main legislative measure they have to tackle ‘head 
shops’ that are selling NPS (Home Office, 2015h).
Scotland
Following a recommendation made by the Scottish Government NPS Expert Review Group (26 February 
2015), Scottish Ministers wrote to Scottish licensing authorities to request conditions and restrictions be 
added to public entertainment licences to ban the sale of NPS at music festivals and events.
Local Initiatives targeting new psychoactive substances
England 
Lincoln ‘legal high’ ban
Following a public consultation on banning the consumption of intoxicating substances18 in public 
(where 97% of respondents supported the ban) the City of Lincoln Councillors, in February 2015, voted 
to introduce a Public Space Protection Order (PSPO). This allowed the council to place an order to ban 
persistent activities that are having a detrimental effect on the quality of life for people in their community. 
The ban came into action in April 2015. This new power was introduced as a replacement of an existing 
Designated Public Place Orders (DPPO), which allowed only the prevention of alcohol consumption in 
certain areas under specific circumstances. Since the Lincoln ban, other LAs have introduced similar 
measures.
Northern Ireland 
Belfast City Council Injunction and Prosecution
Following action under General Product Safety Regulations (GPSR) 2005,19 Belfast City Council (BCC) 
was granted forfeiture orders at Belfast Magistrates Court in respect of NPS products seized from a 
number of shops that refused to voluntarily surrender their stock. The Council, working with the Attorney 
General for Northern Ireland, sought an injunction to try to stop the sale and distribution of NPS in 
Northern Ireland. This was granted by the High Court against a number of defendants on two grounds. 
The first was to stop the further commission of offences under the GPSR, and the second was on the 
basis that their sale in the locality of the shops constituted a public nuisance. In tandem with the injunctive 
proceedings, BCC also took a prosecution against the defendants for breaching the GPSR as the NPS 
products did not meet the safety standards set out in the Regulations. All the defendants pleaded guilty. 
The offences were as follows: Regulation 8(1)a — supplying a product which they knew or should have 
presumed to be dangerous; Regulation 8(1)b(ii) — failure to keep documentation necessary for tracing 
the origin of the product; and Regulation 8(b)(iii) — failure to produce documentation necessary for 
tracing the origin of the product and failure to co-operate with action taken by BCC. Following the joint 
prosecution, a full injunction against the defendants was granted and this has had a significant impact 
on the retail of NPS in Belfast.
18 Intoxicating substances are defined as ‘Substances with the capacity to stimulate or depress the central nervous system’ 
and they include alcohol and so called ‘legal highs’
19 See: http://www.legislation.gov.uk/uksi/2005/1803/pdfs/uksi_20051803_en.pdf 
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2.3 Drug law offences
2.3.1 Types of offences and range of penalties
There are a number of activities related to controlled drugs that are considered offences under the 
Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971). These are: possession; supply (dealing); 
possession with intent of supply; production; importation and exportation (trafficking); and offences 
related to the use of a controlled drug on premises. The severity of the penalty applied is dependent on 
the ‘class’ of the drug involved and the individual circumstances of the case. For each type of offence, 
the court has to consider the size of the operation/quantity of drugs involved, the individual’s role in the 
crime, and any aggravating or mitigating factors in order to impose an appropriate penalty in accordance 
with the definitive guidelines (Sentencing Council, 2009, 2012).
Table 2.2: summarises the maximum penalties according to the offence and the type or ‘class’ of the 
drug involved.
Table 2.2: Maximum penalties for drug possession
CLASS DRUG POSSESSION
SUPPLY AND 
PRODUCTION
A
Crack cocaine, cocaine, ecstasy (MDMA), heroin, LSD, 
magic mushrooms, methadone, methamphetamine
Up to seven years in prison, 
an unlimited fine or both
Up to life in prison, an 
unlimited fine or both
B
Amphetamines, barbiturates, cannabis, codeine, 
ketamine, methylphenidate, synthetic cannabinoids, 
synthetic cathinones
Up to five years in prison, an 
unlimited fine or both
Up to 14 years in prison, an 
unlimited fine or both
C
Anabolic steroids, benzodiazepines (e.g. diazepam), 
gamma hydroxybutyrate (GHB), gamma-butyrolactone 
(GBL), piperazines (e.g. BZP), khat
Up to two years in prison, 
an unlimited fine or both 
(except anabolic steroids – it 
is not an offence to possess 
them for personal use)
Up to 14 years in prison, an 
unlimited fine or both
TCDO*
(Currently) Ethylphenidate, 3,4-dichloromethylphenidate 
(‘3,4-DCMP’), methylnaphthidate (‘HDMP-
28’), isopropylphenidate (‘IPP’ or ‘IPPD’), 
4-methylmethylphenidate (‘4-Me-TMP’), 
ethylnaphthidate (‘HDEP-28’), propylphenidate, and their 
simple derivatives
None, but police can take 
away a suspected temporary 
class drug
Up to 14 years in prison, an 
unlimited fine or both
* The government can ban new drugs for one year under a “temporary banning order” while they decide how the drugs should 
be classified.
Source: https://www.gov.uk/penalties-drug-possession-dealing
First and second simple possession offences for cannabis and khat (for personal use) are dealt with 
using out-of-court disposals in England and Wales. In the case of first offences, this takes the form of 
a spoken ‘cannabis warning’ or ‘khat warning’ respectively. Second offences generally incur a penalty 
notice for disorder of £80 under the Criminal Justice and Police Act 2001 and the Schedule to the 
Penalties for Disorderly Behaviour (Amount of Penalty) Order 2002 (Her Majesty’s Government, 2001a).
2.3.2 Data on drug law offences 
Data on drug law offences are available at various points in the criminal justice system:
•	 Recorded crime data count the number of drug offences brought to the attention of police and 
represent the widest measure of drug offences available in the UK. However, at present the individual 
drug involved is not recorded (except for cannabis possession offences). 
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•	 Arrests data record the number of persons who are arrested for a drug offence and represent a 
smaller proportion of drug offences, since some penalties such as formal warnings for cannabis do 
not constitute an arrest. These data are not available by drug or by offence type. 
•	 Finally, cautions and convictions data record the number of offences where an individual is found 
guilty at court or cautioned for a drug offence. 
Data from each level of the criminal justice system cannot be compared for a number of reasons 
including: time lag between offence and conviction; the basis on which the data are provided (offender 
or offence); counting rules; and year of data (calendar or financial year). It should be noted that changes 
in police activities and priorities will impact on the recording of drug offences and, as such, trends may 
not be entirely reflective of underlying levels of drug offending. Further information on the recording of 
drug offence data are contained in a selected issue chapter on sentencing statistics in the UK Focal 
Point Report 2008 (UK Focal Point, 2008). 
Recorded crime: drug offences
There has been a downward trend in recorded drug offences in the UK in recent years; however, trends 
differ between the administrations. Northern Ireland has seen a fairly steady increase in both trafficking 
and possession offences recorded over the last decade with around twice the number of each category 
reported in 2014/15 as were in 2006/07 (although slightly fewer trafficking offences were reported in 
2014/15 than in the previous year).20 While the overall number of recorded drug offences in Scotland 
has fallen over the last five years, this is due to a substantial fall in trafficking offences, while possession 
offences have risen (Scottish Government, 2015d). Due to size, the trends for England and Wales (which 
are reported together) are broadly similar to the overall UK picture, with both possession and trafficking 
offences having fallen in recent years (Home Office, 2015e).
Figure 2.1: Trends in recorded possession and trafficking offences in the UK: 2004/05 to 2014/15
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Source: (Home Office, 2015e; Scottish Government, 2015d) Police Service of Northern Ireland21
20 See: http://www.psni.police.uk/index/updates/updates_statistics/updates_crime_statistics/updates_crime_statistics_archive.htm 
21 See: http://www.psni.police.uk/index/updates/updates_statistics/updates_crime_statistics/updates_crime_statistics_archive.htm
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Arrests for drug offences
Having risen between 2006/07 and 2010/11, arrests for drug offences in England and Wales have 
dropped in recent years but remain more numerous than before the rise.
Convictions and cautions for drug offences
There were 139,759 drug offences where the person was found guilty at court or cautioned in the UK 
during 2013 (Table 2.3), a three per cent reduction on the previous year (n= 144,434). Having fallen 
sharply from 2010 to 2012 (a total decrease of 31%), convictions relating to heroin have plateaued since 
2012 (one per cent decrease). The decrease of heroin convictions seen between 2010 and 2012 may 
reflect the reduced availability of heroin during this period; a pattern seen in other indicators. Having 
steadily risen between 2007 and 2011, the number of cannabis convictions fell by four per cent in 2013 
but is still far higher than in 2007 (+30%). Cocaine powder convictions continued to fall in 2013 (two per 
cent), if less sharply than in previous years. The number of convictions for other drugs remained fairly 
stable, apart from ecstasy offences which continued to increase by nine per cent since 2012, a total rise 
of 83% since 2010.
Figure 2.2: Trends in arrests for drug offences in England and Wales: 2004/05 to 2013/14
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Out of court disposals and sentencing of drug offenders
In 2014, there were 143,120 proven drug law offences22 in England and Wales, representing a 17% 
decrease from the previous year (Ministry of Justice, 2013a). The majority of drug offences were dealt with 
outside of a court setting (64%). Of the drug offences settled outside of court, over half were in the form of a 
cannabis warning (55%), followed by cautions (32%), with penalty notices for disorder accounting for 12%.
22 Defendants who have been proven to have committed an offence (includes convictions, cautions, cannabis warnings and 
Penalty Notices for Disorder).
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Table 2.3: Drug offences where the offender was found guilty or issued a caution in the United Kingdom
 DRUG 2004* 2005 2006 2007 2008 2009 2010 2011 2012 2013
Amphetamines 6,249 6,864 7,422 7,478 7,822 7,096 7,487 7,831 6,488 6,338
Cannabis 82,845 54,813 55,984 55,563 63,103 66,598 75,284 80,023 75,116 71,980
Cocaine powder 9,382 12,028 15,470 19,216 22,874 22,529 20,034 20,102 18,723 18,381
Crack cocaine 2,450 3,734 4,076 4,613 5,895 4,241 3,679 3,791 3,845 3,815
Ecstasy 6,209 6,337 6,233 7,189 5,107 3,608 1,812 2,512 3,045 3,323
Heroin 12,412 15,629 15,741 16,557 17,926 16,354 16,648 12,816 11,438 11,326
LSD 90 183 172 165 156 106 69 88 50 63
Total† 122,459 118,706 124,344 135,655 149,203 147,013 152,451 154,212 144,434 139,759
* Data since 2005 are on an all offence basis; data for the years before 2005 are based on principal drug offence.
† The total refers to the total number of reports against drug legislation. Not all drug offences data are reported by drug type; therefore, 
the total reported in the table includes other type of offences such as those involving premises and miscellaneous drug offences.
Source: ST11
Of the 51,297 individuals sentenced at court for drug offences in England and Wales during 2014, 17% 
were given immediate custody (Ministry of Justice, 2015a), a similar proportion to previous years. The 
most common sentence was a fine, meted out in 38% of cases. The vast majority of those convicted 
of import/export offences received immediate custody (82%) (Table 2.4), with an average custodial 
sentence length of 81.9 months for Class A importation offences (Table 2.7). The distribution of 
sentencing outcomes for drug law offences was similar in Northern Ireland in 2014 although with greater 
use of conditional discharges and a smaller proportion of offenders given fines.
Table 2.4: Number and percentage of offenders receiving each disposal at court for drug offence type 
in England and Wales, 2014
 
IMMEDIATE 
CUSTODY
SUSPENDED 
SENTENCE
COMMUNITY 
SENTENCES
FINE OTHER
TOTAL 
SENTENCED
 n % n % n % n % n % n %
Import/export 375 82.1 49 10.7 18 3.9 8 1.8 7 1.5 457 100
Trafficking* 7,143 43.3 4,754 28.8 2,889 17.5 969 5.9 744 4.5 16,499 100
Possession 1,184 3.5 602 1.8 4,029 12.0 18,519 54.9 9,371 27.8 33,705 100
Other 54 8.5 120 18.9 218 34.3 136 21.4 108 17.0 636 100
Total 8,756 17.0 5,525 10.8 7,154 13.9 19,632 38.3 10,230 19.9 51,297 100
*Includes production, supply and possession with intent to supply.
Source: (Ministry of Justice, 2015a)
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2.4 Drug interventions in the criminal justice system
Rehabilitative and treatment opportunities are made available to those who need them at all stages of 
the criminal justice system (police station, court, community sentence or custody), either on a voluntary 
basis, or as part of a court mandated sentence or post-release licence.
2.4.1 Drug Rehabilitation Requirement in England and Wales 
Under Section 209 of the Criminal Justice Act 2003 (Her Majesty’s Government, 2003), a Drug 
Rehabilitation Requirement (DRR), comprising structured treatment and regular drug testing, was made 
available to courts as a sentencing option for offences from April 2005. A DRR can be made as part 
of a Community Order (CO) or a Suspended Sentence Order (SSO). These provisions aim to present 
local providers with flexibility to tailor requirements to individual needs, changing patterns of substance 
misuse and moving towards a recovery-focused approach to treatment. In England, separate provision 
is not generally commissioned to support DRRs; rather the treatment element of DRRs is provided from 
drug treatment services commissioned for the mainstream local treatment population. 
The supervision on licence of low to medium risk offenders is now managed by Community Rehabilitation 
Companies as part of the changes brought in by Transforming Rehabilitation: A strategy for reform 
(Ministry of Justice, 2013b), with high risk offenders being supervised by the new the National Probation 
Service (see section 8.3.1). In Wales, the Director of National Offender Management Service (NOMS) Wales 
is responsible for the planning and commissioning of drug treatment services for offenders on DRRs. 
2.4.2 The Former Drug Interventions Programme in England and Wales
The Drug Interventions Programme (DIP), established in 2003, was the primary method of engaging 
drug misusing offenders with drug treatment services in England and Wales between 2003 and 
2013. Under the national DIP programme, Criminal Justice Intervention Teams (CJITs) provided case 
management, low threshold interventions and referrals to structured treatment. Mandatory test on arrest 
was implemented in 2006 for specified ‘trigger offences’ (i.e. those most associated with drug use: 
shoplifting, robbery, theft) in areas designated as being ‘DIP intensive’. DIP ceased to be a national 
programme from April 2013. The funding from the Home Office and the Department of Health that 
was previously ring-fenced for the programme has been subsumed into the Police Main Grant and the 
Public Health Grant, with the decision as to whether to continue funding such interventions taken locally 
according to an assessment of local need. The majority of LAs continue to report CJIT activity to Public 
Health England (PHE) and around 28 police forces still run a drug intervention initiative based on drug 
testing on arrest, suggesting that the provision of such services has largely survived the transition to a 
locally led commissioning structure (personal communication — Home Office).
2.4.3 Liaison and Diversions
The Liaison and Diversion (L&D) programme was created in 2010 in response to the findings of the 
Bradley Report (Department of Health, 2009). L&D schemes are designed to identify, assess, screen 
and refer offenders who have mental health, learning disability, substance misuse or other vulnerabilities 
to an appropriate treatment or support service. 
Key elements of the operating model are: 
•	 an all-age service;
•	 meets a wide range of vulnerabilities;
•	 available throughout varying points of the justice pathway;
•	 provides a 24/7 service;
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•	 there is a core team who are supported by an extended team and engagement workers liaising 
between the two; and 
•	 has three distinct phases which are case identification, secondary screening/triage and assessment 
including specialist assessment
Ten trial schemes were implemented from 1 April 2014 with a further 15 schemes instigated from 1 April 
2015, taking coverage up to 50% of England. It is anticipated that full coverage will occur from 2017. 
2.4.4 Out-of-Court Disposal Pilots
The Government is piloting (in three police forces) a new out-of-court disposal framework for cannabis 
and khat possession offences, which seeks to direct users into appropriate treatment to help modify 
drug misuse behaviour. 
A community resolution replaces the existing initial warning for cannabis and khat possession offences 
and a conditional caution replaces the old Penalty Notice for Disorder (PND). The aim is for individuals to 
be referred to drug treatment workers who have a range of interventions available to them. Interventions at 
the community resolution stage are voluntary but the interventions are enforced as part of the conditional 
caution, with the individual subject to prosecution if they do not comply. 
The pilots also provide an opportunity for more effective use of disposals with a greater focus on 
rehabilitation and reduction of reoffending — they provide a wide scope to impose ‘positive conditions’ 
on a disposal. They also provide an opportunity to help to ensure that those who would benefit from 
more structured treatment would be referred on.
Prison drug treatment and reintegration of drug users after release from prison is covered in the prison 
chapter (see section 8.5.2).
Scotland
In Scotland, there are a number of interventions at different levels of the criminal justice system, including 
diversion from prosecution to drug treatment/education, community payback orders with a drug treatment 
requirement and Drug Treatment and Testing Orders (DTTOs) for particularly high tariff offenders who 
are entrenched in their drug use, as well as services for prisoners post-release, including Throughcare 
Addiction Services. DTTOs provide offenders with access to treatment services, which they are required 
to comply with, combined with regular progress reviews from the Court. A less intensive version (DTTO 
II) has been developed for lower tariff offenders and rolled out on a pilot basis in Edinburgh and the 
Lothians from June 2008, and currently accounts for about a quarter of the DTTOs in these areas.
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3. Prevalence, availability and relative importance 
of different drugs
3.1 Introduction
The principal sources of information on the prevalence of drug use in the United Kingdom (UK) are 
General Population Surveys (GPS). The Crime Survey for England and Wales (CSEW) provides estimates 
of the prevalence of drug use in the general population in England and Wales. Scotland and Northern 
Ireland also undertake similar surveys. In addition to these household surveys conducted on adults, 
there are also surveys targeted at school children which include questions on drug use. Descriptions of 
the main surveys used for monitoring the prevalence of illicit drugs in the UK can be found at the end of 
this chapter.
In England and Wales, for which the most complete time series data are available, prevalence of last year 
use of any illicit drug among the adult population had been fairly stable at around 12% between 1998 
and 2003/04, then decreasing steadily to 9.4% in 2007/08; and then falling again to 8.5% in 2009/10. 
Since then, the prevalence of last year use of any illicit drug has fluctuated between eight and nine per 
cent. GPS indicate that cannabis is the most commonly used illicit drug in the UK and it has been in 
each year that relevant surveys have been conducted. Due to its relatively high prevalence, cannabis is 
a substantial driver of overall drug trends. Cocaine is the next most commonly used drug, followed by 
ecstasy. Cocaine prevalence reported through surveys reached a peak in 2007/08 but has also since 
declined, although this has increased in the most recent surveys.
Although its use in the general population is relatively uncommon, heroin is associated with causing 
substantial health and social harms to users as well as harms to society in the form of drug-related crime 
and, as such, is of particular importance to policy makers in the UK. Around 80% of people in treatment 
for issues with drugs cite heroin as a problematic substance. 
3.2 Overview of cannabis
Cannabis is the most commonly reported drug used in GPS carried out in each country of the UK, and 
it has been in each year that any of these surveys has been conducted. Last 12 month prevalence in the 
most recent CSEW stands at 6.7%, compared with 2.3% of respondents using cocaine (the next most 
commonly reported illicit drug) (Home Office, 2015f). Use of cannabis in the general population has been 
on a long-term downward trend since 2003/04, but the trend since 2009/10 has been relatively flat. Use of 
cannabis is most common among younger respondents and the long-term downward trend is also more 
apparent among this group, with last year prevalence for 16-24 year olds decreasing from a high of 28.2% 
in 1998 to 16.3% in 2014/15. However this declining trend may be levelling out (Home Office, 2015f).
The proportion of those who reported having used cannabis in the last year having done so more than 
once a month has fallen in recent years, from 52.0% in 2009/10 to 46.0% in the last CSEW (Home 
Office, 2015f). However, this remains a very high proportion of last year users compared to other drugs 
(excluding heroin for which household survey data is not reliable). Furthermore, those using cannabis 
in the last month are more likely to have used more than once a week than users of other commonly 
reported drugs.
The greater prevalence of use of cannabis compared with other illicit drugs is also reflected in seizures 
data, with cannabis being involved in far more seizures than any other illicit drugs (see section 9.5.1). 
Despite the fall in prevalence of cannabis use since 2003/04 there has been an increase in the number of 
people accessing treatment for this drug over the same period (see section 5.4.4). There is no universally 
accepted explanation for the divergence in these trends. Rising treatment presentations may indicate a 
greater proportion of users experiencing harms from their cannabis use (potentially as result of increasing 
potency). However, this could also indicate improving treatment penetration of those cannabis users in 
need of drug treatment. 
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3.3 Overview of the most commonly used stimulants
There has been a small long-term downward trend in the overall use of any stimulant drug23 among 16-59 
year olds reported in the CSEW since the beginning of the time series, from 4.4% in 1996 to current levels 
of around 3.5%. The dip to three per cent reported in 2012/13 appears not to be reflective of the longer 
term trend (Home Office, 2015f).
Cocaine 
Powder cocaine is the most prevalent stimulant in the UK and the second most prevalent drug overall, 
with last year use reported at 2.3% in the latest CSEW (Home Office, 2015f). 
Since 2008/09, an overall fall in the prevalence of cocaine use has been reported by the CSEW among all 
ages. This appears to have been driven by lower levels of use in younger age groups, suggesting there 
were fewer initiates among this generation. However, the drop off was not seen in the 35 to 44 group; 
indeed, prevalence amongst this group has increased over the last decade to two per cent in 2014/15. 
The increasing prevalence in this age bracket may indicate that a greater proportion of people from this 
generation are continuing to use cocaine as they transition into middle age than was the case among 
those born a few years earlier.
Figure 3.1: Trends in last year cocaine use amongst under 45s in England and Wales, 2002/03 to 
2014/15, by age group
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23 ‘Any stimulant drug’ in the CSEW comprises powder cocaine, crack cocaine, ecstasy, amphetamines and amyl nitrite, 
plus methamphetamine since 2008/09 interviews and mephedrone since 2010/11 interviews.
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The proportion of last year users of cocaine who reported using in the last month in the CSEW has 
fallen each year in which the question was asked, from a high of 43.6% in 2006/07 to a record low in 
2013/14 of 13.5%.
The same level of last year cocaine use reported by the CSEW was also observed by the most recent 
survey in Scotland (2.3%) (Scottish Government, 2014b). Last year cocaine prevalence in Northern 
Ireland was slightly lower at 1.5% in 2010/11 (National Advisory Committee on Drugs (NACD) & Public 
Health Information and Research Branch (PHIRB), 2012).
Among the general population, use of powder cocaine is far more common than use of crack cocaine. 
Although crack cocaine use is relatively rare, it is associated with very problematic use and drug-related 
crime, predominantly among those also using opioids. Due to the often chaotic nature of users’ lives, it 
is likely that household surveys underestimate crack use. The last indirect estimate of problematic crack 
use in England puts the rate at 4.76 per 1000 population aged 15 to 64 years (Hay, Rael dos Santos, & 
Worsley, 2014). Cocaine (powder) is also the most seized stimulant in the UK, both in terms of number 
and quantity of seizures (see ST13). Having been 51% in 2003, the purity of domestic resale powder 
cocaine fell to 20% in 2009. However, it has risen since then and was 36% in 2014. 
Ecstasy
Ecstasy (MDMA) is the second most commonly reported stimulant from UK household surveys (for 
example, last year use was reported as 1.7% in the 2014/15 CSEW). Following a gradual decline in 
ecstasy prevalence among the general population, as reported in the CSEW, which was reflective of overall 
stimulant use, there has been a small (but not statistically significant) increase in the rate reported since 
2012/13. This increase appears far more pronounced in men aged 16 to 24 for whom the prevalence rate 
reported in 2014/15 was higher than in any year since 2001/02 and at least a clear percentage point higher 
than in the previous 10 surveys. However, these differences have not been tested for significance.
Figure 3.2: Trends in last year ecstasy use amongst all respondents and 16 to 24 year old men in 
England and Wales, 1996 to 2014/15
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
2002/0320001996 2004/05 2006/07 2008/09 2010/11 2012/13
ALL RESPONDENTS MEN 16-24
2014/15
Source: (Home Office, 2015f) 
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The proportion of last year users of ecstasy who reported using in the last month in the CSEW has fallen 
each year in which the question was asked, reaching a record low in 2013/14 of 3.8%, having been 
35.9% in 2003/04 when this was first included in the survey. There was a pronounced drop between 
2008/09 and 2009/10 from 28.0% to 12.5%. Substitution with mephedrone is one possible explanation 
for this drop; however, prevalence of mephedrone was not included in the survey until 2010/11. Findings 
from the CSEW also suggest a relatively small proportion of people who use ecstasy do so more than 
once a month (four per cent compared with 13% and 12% of cocaine and amphetamine last year users 
respectively) (Home Office, 2015f). 
The age profile for ecstasy is younger than cocaine and amphetamines. It is sold in powder/crystal form 
as well as in pills. Purity has risen in recent years, with batches of super-strength tablets causing some 
concern. After having dropped sharply to a low in 2009, deaths in England involving MDMA have risen 
in recent years to levels similar to those seen before the drop. However, aside from MDMA itself, there 
have been several deaths since 2011 resulting from overdoses of the far more toxic substances PMA 
and PMMA which are likely to have been sold to users as ecstasy.
Amphetamine 
Despite a long-term downward trend in prevalence of use of amphetamine, this remains one of the 
most commonly reported stimulants in surveys (0.6% in the last CSEW) (Home Office, 2015f). Although 
prevalence of use of amphetamine is lower than ecstasy, the overall numbers of amphetamine seizures 
in the UK are roughly twice that of ecstasy. This may indicate that amphetamine users are more likely to 
come into contact with police and/or that amphetamine users may (like crack or heroin users) be less 
well represented in household surveys than users of other drugs (Home Office, 2015f).
Mephedrone
Of all the stimulant new psychoactive substances (NPS), mephedrone is the only one to have become 
established alongside traditional substances among recreational drug users within the general 
population. Although prevalence has fallen since mephedrone was controlled in 2010, it remains at 
0.5%, having been 1.3% (akin to ecstasy) in 2010/11 (the first year for which mephedrone prevalence 
was collected on the CSEW). Like ecstasy, the age distribution of mephedrone users is younger than that 
of either cocaine or amphetamine. Almost all users of mephedrone report also having used other illicit 
drugs, suggesting that mephedrone is more likely to be used by existing users of drugs rather than new 
users being initiated into drug taking behaviour (Home Office, 2011). Use of mephedrone is of concern 
among specific groups such as injecting problematic drug users (particularly in Wales) and men who 
have sex with men (MSM) due to its association with chemsex.
Khat 
Khat became controlled as a Class C drug in June 2014. The 2014/15 CSEW reported a significant fall 
in the consumption of Khat, with 0.04% of respondents aged 15 to 59 years reporting using the drug in 
the last year compared with 0.2% in 2011/12 when Khat use was last measured by the CSEW24 (Home 
Office, 2015f).
3.4 Overview of heroin and other opioids
Heroin is the most commonly used illicit opioid in the UK. While some non-opioid drugs including 
cannabis, cocaine and ecstasy are used by a larger proportion of the population, heroin is associated 
with causing the most health and social harm to users as well as harms to society in the form of drug-
related crime. As such, heroin is of key importance to policy-makers in the UK. The misuse of opioids 
prescribed for pain–relief (e.g. tramadol and codeine) among the general population is a concern 
particularly given the increasing practice of prescribing such medicines. There is currently limited data to 
24 Khat is generally used by individuals of a specific national origin; therefore, household surveys such as the CSEW in 
their general population estimates may not adequately capture levels of use of low prevalence drugs within such a small 
subgroup of the population. 
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monitor this issue, but the UK is not considered to have a problem similar in scale to that of the USA.25 
The 2014/15 CSEW included a question for the first time on the misuse of prescription-only painkillers, 
asking respondents whether they had taken prescription-only painkillers not prescribed to them, which 
they took only for the feeling or experience it gave them. Approximately 5.4% of adults aged 16 to 59 
had misused a prescription-only painkiller not prescribed to them in the last year (Home Office, 2015f).
Medications prescribed in opioid substitution treatment (OST) are sometimes diverted from the treatment 
system and, as such, methadone and buprenorphine also form part of the range of drugs used illicitly 
by the problem opioid using population. Supervised consumption, the need for which is determined in 
accordance with clinical guidelines (Department of Health England and the devolved administrations, 
2007), was introduced in the late 1990s and is an effective way of reducing diversion (Strang, 2010). 
Given both the source of supply and the population at risk of abusing them, diverted OST medications 
may be considered an adjunctive issue to the heroin problem.
England, Scotland and Wales all commission regular indirect estimates of their problem drug using 
populations and they each include problem opioid users within their definitions. While none of the studies 
include estimates of the number of users of specific opioids, based on the methods used, the target 
populations are made up principally of current heroin users as well as former users who are successfully 
managing their problem through OST. UK Focal Point estimates there are about 370,000 problem drug 
users in the UK (see section 3.5). Due to their often chaotic lives, problem opioid users are greatly 
underrepresented in household surveys. Nevertheless, among respondents who reported having ever 
used illicit opioids in the most recent CSEW, similar numbers reported having used illicit methadone as 
reported having used heroin (both less than one per cent of respondents). It should be noted that the 
relative use of these substances among opioid users responding to the CSEW may not be reflective of 
that in the wider opioid using population (Home Office, 2015f).
Of the 50,592 Treatment Demand Indicator (TDI) cases in 2014 citing an opioid as their primary problem 
substance on entering treatment, 85% cited heroin compared with four per cent each citing one of either 
illicit methadone or buprenorphine. Of all the 100,456 TDI cases heroin was cited as a secondary drug 
in just three per cent of cases, indicating that heroin is almost always seen as the most problematic 
substance for those who use it. A further two per cent and one per cent respectively cited illicit methadone 
and illicit buprenorphine as a secondary drug. 
In terms of drug seizures, a far greater quantity of heroin is seized each year in the UK than is seized 
of other opioids (see ST13). A negligible quantity of methadone is seized by Border Force suggesting 
diversion from OST is the only significant source of illicitly used methadone in the UK.
3.5 Estimates of High Risk Drug Use
Due to the association between illicit opioid use and both individual and societal harms, estimating the 
size of the problem opioid using population is a key element of the evidence base used to formulate 
policy and inform service provision. It additionally provides a context in which to understand the 
population impact of interventions to reduce drug-related harm. Direct enumeration of those engaged 
in a largely covert activity such as the use of heroin is not possible, and household surveys such as the 
CSEW tend to underestimate numbers of those individuals whose drug use is the most problematic 
(Home Office, 2015f). However, indirect techniques can be applied to provide estimates of high risk drug 
use prevalence.
Estimates of high risk drug use (HRDU) in the UK are derived using two indirect measurement techniques: 
the capture-recapture (CRC) method; and the multiple-indicator method (MIM). Since 2006, all four UK 
administrations have published prevalence estimates to meet their policy requirements. The drugs, data 
and time periods covered by these estimates differ across the administrations. In England, estimates 
are produced for opioid and/or crack cocaine users (OCUs) (together and separately) and injecting 
among users of those drugs. In Scotland, HRDU refers to the problematic use of opioids and/or the illicit 
25 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/456464/ACMD_DISM_Interim_
Advice_-_Aug_15.pdf
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use of benzodiazepines and drug injecting. Wales have commissioned a new suite of estimates over 
11 years with an expanded scope. The last published estimates look at long duration or regular use of 
opioids, cocaine powder and/or crack cocaine. The last estimates in Northern Ireland covered 2004 and 
estimated high risk opioid and/or problem cocaine powder use.
In England, the latest national and regional estimates are for 2011/12 for OCUs, with separate estimates 
available for opioid use, crack cocaine use, and injecting drug use. It should be noted that the case 
definition focuses on the ‘use’ of opioids and/or crack cocaine rather than the ‘misuse’/addiction to 
these drugs. The estimates therefore include people using prescribed opioids such as methadone or 
buprenorphine. In Scotland, the latest national and regional estimates for problematic opioid and/or 
benzodiazepine use are for 2012/13. In Wales, local and national estimates for 2009/10 for long duration 
or regular use of heroin, other opioids, crack cocaine and/or cocaine powder were published in 2011 (UK 
Focal Point, 2012). Estimates for Northern Ireland for 2004 were published in 2006 and cover problem 
opioid and/or problem cocaine powder use (UK Focal Point, 2006).
Table 3.1: The estimated number of high risk drug users: number and rate per 1,000 population aged 
15 to 64, by country
COUNTRY ESTIMATE 95% CONFIDENCE INTERVAL RATE 95% CONFIDENCE INTERVAL
England 293,879 291,029 302,146 8.40 8.32 8.63
Scotland 59,500 57,500 61,600 16.8 16.3 17.4
Wales 30,443 23,172 38,809 15.72 11.96 20.04
Source: (Hay et al., 2014; Information Services Division, 2011; Welsh Assembly Government, 2011) 
The estimates produced by UK Focal Point relate to high risk drug use and incorporate each of the 
definitions used by the three administrations included (as listed above). Based on the 2011/12 English 
estimate (Hay et al., 2014) and the 2009/10 Scottish and Welsh estimates (Information Services Division, 
2011; Welsh Assembly Government, 2011), it is estimated that there are 371,279 (CI: 364,418 – 388,306) 
HRDUs in the UK,26 a rate of 9.16 per 1,000 population (CI: 8.99 – 9.58) aged 15-64 (Table 3.2). For 
consistency with the rest of the time–series, the original method Welsh HRDU estimates for 2009/10 
have been used.
Table 3.2 shows the HRDU estimates for Great Britain since 2007.27 The ‘year of estimate’ refers to the 
year the estimate was reported by the UK Focal Point rather than the year the estimate is for.
Between 2007 and 2009 there was an increase in HRDU in Great Britain from 399,150 (CI: 397,267 – 
420,767) to 404,876 (CI: 393,088 – 430,575), but this has since declined to the 371,279 estimated HRDU 
in 2014. This also represents a reduction in the rate per 1,000 population from 10.41 (CI: 10.36 – 10.98) in 
the 2007 estimate to 9.16 (CI: 8.99 – 9.58) in the 2014 estimate. The reduction in HRDUs in Great Britain 
has been driven by a fall in the number of opioid users.
26 Northern Ireland have been excluded due to the age of the latest estimates available
27 In 2014, the UK Focal Point revised the methodology to calculate UK estimates of HRDU. Previous UK estimates have 
taken the approach of summing published figures of both the reference population and the number of HRDUs from 
each devolved administration to arrive at a UK estimate of HRDU. These estimates were based on different years of data 
and this approach created an artificially derived UK population estimate. From 2014 onwards, population estimates that 
correspond to the latest year of HRDU estimate will be utilised when calculating a UK HRDU estimate. Furthermore, as 
opposed to summing the number of HRDU for each of the published estimates, the latest published rates of HRDU from 
each devolved administration will be applied to the most recent population estimate. This slight methodological change is 
unlikely to result in any major changes to the estimate.
 Following the UK 2011 census, the Office for National Statistics (ONS) published updated population estimates covering 
the period 2001-2010 (see: http://www.ons.gov.uk/ons/dcp171778_345500.pdf). Considering the changes to the UK HRDU 
methodology, and in turn the resulting comparability of trends, the UK Focal Point has retrospectively amended all UK HRDU 
estimates based on these refreshed population estimates with the aim of increasing comparability across years.
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Table 3.2: The estimated number of high risk drug users: number and rate per 1,000 population, aged 
15 to 64 in Great Britain, by year of estimate*  2829303132333435
YEAR OF ESTIMATE** ESTIMATE 95% CONFIDENCE INTERVAL RATE 95% CONFIDENCE INTERVAL
200728 399,150 397,267 420,767 10.41 10.36 10.98
200829 404,832 396,566 424,904 10.45 10.23 10.96
200930 404,876 393,088 430,575 10.34 10.04 11.00
201031 396,793 386,600 418,982 10.04 9.78 10.60
201132 379,953 369,114 399,647 9.54 9.27 10.04
201233 385,067 373,827 404,498 9.62 9.34 10.11
201334 378,269 370,101 395,347 9.40 9.19 9.82
201435 371,279 364,418 388,306 9.16 8.99 9.58
*Data has been revised according to new methodology and will therefore not match previous reports
**Refers to the year in which the estimate was produced rather than the year the estimate relates to
Source: ST07
3.6 Injecting drug use
There are current concerns about the changes in the patterns of psychoactive drug injection in the UK, 
in particular the increased injection of amphetamine-type stimulants and the emergence of the injection 
of NPS. This has occurred at a time when there has probably been a decline in the injection of opiates 
and of crack–cocaine in England at least. 
Data from the Unlinked Anonymous Monitoring (UAM) survey of people who inject drugs (PWID) indicates 
that the proportion of people in England, Wales and Northern Ireland reporting injecting amphetamines 
and amphetamine-type drugs as their main drug rose from 3.9% (58/1,460) in 2004 to 12% (159/1,354) 
in 2014, though opioids remained the most common main drugs injected (Figure 3.3) (Public Health 
England, 2014b).
28 2007 estimate is based on estimates of opioid and/or crack cocaine use in England for 2004/05 (Hay et al., 2006), 
and opioid and/or benzodiazepine use in Scotland, 2003 (Hay, Gannon, McKeganey, Hutchinson, & Goldberg, 2004). 
Estimates for Wales are extrapolated from the estimates for England.
29 2008 estimate is as 2007 above, except for England which refers to 2005/06 (Hay et al., 2007)
30 2009 estimate is based on estimates of opioid and/or crack cocaine use in England for 2006/07 (Hay et al., 2008), opioid 
and/or benzodiazepine use in Scotland for 2006 (Hay, Gannon, Casey, & McKeganey, 2009) and long duration or regular 
use of opioids, powder cocaine and/or crack cocaine in Wales for 2006/07 (Welsh Assembly Government, 2009).
31 2010 estimate is as 2009 above, except for England which is based on estimates of opioid and/or crack cocaine use for 
2008/09 (Hay, Gannon, Casey, & Millar, 2010).
32 2011 estimate is based on estimates of opioid and/or crack cocaine use in England for 2009/10 (Hay, Gannon, Casey, & 
Millar, 2011), opioid and/or benzodiazepines use in Scotland for 2006 (Hay et al., 2009), and long duration or regular use 
of opioids and/or crack cocaine/ cocaine powder in Wales for 2009/10 (Welsh Assembly Government, 2011).
33 2012 estimate as 2011 above, except for Scotland which is based on estimates of opioid and/or benzodiazepine misuse 
in Scotland for 2009/10 (Information Services Division, 2011).
34 2013 estimate is as 2012 above, except for England which is based on estimates of opioid and/or crack cocaine use in 
2010/11 (Hay, Rael dos Santos, & Millar, 2013).
35 2014 estimate as 2013 above, except for England which is based on estimates of opioid and/or crack cocaine use in 
England for 2011/12 (Hay et al., 2014).
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Figure 3.3: Main drug type injected among those currently* injecting psychoactive drugs in England, 
Wales and Northern Ireland: 2004 to 2014
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*Among those who had injected during the preceding 28 days.
Source: (Public Health England, Health Protection Scotland, Public Health Wales, & Public Health Agency Northern Ireland, 2015) 
There have been concerns about the emergence of the injection of NPS, particularly mephedrone 
and other synthetic cathinones. In England, Wales and Northern Ireland, 5.9% (92/1,554) of those 
participating in the UAM Survey during 2014 reported that they had injected mephedrone during the 
preceding month, and 8.9% (184/2,054) had injected this drug at some point during the preceding year 
(Public Health England et al., 2015).
In Scotland, among people who injected drugs during the last six months surveyed at services providing 
injecting equipment, heroin was the most commonly injected drug, at over 93% between 2008 and 2012. 
The proportion reporting amphetamines as their main drug of injection in the last six months was typically 
very low, and was 1.3% (23/1,800) in 2011/12. Reports of any other amphetamine-type drugs were also 
rare, with less than one per cent of respondents reporting injection of these drugs in each survey year 
(Public Health England et al., 2015).
In 2014 a section of the injecting population in the Edinburgh area began to inject ethylphenidate-based 
NPS with brand names such as Burst and Blue Stuff. Health, social care and police all reported a rapid 
increase in chaotic and aggressive behaviour. These short-acting, but intense stimulants were easily 
accessible from a number of shops across the area. From October 2014 presentations of extensive, 
necrotic-style wounds were common and over the next six months 200 individuals were infected with 
Staphylococcus aureus and Group A Streptococcus. The Group A strep was almost exclusively typed 
as M76. An incident management team has been addressing this outbreak. It is thought that the spread 
of the infection is via person-to-person contact, and not through contamination of the products, though 
this cannot be fully ruled out. The UK-wide Temporary Class Drug Order (TCDO) banning the sale and 
distribution of ethylphenidate reduced the high street access to this drug, and seems to have slowed the 
number of new infections amongst the injecting population; however many are still experiencing physical 
harms and poor mental health as a result of their polydrug use.
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There is an ongoing decline in the numbers of drug users injecting opioids and crack–cocaine in 
England (National Treatment Agency for Substance Misuse, 2010). However, opioids continue to 
be the most commonly injected drug, (see Figure 3.3) with around 70% of PWID reporting injecting 
opioids alone, a decline from the higher percentage reported before 2010 (over 80%) (Public Health 
England et al., 2015).
3.7 Image and performance enhancing drugs
In recent years there have been growing concerns related to the use of image and performance 
enhancing drugs (IPEDs). However, only limited information exists regarding the prevalence of use of 
these substances. The latest CSEW estimates that in 2014/15 prevalence among 16 to 59 year olds 
for lifetime use of anabolic steroids was 293,000 (range 242,000 – 345,000) and for use in the previous 
12 months, 73,000 (range 48,000 – 99,000). This represents approximately a nine per cent increase 
compared to the relative 2013/14 figures (Home Office, 2015j). Moreover, data from the CSEW indicates 
that lifetime prevalence of anabolic steroid use among 16 to 59 year olds has risen over time from 0.5% 
in 2004/05 to 0.9% in 2014/15, a substantial 80% increase (Home Office, 2015j). 
In July 2015 the results of the second IPED online survey were published (McVeigh, Bates, & Chandler, 
2015). One hundred and eight people from the UK took part in the survey which represents an 
emergent platform to provide evidence-based information and advice to reduce the harms associated 
with the use of IPEDs. Participants were aged between 17 and 64 years old with a mean age of 
33 years, and the vast majority of respondents reported taking IPEDs both orally and via injection 
(McVeigh et al., 2015). The most commonly used substances taken orally were anabolic steroids 
(65%); nearly two-thirds (64%) of participants had injected testosterone enanthate in the past year 
and 16% reported injecting the tanning agents melanotan I or II in the previous 12 months. The survey 
also found evidence of the concurrent use of psychoactive drugs, with 32% of participants reporting 
use of psychoactive drugs, particularly cocaine and cannabis, in the previous year (McVeigh et al., 
2015). The survey concluded that the IPED market is very dynamic and fast paced with practices and 
preferences of this population sub-group frequently changing along with the associated health risks. 
Consequently the main public health concerns for people using IPEDs remain those related to the 
risks associated with injecting practices and with transmission of blood borne viruses (BBVs) (see 
section 6.2.2). 
3.8 Drug use in the school population
Smoking, drinking and drug use amongst young people in England
Data from the Smoking, drinking and drug use among young people in England survey (SDD) showed 
that the prevalence of drug use among 11 to 15 year olds in England is continuing to decline, although 
at a slower rate than in the period between 2001 and 2010 (Fuller, 2015).
In 2014, 14.6% of pupils aged 11 to 15 years old had ever taken drugs, 10.3% had used drugs in the last 
year (recently), and 6.1% had used drugs in the last month (Table 3.3). Cannabis was the most prevalent 
drug, with 6.7% of pupils having used it in the last year. Volatile substances36 were the second highest, 
with 2.9% of pupils having used them recently. 
The proportion of pupils (aged 11 to 15) reporting use of stimulants in the last year has come down from 
6.9% in 2007 to 2.1% in 2014. The decline in prevalence rates over this period was most prominent for 
poppers which had been the most commonly reported stimulant in the SDD in 2007, with 4.9% reporting use 
in the last 12 months compared with 1.8% for cocaine (the next most prevalent stimulant) (Fuller, 2015). Only 
0.7% reported using poppers in the last 12 months in the 2014 SDD compared with 0.9% reporting cocaine.
36 Glue, gas, aerosols or solvents.
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Figure 3.4: Proportion of pupils aged 11 to 15 years who have taken drugs ever, in the last year and in 
the last month, 2001-2014
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Source: (Fuller, 2015)
Scottish Schools Adolescent Lifestyle and Substance Use Survey 
The Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) was last carried out in 
2013, and results were published in November 2014 (Information Services Division, 2014b).
The key findings were:
•	 one-fifth of 15 year olds (18%) and four per cent of 13 year olds had ever used drugs;
•	 one-sixth of 15 year olds (16%) and three per cent of 13 year olds had used drugs in the last year;
•	 cannabis was the most commonly used drug for both ages and across all recall periods;
•	 15 year old boys were more likely than girls to be recent (17% compared to 14%) and current (11% 
compared to eight per cent) drug users;
•	 at age 13, drug use was similar for boys and girls (last year use was four per cent for boys and three 
per cent for girls, and last month use was two per cent for both); and
•	 among 15 year olds, synthetic cannabinoids including Spice37 (two per cent) followed by mephedrone 
and salvia (both at one per cent) were the most commonly used NPS. 
The survey also reported that five per cent of 15 year olds reported ever using stimulants, compared 
with one per cent of 13 year olds. Cocaine and ecstasy were also the most commonly used stimulant 
drugs (two per cent in the last 12 months) by 15 year olds with a smaller proportion (one per cent or less) 
of 13 year olds using them (Information Services Division, 2014b).
37 In the SALSUS Spice was previously listed as a separate drug.
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Table 3.3: Percentage of pupils aged 11 to 15 years reporting lifetime, last year and last month use of 
individual drugs in England in 2014, by gender
 LIFETIME USE LAST YEAR USE LAST MONTH USE
 Male Female Total Male Female Total Male Female Total
Any drug 15.7 13.5 14.6 10.8 9.8 10.3 6.5 5.7 6.1
Amphetamines 1.1 0.8 0.9 0.8 0.5 0.7 0.5 0.2 0.3
Cannabis 8.8 7.2 8.0 7.2 6.2 6.7 4.4 3.4 3.9
Cocaine powder 1.3 0.8 1.0 1.1 0.6 0.9 0.6 0.2 0.4
Crack cocaine 0.5 0.4 0.5 0.3 0.3 0.3 0.3 0.2 0.2
Ecstasy 1.2 0.8 1.0 1.0 0.6 0.8 0.5 0.3 0.4
LSD 0.8 0.4 0.6 0.7 0.3 0.5 0.4 0.1 0.3
Magic mushrooms 1.2 0.7 1.0 1.1 0.5 0.8 0.5 0.2 0.4
Poppers 1.0 0.6 0.8 0.9 0.4 0.7 0.5 0.2 0.3
Mephedrone 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.3 0.4
Opioids 0.8 0.5 0.6 0.5 0.3 0.4 0.4 0.2 0.3
Volatile substances 6.8 5.9 6.4 2.8 3.0 2.9 1.5 1.7 1.6
Base 3104 3104 3104 3011 3011 3011 6115 6115 6115
Source: (Fuller, 2015) 
3.9 New psychoactive substances
Prevalence of NPS use reported in surveys is low compared to the main traditional illicit drugs in the 
UK. In the 2014/15 CSEW, 0.9% of those aged 16 to 59 said they had used NPS in the previous 12 
months and 2.9% had used NPS as some point in their lifetime (Home Office, 2015j). NPS use is higher 
in younger adults, with 2.8% of 16 to 24 year olds (174,000 people) having used NPS in the last year. 
Data from the SDD (Fuller, 2015) show that 2.5% of pupils aged 11 to 15 had used NPS at least once 
in their lifetime. In the latest SALSUS, four per cent of pupils aged 15 reported having used one or 
more NPS in their lifetime38. Among 15 year olds, the most commonly offered and used NPS were 
synthetic cannabinoids (five per cent), followed by mephedrone (three per cent) and salvia (three per 
cent) (Information Services Division, 2014b). Use of NPS, particularly synthetic cannabinoids, among the 
prison population is an area of concern (see section 8.7.1).
3.10 Sources of information on the prevalence of drugs
Below are descriptions of the main surveys used for monitoring trends in the prevalence of drug use in 
the UK.
The Crime Survey for England and Wales
The CSEW (formerly the British Crime Survey) is an annual survey which gathers information about 
experience of crime in England and Wales. It is designed to provide a complementary measure of crime 
to police recorded crime statistics. It was first carried out in 1982, and since 2001/02 it has been a 
continuous survey. Since 1996, it has also asked respondents aged 16 to 59 about their use of illicit 
38 The NPS reported in the SALSUS 2013 are: GHB/GBL, mephedrone, salvia, synthetic cannabinoids (including Spice), and 
powders and/or pills that are sold as ‘legal highs’.
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drugs in a self-completion module using Computer Assisted Self Interviewing (CASI). Since 2009 there 
has been an additional survey element covering 10 to 15 year olds’ experience of crime. This includes 
questions on drinking and cannabis use but the main focus is on victimisation. The annual school 
surveys are the main source of data on drug use among children.
The Scottish Crime and Justice Survey
The Scottish Crime and Justice Survey (SCJS) (previously the Scottish Crime and Victimisation Survey 
(SCVS) and the Scottish Crime Survey) is similar in scope and aims to the CSEW, although questions 
on drug use are asked of all respondents aged 16 years and over. The latest published results are for 
2012/13. Surveys were carried out as part of the former British Crime Survey (BCS) in 1982 and 1988; as 
the independent Scottish Crime Survey in 1993, 1996, 2000, 2003; as the SCVS in 2004, 2006; and as 
the SCJS in 2008/09, 2009/10, 2010/11 and 2012/13. The survey asks questions about drug use using 
Computer Assisted Personal Interviewing (CAPI).
The Northern Ireland Crime Survey
The Northern Ireland Crime Survey (NICS) is also similar to the CSEW. Surveys containing a drug use 
module were carried out in 1994/95, 1998, 2001 and 2003/04 and the survey became continuous from 
January 2005. However, after March 2009 the drugs module was no longer included, hence the last 
published results on drug use were for 2008/09. In addition, a Drug Prevalence Survey, based on the 
EMCDDA model questionnaire, was carried out in Northern Ireland (and Ireland) in 2002/03, 2006/07 and 
2010/11 among people aged 15 to 64 years old using CAPI.
Smoking, Drinking and Drug Use among Young People in England
The SDD is carried out by NatCen Social Research and the National Foundation for Educational Research 
(NFER) on behalf of the Health and Social Care Information Centre (HSCIC). It is an annual survey and 
provides national estimates and information on the smoking, drinking and drug use behaviours of young 
people aged 11-15 (it is carried out by pupils in years 7-11).
In England each year around one in ten secondary schools are randomly selected to take part in the 
survey. Different schools are chosen each year and schools are never asked to take part two years in a 
row. Around 35 pupils from each school are randomly selected to take part anonymously to the survey. 
The survey provides information on: 
•	 prevalence of smoking, drinking and drug taking among school children;
•	 the number of pupils who have never smoked, drunk alcohol or taken drugs;
•	 types of alcohol and drugs taken;
•	 how often pupils smoke, drink and take drugs;
•	 where pupils obtain cigarettes, alcoholic drinks and drugs;
•	 pupils’ attitudes to these behaviours; and
•	 predictors of the likelihood of smoking, drinking and drug use among school children.
Scottish Schools Adolescent Lifestyle and Substance Use Survey
The latest SALSUS report was published in November 2014. The research was commissioned by the 
Scottish Government and undertaken by NHS Information Services (ISD Scotland), National Services 
Scotland and Ipsos MORI Scotland. It is a biennial survey and provides estimates and information on the 
smoking, drinking and drug use behaviours of young people aged 13 and 15. 
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The survey provides information on:
•	 prevalence and trends in smoking, drinking and drug use among young people at Scotland level; 
•	 disaggregated data at Alcohol and Drug Partnership (ADP), Local Authority and NHS Board level; 
•	 patterns of behaviour in relation to smoking, drinking and drug use; 
•	 sources of cigarettes, alcohol and drugs; 
•	 pupils’ attitudes to substance use; 
•	 the attitudes of families and friends to substance use; and 
•	 contextual information on the relationship between substance use and other lifestyle, health and 
social factors.
The Young Persons’ Behaviour and Attitudes Survey
The Young Persons’ Behaviour and Attitudes Survey was undertaken in Northern Ireland in 2000 for the 
first time and repeated in 2003, 2007, 2010 and 2013. 
Health Behaviour in School Age Children Survey
The Health Behaviour in School Age Children Survey (HBSC) provides data from Wales and is 
undertaken every four years with a two-year interim survey. The most recently published survey results 
are for 2009/10. Fieldwork for the 2013/14 survey has been carried out with results expected in 2014/15.
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4. Prevention
4.1 Introduction
Reducing drug misuse is a key part of the United Kingdom (UK) Government’s 2010 Drug Strategy 
which is aimed at ‘creating an environment where the vast majority of people who have never taken 
drugs continue to resist any pressures to do so, and making it easier for those that do to stop’ (Her 
Majesty’s Government, 2010) (see section 1.2.1). The ‘Reducing Demand’ strand of the 2010 strategy 
has recently been refreshed and now mixes universal actions aimed at all young people with targeted 
actions for those most at risk of using drugs or who have already started using drugs, and tackles the 
range of risk factors that make people vulnerable to substance misuse. This includes investing in a range 
of evidence-based programmes, which have a positive impact on young people and adults, giving them 
the confidence, resilience and risk management skills to resist drug use. 
Since the late 1990s, many prevention programmes have been evaluated in the UK showing that the 
impact of drug education alone is unlikely to prevent young people from using drugs. It has been 
demonstrated that ‘scare’ approaches are likely to be ineffective, if not counterproductive. However, if 
drug education is delivered as part of a more holistic approach it can contribute towards a decrease in 
harmful behaviours, and increase safety for young people, their families and communities. Therefore, 
in recent years the focus of prevention policy has shifted away from interventions aimed specifically 
at drugs to strengthening general resilience factors associated with the aim of reducing the desire to 
explore risky behaviours including drug use (Faggiano, Minozzi, Versino, & Buscemi, 2014; James, 
2011; UK Drug Policy Commission, 2012). A stronger emphasis has also been put on the importance 
of parents/carers and family influence on children’s substance misuse and associated behaviours, and 
how early-life intervention, which should include prenatal family support, can reduce risk factors and 
strengthen the associated protective factors. Such intervention can include parenting skills education, 
support for families from pregnancy such as the Family Nurse Partnership, and parent and family skills 
training such as the Strengthening Families Programme (UK Focal Point, 2014).
The recent report by the Advisory Council on the Misuse of Drugs (ACMD), Prevention of drug and 
alcohol dependence (Advisory Council on the Misuse of Drugs, 2015b), highlighted a range of effective 
and ineffective practice in preventing substance misuse. There has also been a shift in how drug 
education and prevention programmes aimed at young people have been delivered. Early prevention 
strategies focused on approaches that provide information on the consequences of engaging in risky 
behaviour, usually targeting individual risky behaviour such as smoking, alcohol consumption, risky 
sexual behaviour, and drug use. Such approaches are based on the hypothesis that young people 
do not have a clear understanding of the potential consequences involved in participating in risky 
behaviour, and providing them with this information would make such behaviour less appealing. Often 
the information was provided using a passive form of learning, with very little or no participation from the 
targeted audience. 
More recent education and prevention programmes also take into account the concept that young 
people’s behaviour is affected by the perceived behaviour of their peers, in particular their tendency 
to overestimate the prevalence of risky behaviours amongst their peers. Therefore, providing them 
with information about the real prevalence of such risky behaviours might reduce their participation 
in such actions (such as the ‘Social norm’ approach (Chowdry, Kelly, & Rasul, 2013)). Some of these 
programmes tend to focus on relationships between individual behaviours and a range of social and 
environmental influences they are subject to, and the inter-relationship between individual behaviours 
as ‘lifestyles’, putting an emphasis on the need to communicate effectively with young people through 
a range of networks (such as web-based activity) and through the media, as well as through traditional 
school health education. These approaches have increasingly used social marketing methodologies, 
which advocate an integrated ‘whole person’ approach, to disseminate their message and to support 
behaviour change in young people, as well as in older groups (Andreasen, 2002).
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Similar approaches to prevention are adopted by the devolved administrations; in Wales through Rights of 
Children and Young Persons (Wales) Measure 2011 (Welsh Government, 2011). The Welsh Government 
in the Working Together to Reduce Harm Substance Misuse Strategy Annual Report — 2014 (Welsh 
Government, 2014c) also emphasised the importance of delivering prevention messages within the 
workplace and that the early identification of young people at risk of engaging in risky behaviours can be 
an important aspect of prevention. The Getting It Right For Every Child (GIRFEC) programme39 provides 
the methodology for delivering the Scottish Government’s three social policy frameworks: the Early Years 
Framework; Achieving our Potential; and Equally Well (Scottish Government, 2008a), which aim to 
develop the prevention and early intervention agenda. More recently updated practice guidance, Getting 
Our Priorities Right, was developed in Scotland for agencies and practitioners working with children, 
young people and families affected by substance use (Scottish Government, 2013). This built on original 
guidance produced in 2003 (Scottish Government, 2006). In Northern Ireland, Our Children and Young 
People – Our Pledge: A 10 year strategy for children and young people in Northern Ireland, 2006-2016 
(Office of the First Minister and Deputy First Minister for Northern Ireland, 2006) sets a framework for 
addressing the needs of young people. Improved education and early interventions for young people and 
families (especially those most at risk) and improved public information about drugs are priority areas.
4.2 Environmental prevention
Environmental prevention strategies aim to alter the immediate cultural, social, physical and economic 
environments in which people make their choices about drug use.
4.2.1 Alcohol and tobacco policies in the United Kingdom
Across the UK there are a number of policies and strategy documents concerned with licit substances 
such as tobacco and alcohol. In Wales and Northern Ireland there are global strategies covering both 
illicit and licit substances.
Minimum unit pricing
Minimum unit pricing in Scotland, Northern Ireland and Wales
In 2009 the Sheffield Alcohol Research Group (SARG) at Sheffield University developed the Sheffield 
Alcohol Policy Model (SAPM) to evaluate the possible impact of alcohol policies (including different 
levels of Minimum Unit Pricing (MUP)) on the English population (Purshouse et al., 2009). Since then, 
the SAPM has been adapted to a range of international settings including Scotland, Wales and Northern 
Ireland (Angus, Scafato, et al., 2014; Hill-McManus et al, 2012; Meng, Brennan, & Meier, 2012). 
Scotland
The Alcohol (Minimum Pricing) (Scotland) Bill was passed on 24th May 2012. The Bill received Royal 
Assent and became the Alcohol (Minimum Pricing) (Scotland) Act 2012 on 29 June 2012.40 The 
Scotch Whisky Association (SWA) (in conjunction with the European Spirits Organisation and the 
Comitée Européen Des Entreprises Vins) sought a judicial review of this Act; this was held in January 
2013, and found comprehensively in favour of the policy. The SWA et al. appealed that decision and 
following a hearing in February 2014 the case was referred to the Court of Justice of the European 
Union (CJEU) to clarify points of European Union (EU) law. On 3 September 2015 the Advocate 
General of the European Court of Justice stated that in their opinion the Scotland’s Alcohol Minimum 
Unit Price (MUP) legislation does not contravene European law.41 Following this deliberation, the case 
will return to the domestic court to make its judgement in light of the CJEU’s ruling. 
39 See: http://www.scotland.gov.uk/Topics/People/Young-People/gettingitright/publications/practice-guide 
40 See: http://www.legislation.gov.uk/asp/2012/4/contents/enacted 
41 See: http://curia.europa.eu/juris/document/document.jsf?text=&docid=166846&pageIndex=0&doclang=en&mode=req
&dir=&occ=first&part=1&cid=203295 
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Table 4.1: United Kingdom strategy documents for alcohol, tobacco and illicit drugs
COUNTRY 
SUBSTANCE(S) 
COVERED
REFERENCE 
UK/England
Illicit drugs
The Drug Strategy 2010, ‘Reducing demand, restricting supply, building recovery: supporting 
people to live a drug-free life’ (Her Majesty’s Government, 2010)
Alcohol The Government’s Alcohol Strategy (Her Majesty’s Government, 2012a)
England Tobacco
Healthy Lives, Healthy People: A Tobacco Control Plan for England (Her Majesty’s 
Government, 2011a)
Wales
Illicit drugs 
and alcohol
Working Together to Reduce Harm. The Substance Misuse Strategy for Wales 2008-2018 
(Welsh Assembly Government, 2008b)
Working together to reduce harm. Substance misuse delivery plan 2013-2015 (Welsh 
Government, 2013)
Tobacco Tobacco Control Action Plan for Wales (Welsh Government, 2012) 
Scotland
Illicit drugs
Road to Recovery: A New Approach to Tackling Scotland’s Drug Problem (Scottish 
Government, 2008c)
Alcohol
Changing Scotland’s Relationship with Alcohol: A Framework for Action (Scottish 
Government, 2009a)
Changing Scotland’s Relationship with Alcohol: A Framework for Action — Progress Report 
(Government, 2012) 
Tobacco Scotland’s Future is Smoke Free: A Smoking Prevention Action Plan (Scottish Government, 2008d)
Northern 
Ireland
Illicit drugs 
and alcohol
New Strategic Direction for Alcohol and Drugs Phase 2 2011-2016. A Framework for Reducing 
Alcohol and Drug-Related Harm in Northern Ireland (Department of Health Social Services and 
Public Safety Northern Ireland, 2011a)
Tobacco
Ten-Year Tobacco Control Strategy of Northern Ireland (Department of Health Social Services and 
Public Safety Northern Ireland, 2012)
Northern Ireland
In 2013, the Department of Health, Social Services and Public Safety (DHSSPS) and the Department 
for Social Development commissioned SARG to adapt the Sheffield Model to Northern Ireland (Angus, 
Meng, Ally, Holmes, & Brennan, 2014). The study modelled the potential impact of a range of MUP 
policies from 35-75 pence per unit of alcohol over a 20 year period. The study also separately modelled 
the impact of bans on below-cost selling and on price-based promotions in the off-licensed trade. The 
study concluded that MUP would be effective in reducing alcohol consumption, alcohol-related harms 
and the costs associated with them. It was estimated that the ban on below-cost42 selling would have 
almost no impact on the population’s alcohol consumption and spending or on alcohol-related harms. 
However, a ban on price-based promotions in the off-licensed trade, either alone or in conjunction with 
a MUP policy, would be effective in reducing alcohol consumption, related harms and associated costs. 
Following from the evidence provided by this study, in December 2014 the Northern Ireland Health 
Minister announced the intention to develop a policy to introduce MUP in Northern Ireland. A consultation 
paper is under development. 
42 Below-cost selling refers to a ban on selling any alcoholic drinks for below the cost of duty plus the VAT payable on the duty.
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Wales
In 2014 SARG was commissioned by the Welsh Government to adapt the Sheffield Model to the Welsh 
population and a report was published later in the year (Angus, Meng, et al., 2014). The Welsh analysis 
also modelled the possible impact of MUP policies ranging from 35-70p per unit of alcohol over a 20 
year period. The study also looked at the estimated impact of a ban on below-cost selling. Analogous 
conclusions to those obtained by the application of SAPM to NI were found when the model was applied 
to Wales. However, the Welsh study did not look at the estimated impact of a ban on price-based 
promotions in the off-licensed trade.
The draft Public Health (Minimum Price for Alcohol) (Wales) Bill43 was launched for consultation on 
15 July 2015 and proposes:
•	 a formula for calculating the MUP using the Alcohol by Volume (ABV) measure;
•	 powers for Welsh Ministers to make subordinate legislation to set the MUP for alcohol sold or 
supplied in Wales;
•	 a duty on local authorities (LAs) to appoint authorised officers (AOs) to enforce the MUP and powers 
to prosecute; and 
•	 a duty on LAs to enforce the MUP, including provision for powers of entry for AOs, an offence of 
obstructing an AO, and the power to issue fixed penalty notices
The consultation ran until 11 December 2015.
Drink and drug driving legislation
England and Wales
In March 2015 levels for the maximum blood concentration allowed for a selection of legal and illicit 
drugs for drivers was introduced in England and Wales. Limits are specified for eight illicit drugs such 
as cannabis, heroin and cocaine,44 and eight medicines that are sometimes abused (the limits for these 
compounds are higher to reflect their medical use)45 (see section 2.2.1).
Scotland 
In December 2014 the legal blood alcohol limit for drivers in Scotland was reduced from 80mg in every 
100ml of blood, to 50mg in every 100ml of blood, aligning Scotland with most other European countries.
Northern Ireland
Plans to tackle drink driving, including new lower legal blood alcohol limits, graduated penalties and 
increased police enforcement powers, are included in a Bill currently being considered by the Northern 
Ireland Assembly.46 Subject to approvals, the current prescribed alcohol limit will be reduced from 80mg 
in 100ml of blood to 50mg for most drivers and 20mg for new and professional drivers, and may be in 
place by mid–2016. Given that alcohol remains a more significant issue than drugs in terms of road 
casualties, the priority has been to update drink drive legislation. The effects of the new drug driving 
legislation in England and Wales — and the progress of convictions before the courts under the new 
law — will be monitored before advancing any legislative change in this area.
43 See: http://gov.wales/docs/dhss/consultation/150715consultationen.pdf 
44 List of illicit drugs and limits in the new legislation: benzoylecgonine (a cocaine metabolite), 50µg/L; cocaine, 10µg/L; 
cannabis, 2µg/L; ketamine, 20µg/L; LSD, 1µg/L; methylamphetamine, 10µg/L; MDMA, 10µg/L and heroin, 5µg/L.
45  List of medicines and limits in the new legislation: clonazepam, 50µg/L; diazepam, 550µg/L; flunitrazepam, 300µg/L; 
lorazepam, 100µg/L; methadone, 500µg/L; morphine, 80µg/L; oxazepam, 300µg/L; and temazepam, 1,000µg/L.
46 See: http://www.niassembly.gov.uk/globalassets/Documents/RaISe/Publications/2014/general/7214.pdf
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Standardised packaging of tobacco
In January 2015 the Government announced that it would support the introduction of standardised 
packaging for tobacco products. In March, both Houses of Parliament approved the regulations. The policy 
will cover cigarettes and hand rolling tobacco, and is due to take effect on 20 May 2016 to coincide with the 
implementation of the revised EU Tobacco Products Directive (Official Journal of the European Union, 2014).
E-cigarettes
In the UK, from May 2016 all e-cigarettes and e-liquids will either meet the provisions of the Tobacco 
Products Directive (TPD) (40/2014/EU) or be licensed as a medicine or medicinal device by the 
Medicines and Healthcare Products Regulatory Agency (MHRA). In areas outside of the harmonised 
rules set out in the TPD the countries of the UK may, within the scope of their devolved powers, make 
their own policy on e-cigarettes. 
England 
On 1 October 2015 the Nicotine Inhaling Products (Age of Sale and Proxy Purchasing) Regulations 
2015 came into force in England and Wales, banning the sale of e-cigarettes to under–18s and the 
purchase of e-cigarettes by adults on their behalf. In August 2015, Public Health England (PHE) 
published a comprehensive independent review of the latest evidence on e-cigarettes. The expert 
review synthesises the international peer–PHE-reviewed evidence base on ecigarettes (Public Health 
England, 2015c). It provides a firm foundation for further policy development and public health practice 
in the context of the new regulatory regime for e-cigarettes. In spring 2016 PHE will publish non-binding 
guidance for employers and other authorities on the use of e-cigarettes in enclosed public places and 
workplaces, designed to maximise the health benefits while minimising the harm in any particular setting.
Wales
In June 2015 the Welsh Government announced their Public Health (Wales) Bill,47 which details a 
series of specific proposals in priority areas of public health policy, including policies on tobacco and 
nicotine products.
The new tobacco and e-cigarette measures introduced by the Bill will: 
•	 restrict use of e-cigarettes, banning them in enclosed public spaces and workplaces; 
•	 require sellers to join a register for retailers of tobacco and e-cigarettes; and
•	 be an offence to “hand over” tobacco and e-cigarettes products to people under the age of 18
The Bill is expected to come into force in 2017.
Scotland
In June 2015, the Scottish Government introduced the Health (Tobacco, Nicotine Etc. and Care) 
(Scotland) Bill.48 Alongside the Scottish Government‘s latest Tobacco Control Strategy, this Bill supports 
the Scottish Government‘s objective to support longer, healthier lives and to tackle the significant 
inequalities in Scottish society. It will do this in the main by restricting the accessibility of Nicotine Vapour 
Products to young people; reducing their visibility and appeal to young people and non-smokers; 
reinforcing the age restriction on tobacco products to further protect young people; and introducing 
statutory smoke-free perimeters around buildings on National Health Service (NHS) hospital sites.
47 See: http://www.assembly.wales/laid%20documents/pri-ld10224/pri-ld10224-e.pdf 
48 See: http://www.scottish.parliament.uk/S4_Bills/Health%20Tobacco%20Nicotine%20etc.%20and%20Care%20
Scotland%20Bill/b73s4-introd.pdf
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Smoking in private vehicles carrying children.
In October 2015 a new law was introduced in England and Wales that prohibits smoking in private 
vehicles carrying passengers less than 18 years of age (Her Majesty’s Government, 2015c). 
Scotland
On 15 December 2014, Jim Hume, Member of the Scottish Parliament (MSP) and Liberal Democrat 
Spokesperson, introduced his Private Member’s Bill on smoking in cars. The Smoking Prohibition 
(Children in Motor Vehicles) (Scotland) Bill proposes to prohibit adults from smoking in private vehicles 
in a public place where a person under the age of 18 is present in the vehicle.
Blanket ban on new psychoactive substances
The UK Government is proposing a Bill for a blanket ban of new psychoactive substances (NPS) in the 
UK, with the aim of prohibiting and disrupting the production, distribution, sale and supply of NPS in the 
country (see section 2.2.3). 
4.3 Universal prevention
Universal prevention targets the entire population, regardless of individual levels of risk, with programmes, 
initiatives and messages aimed at preventing or delaying the onset of illicit drug use. 
4.3.1 Schools and young people
England
Universal drug education is included in the national curriculum in England, where it is a statutory part of 
the science curriculum for schools and can be expanded through the non-statutory Personal, Social and 
Health Education (PSHE) programme (Department for Education, 2013).49 In 2013, Ofsted50 published a 
report evaluating the strengths and weaknesses of PSHE education in primary and secondary schools in 
England (Ofsted, 2013). The report concluded that in 40% of the schools examined, the PSHE curriculum 
required improvement or was inadequate, and many teachers did not have sufficient experience and 
training on drug education.
To address Ofsted’s concerns and provide practical support and guidance to schools in 2014 the Alcohol 
and Drug Education and Prevention Information Service (ADEPIS) published a set of evidence-based 
quality standards covering the delivery of alcohol and drug education within the classroom (Alcohol and 
Drug Education and Prevention Information Services, 2014; UK Focal Point, 2014).
Alcohol and Drug Prevention Briefing Paper
As part of a series of briefing papers for alcohol and drug education and prevention for teachers and 
practitioners, Mentor ADEPIS has published a new document that looks at how building resilience in 
young people can prevent substance abuse. It also tries to define resilience and why it is important, 
explores the ways that these concepts can be translated into practice (giving evidence and examples) 
and what roles schools and other education settings have in building resilience.51
49 The National Institute for Health and Care Excellence (NICE) provided evidence to the Department for Education for 
a review of PSHE. The evidence emphasised that effective programmes of alcohol and drug education contribute to 
reducing the risks associated with alcohol or drug use.
50 Office for Standards in Education, Children’s Services and Skills (Ofsted) is a non-ministerial department responsible to 
regulate and inspect services that care for children and young people, and services providing education and skills for 
learners of all ages. 
51 See: http://mentor-adepis.org/wp-content/uploads/2015/03/Building-resilience-and-character-in-young-people-ADEPIS.pdf 
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Rise Above
In November 2014 PHE lunched Rise Above, an interactive online resource where young people can 
find material aimed at encouraging them to talk about important issues in their life (UK Focal Point, 
2014). This service was activated in February 2015. The website not only provides information but 
also supports a range of situational tools and skills-based resources. It aims to build young people’s 
resilience and empower them to make positive choices for their health (including areas such as drugs, 
alcohol, smoking, body confidence, relationships and exam stress).
PHE has also developed its role in supporting local areas by sharing evidence to support commissioning 
and the delivery of effective public health prevention activities, and launching toolkits to support local 
areas’ responses on specific issues around NPS and other drug groups.
Scotland
In Scotland, education has developed to encapsulate broader life-learning for children and young people 
through the Curriculum for Excellence52 where traditional education is integrated with wider life-learning 
for three to 18 year olds. In the Curriculum for Excellence, learning in health and well-being is designed 
to promote confidence, independent thinking and positive attitudes. This learning helps enable children 
and young people to become resilient to risk taking behaviours, and understand the wider impacts of 
staying safe and making positive choices
Choices For Life
The Scottish Government funds Choices For Life,53 a diversionary and educational substance use 
initiative delivered by Police Scotland in partnership with Young Scot and Education Scotland. This 
tobacco, alcohol and drugs education programme for schoolchildren includes an information website 
for young people and their teachers, parents and carers. The newly revised Choices for Life website was 
fully integrated into the Young Scot website in May 2015. The digital aspect of the programme also uses 
social media platforms that young people are likely to use themselves including Twitter, YouTube, and a 
dedicated Choices for Life phone application.
The programme of work also includes a series of targeted community events delivered in conjunction 
with local partners to engage young people directly at the local level, interactive digital resources, and a 
summer festival safety campaign. The community events are aimed at local areas of need identified in 
each community, and are delivered via face-to-face events. Evaluation and feedback is sought from the 
events, and this learning is shared at a national level. 
A short interactive film has been launched by Choices for Life to educate teenagers on the dangers of 
NPS and alcohol.54 This new resource was produced in collaboration by Pace Media Productions, Police 
Scotland, Young Scot and the Scottish Government. The short film has an interactive element that allows 
the viewer to play the part of the main character and make decisions along the way, which will lead to 
further choices and an ultimate outcome. This increases the value of the film by offering the viewer the 
option to look at various outcomes of taking drugs, alcohol, or tobacco. Other issues can be drawn 
out, including parental relationships and sexual assault. These all help demonstrate that no single issue 
exists in a vacuum.
52 See: http://www.educationscotland.gov.uk/thecurriculum/whatiscurriculumforexcellence/index.asp 
53 See: http://choicesforlifeonline.org/ 
54 See: http://www.scotland.police.uk/whats-happening/news/2015/may/288264 
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Wales
In Wales, in line with the goal laid out by the Working Together to Reduce Harm: The Substance Misuse 
Strategy for Wales 2008-18 (Welsh Assembly Government, 2008a), the All Wales School Liaison Core 
Programme has been developed to deliver drugs education in primary and secondary schools.55 In the 
last year, the Steroids and Image Enhancing Drugs Educational Toolkit for young people (11-16 years) 
has been developed and issued for all schools and youth groups across Wales.56 
Northern Ireland
The school curriculum places a specific focus on the development of relevant “life skills” among pupils. 
In particular, through Personal Development and Mutual Understanding (PDMU)57 in primary schools, 
pupils are provided with opportunities to develop strategies and skills for keeping themselves healthy and 
safe. Post-primary school pupils, through Learning for Life and Work,58 are provided with opportunities 
to investigate the effects on the body of legal and illicit substances and the risks and consequences of 
their misuse.
During the 2014/15 financial year the Council for Curriculum, Examinations and Assessment (CCEA) 
progressed work to update CCEA/Department of Education guidance on drugs and alcohol. The new 
guidance was published on the CCEA website in August 201559 and it is also available via the C2k 
information and communications technology (ICT) Managed Service and the Department of Education 
(DENI) website.60
4.3.2 Family
England 
The Early Intervention approaches are activities that are designed to influence a child’s environment in 
early life, and prevent future adverse outcomes such as drug use. Programmes such as the Family Nurse 
Partnership61 have been introduced by the Government to help families create a healthy environment for 
their children. Early interventions are not directly targeted at drug use, but are part of a holistic approach, 
which recognises that broader social, health and behaviour approaches are needed for effective drug 
prevention programmes.
4.3.3 Community
Prevention of drug and alcohol dependence
In 2015 the ACMD Recovery Committee published a document aimed at supporting policy-makers 
and practitioners working in prevention as well as providing recommendations (Advisory Council on 
the Misuse of Drugs, 2015b). It outlines the evidence available for substance misuse prevention, and 
points out effective prevention interventions, recognising that there is still little clear evidence on ‘what 
works’ in drug prevention, but acknowledging that in recent years there has been an increase in the 
quality of evidence generated. The report outlines a number of promising approaches that are likely 
to be beneficial if correctly implemented. The paper concludes with a set of recommendations aimed 
at those working in the prevention field and authorities commissioning prevention programmes. The 
ACMD recommends that: practitioners should be encouraged to use a common language to help make 
55 The All Wales School Liaison Core Programme (AWSLCP) is jointly funded by the Welsh Government and the four Welsh 
police forces and targets pupils aged between five and 16. See: https://www.schoolbeat.org/en/parents/know-the-
programme/national-events/what-is-the-all-wales-school-liaison-core-programme/ 
56 See: http://www.wales.nhs.uk/sitesplus/documents/888/SIEDS%20Toolkit%20English.pdf
57 See: http://ccea.org.uk/curriculum/key_stage_1_2/areas_learning/personal_development_mutual_understanding 
58 See: http://www.rewardinglearning.org.uk/microsites/llw/
59 See: http://ccea.org.uk/curriculum/drugs_guidance 
60 See: https://www.deni.gov.uk/articles/drugs-guidance#toc-1
61 The Family Nurse Partnership provides support to young families (less than 19 years old) from pregnancy until the baby 
reaches two years of age, with structured home visits by trained nurses (see: http://fnp.nhs.uk/).
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prevention strategies more coherent; authorities commissioning prevention programmes should see 
drug and substance use prevention as part of a more general strategy involving all aspects of clients’ 
lives; an evaluation (including an economical evaluation) should be part of all UK prevention projects; 
and policy makers should acknowledge that prevention projects are justified on the basis of reducing 
long-term and meaningful adverse health and social outcomes even without drug abstention.
Sources of support and information about drugs
There are several universal prevention communication programmes in the UK. 
England
•	 ‘Talk to FRANK’.62 The FRANK campaign was launched in 2003 jointly funded by the Home Office 
and Department of Health, and supported by PHE. It provides information about drugs to young 
people (under 16s) and their families, as well as a 24 hour information and helpline service operated 
by fully trained advisers. The service can be accessed through a number of channels including the 
helpline, the FRANK website, SMS, email and the FRANK BOT (an interactive service delivered via 
MSN messenger). 
•	 PHE launched a new online resilience building resource ‘Rise Above’; which is aimed at 11-16 year-
olds and provides resources to help develop their skills to make positive choices for their health and 
well-being, including resisting drug use (see section 4.3.1).
Scotland
•	 ‘Know the Score’63 provides factual information and advice to young people, their families and 
professionals. It is supported by the Scottish Government and provides a 24 hour online information 
service, and a telephone helpline on drugs information and advice from 8am to 11pm, 7 days a week.
•	 The Scottish Government provides a significant package of funding to its main commissioned 
organisations that contribute to the delivery of the drug strategy, The Road to Recovery (Scottish 
Government, 2008c).
•	 The Scottish Government funds the ‘Choices for Life’ schools-based substance misuse education 
programme, delivered in partnership with Young Scot and Police Scotland. This drugs, alcohol 
and tobacco education programme for school children, includes an information website for young 
people and their parents, teachers and carers, as well as a series of community events to engage 
young people directly and provide credible information to help them make the right health choices. 
Northern Ireland
•	 In Northern Ireland, the Public Health Agency64 develops public information campaigns for various 
target groups and settings. In addition, Northern Ireland contributes to the telephone helpline 
element of the FRANK campaign. 
Wales
•	 ‘Dan 24/7’65 is a bilingual (Welsh and English) 24 hour information and telephone helpline service, 
which frequently runs targeted campaigns. It is hosted by the Betsi Cadwaladr University Health 
Board with funding provided by the Welsh Government. The helpline is aimed at assisting individuals, 
their families, carers, and support workers within the drug and alcohol field to access appropriate 
local and regional services.
62 See: http://www.talktofrank.com/ 
63 See: http://knowthescore.info/ 
64 See: http://www.publichealth.hscni.net/ 
65 See: http://www.dan247.org.uk 
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4.4 Selective prevention in at-risk groups and settings
Selective prevention initiatives target subsets of the total population that are deemed to be at greater risk 
of substance misuse or risky behaviour such as truants or young offenders.
4.4.1 Young people 
Substance misuse services for young people
Specialist substance misuse treatment for young people is recognised as a form of prevention in the 
UK, as it aims to stop drug and alcohol use escalating, to reduce harm to young people or others, and 
to prevent them becoming drug or alcohol-dependent adults. The Young People’s Statistics from the 
National Drug Treatment Monitoring System (NDTMS) showed that in 2013/14 19,126 young people 
(under 18 years) accessed specialist substance misuse services, with the majority having presented with 
cannabis (71%) or alcohol (20%) as their primary problem substance (Public Health England, 2014g).
Young people with multiple vulnerabilities
Young people presenting to specialist substance misuse services frequently have multiple vulnerability 
factors such as being a looked after child, having a history of self-harm or offending behaviour. The Young 
People’s Statistics from NDTMS identify 10 of these vulnerability factors.66 Of the 7,965 new presentations 
in 2013/14, 59% had two or more of these vulnerability factors (Public Health England, 2014g).
Northern Ireland
A range of specialist services are commissioned for children and young people in Northern Ireland. 
The Drug Treatment Database shows that in 2013/14 175 under 18s were in treatment for drug misuse 
in Northern Ireland – around seven per cent of all those in treatment (Department of Health, Social 
Services and Public Safety Northern Ireland, 2015). 
New Psychoactive Substances (NPS) Resource pack for informal educators and practitioners
A group of experienced practitioners from Mentor UK, DrugScope, local youth and drug treatment 
services and Youth Offending Teams have developed for the Home Office a resource pack for formal 
and informal educators who work with young people in specialist and targeted services such as youth 
services, drug treatment services or youth offending teams.67 This pack aims to provide information 
on the current knowledge around NPS, interventions available and approaches that will support them 
to respond to the risks that these substances can play in the lives of young people. Even though this 
resource is targeted at NPS, the information provided can be similarly applied to all drug taking behaviour, 
and discussion about NPS should form part of a broader conversation about drug use in general.
66  The 10 vulnerability factors are: a young person
 – began using primary substance aged under 15; 
 – reports involvement in offending behaviour; 
 – reports self-harming; 
 – is a looked after child (LAC); 
 – reports using opioids and/or crack; 
 – is not in education or employment; 
 – reports unsettled accommodation status or has no fixed abode (NFA); 
 – reports using two or more drugs in combination (polydrug use); 
 – is pregnant or a parent; and 
 – reports almost daily drinking or drinking in excess of eight units (males) or six units (females) on an average drinking 
day when drinking 13 or more days of the month
67 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412168/150311_Psychoactive-
drugs11-colour_18-33-44_-_1_.pdf
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4.4.2 At-risk families
Troubled families
The first Troubled Families Programme was launched in 2012 and aimed to turn around the lives of 
120,000 troubled families across England by May 2015. Delivery of the Troubled Families programme was 
unprecedented for an initiative of its kind in the UK in terms of the scale and pace required. Families taken 
on to the programme have multiple problems: children not in school; children committing crime; anti-
social behaviour; parents not working; and other high cost problems, such as drug abuse and domestic 
violence. As well as the cost to family members themselves, these families place a substantial burden 
on the public purse. It was estimated that £9 billion every year was being spent on services for troubled 
families, with £8 billion of that money being spent just reacting to their problems (Communities and Local 
Government, 2012). Despite this expenditure, services may struggle to get to the root of the families’ 
problems if they are only seeing individual family members and their problems in isolation. The Troubled 
Families Programme advocates key workers working with the whole family tackling all of their problems, 
with services working together in the best interests of the whole family (UK Focal Point, 2012, 2013).
In 2013 the Government announced an expansion of the Troubled Families programme to reach up 
to an additional 400,000 families from 2015/16. The new programme retains the focus on families with 
multiple high cost problems and continues to include families affected by poor school attendance, youth 
crime, anti-social behaviour and unemployment. It also seeks to reach out to families with a broader 
range of problems including children in need, adults facing financial exclusion or young people at risk of 
worklessness, families affected by domestic violence and abuse, and parents or children with a range 
of health problems. LAs can claim results’ payments for families in their local programme when they 
can demonstrate that a parent has moved into continuous employment or that significant and sustained 
progress across all the families’ problems has been achieved. This will be assessed against locally set 
outcome measures. The broadening of the eligibility criteria and the ability for local areas to determine 
their own outcomes measures provides greater flexibility to LAs, enabling them to tailor the programme 
to meet local needs. The programme promotes the integration of local public services around the needs 
of families. It has a strong focus on service transformation, incentivising local public services to reduce 
demand on costly reactive services for the long term (e.g. reducing child protection levels, police call 
outs and Accident and Emergency pressures).
Family Drug and Alcohol Court
Family Drug and Alcohol Courts (FDACs) are specialised courts designed to work with parents who 
abuse substances and are involved with the child welfare system. They aim to improve children’s 
outcomes by addressing their parents’ difficulties, and parents and children are able to remain together 
safely during the court proceeding. The courts are able to make quick alternative placement decisions 
for the child if parents are unable to successfully address their substance misuse problems. They have 
been adapted to the English legal system from a model of Family Treatment Drug Courts (FTDCs) which 
has been widely used in the USA (Worcel, Furrer, Green, Burrus, & Finigan, 2008). Key differences 
between FDAC and standard care proceedings are that a dedicated judge will usually preside over all 
hearings in a given case and families are supported by a multi-disciplinary specialist support team, which 
reports back to the judge on progress. There are FDACs in London, Gloucestershire, Milton Keynes and 
Buckinghamshire. In February 2015, the then coalition government announced that they supported the 
expansion of FDACs to new areas across the country (Whitehead, 2014).
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4.4.3 Other at-risk groups
The Mental Health Taskforce
The Mental Health Taskforce was formed in March 2015, and is constituted of health and care leaders 
and experts in the field plus service users. Its aim is to develop a five year national strategy for mental 
health, covering services for all ages.
The strategy will include: prevention; first contact with services; diagnosis; treatment; optimising quality 
of life; and support for those living with complex and long term mental health conditions (including 
dementia) as well as addressing equality and human rights issues related to mental health. The strategy 
will also include recommendations on the mechanisms and data required for its implementation and on 
how to monitor the delivery of its outcomes (ensuring that priorities, costs and benefits within the strategy 
are assessed).68
68 See: http://www.england.nhs.uk/mentalhealth/taskforce/ 
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5. Drug-related treatment: treatment demand and 
availability 
5.1 Introduction
United Kingdom (UK) drug strategies identify treatment as being effective in tackling problem drug use 
and seek to improve its quality and effectiveness. Drug Misuse and Dependence: UK Guidelines on 
Clinical Management (Department of Health England and the devolved administrations, 2007) continues 
to provide guidance for clinicians delivering drug treatment in the UK, although updated guidelines are 
currently in development. The National Institute for Health and Care Excellence (NICE)69 also provides 
guidance on a number of drug-treatment related topics, and these are reviewed and updated regularly 
based on the latest evidence. Co-ordination and integration across a range of service providers is seen 
as key in helping problem drug users reintegrate into society, and all recent UK drug strategies focus 
on this area. While providing treatment remains a priority, housing, employment, education and training 
have also been identified as important, with the most recent drug strategies having a much stronger 
focus on recovery and reintegration.
Treatment interventions in any given area are expected to include advice and information, care planning, 
psychosocial interventions, community prescribing, inpatient drug treatment and residential rehabilitation. 
In addition, drug misusers should be offered relapse-prevention and aftercare programmes; hepatitis B 
vaccinations; testing for hepatitis B and C and HIV; access to hepatitis and HIV treatment; and needle 
exchange. Oral opioid substitution treatment (OST) with methadone is the most common pharmacological 
treatment used in treating heroin addiction. Buprenorphine can also be prescribed, and injectable opioids, 
such as injectable methadone and injectable diamorphine, are also available but are not commonly used. 
Naltrexone70 is recommended as a treatment option to prevent relapse in detoxified formerly opioid-
dependent people who are highly motivated to remain in an abstinence-based programme.
Treatment Demand Indicator (TDI) data on numbers presenting to treatment are from four separate 
systems: the National Drug Treatment Monitoring System (NDTMS) in England; the Scottish Drug Misuse 
Database (SDMD); the Welsh National Database for Substance Misuse (WNDSM); and the Northern 
Ireland Drug Misuse Database (NIDMD). Data from the four systems are combined into UK totals for 
reporting to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Continuous 
national data are available from 2003/04.
5.2 Policy, strategy and quality assurance
5.2.1 Strategy and policy
Main treatment priorities in the national drug strategy
The UK Drug Strategy, Reducing demand, restricting supply, building recovery: supporting people 
to live a drug free life (Her Majesty’s Government, 2010) emphasises supporting those who are drug 
dependent to achieve recovery, and the provision of the integrated support necessary to enable this (see 
section 1.2.1).
The ‘building recovery’ strand of the strategy includes a number of objectives relating to treatment. 
These include: 
•	 ensuring that all those on a substitute prescription engage in recovery activities;
•	 supporting services to work with individuals to draw on a client’s “recovery capital”;
69 Formerly the National Institute for Health and Clinical Excellence.
70 A drug that blocks the effects of opioids and alcohol.
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•	 commissioning drug treatment and recovery services which are locally led, transparent about 
performance and delivered in line with best practice; 
•	 launching Public Health England (PHE) whose role is to support local authorities (LAs) on 
commissioning services most suitable for their area and population;
•	 encouraging local areas to jointly commission services to deliver “end to end” support;
•	 enabling people to successfully reintegrate into their communities following treatment by tackling 
housing needs and helping them find sustained employment; and 
•	 launching six Payment by Results (PbR) pilots to investigate affordability and value for money in 
drugs recovery for adults
Progress has been made towards each of these objectives and new priorities were cited in the 2015 
annual review of the drug strategy. These include: 
•	 evaluation of the PbR pilots;
•	 amend medicines regulations to allow for the wider distribution of naloxone (see section 2.2.1); and 
•	 implement a new drug appointment licence condition that can require prisoners to attend 
appointments at treatment services in the community upon release (see section 8.7.3)
Public Health Outcomes Framework England
The Public Health Outcomes Framework (PHOF)71 (Department of Health, 2012) sets out the Secretary 
of State’s strategic direction in meeting two high level objectives:
•	 to increase healthy life expectancy; and
•	 to reduce differences in life expectancy and healthy life expectancy between communities
This includes indicators which are explicitly related to drugs; the main one being successful completion 
of treatment for opioid and non-opioid users who do not return within six months.
Scotland
The concept of recovery and supporting people to live a drug-free life as active and engaged members 
of society is central to the Scottish Government’s drug strategy, The Road to Recovery: A new approach 
to tackling Scotland’s drug problem (Scottish Government, 2008c) (see section 1.2.1). 
The key treatment-related priorities of the strategy are:
•	 to see more people recover from problem drug use so that they can live longer, healthier lives, 
realising their potential and making a positive contribution to society and the economy; and
•	 improving the effectiveness of delivery at a national and local level
The Scottish Government has developed a Recovery Outcomes Web (ROW) tool for use by local services 
to record and monitor people affected by problem drug and alcohol use. This is an independently 
validated, peer-reviewed tool which has been developed through consultation with Alcohol and Drug 
Partnerships (ADPs), drug and alcohol frontline staff, managers, service users and research groups.
71 See: http://www.phoutcomes.info/ 
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The key aim of the tool is to measure changes in a person’s life as a result of an intervention received 
when they access specialist support from drug and/or alcohol services in Scotland. This tool will help 
to provide a better understanding of an individual’s recovery journey, related needs and motivation for 
change. Secondary benefits of the outcomes measurement tool are to inform workforce development, 
service improvement and future service provision for managers, ADPs, funding bodies and the Scottish 
Government. The ROW tool will be built into Scotland’s new integrated Drug and Alcohol Information 
System (DAISy) which is expected to go live in autumn 2016. 
Wales
The Welsh Government’s drug strategy, Working together to reduce harms 2008-2018 (Welsh Assembly 
Government, 2008a) predominantly focuses on reducing the harms associated with substance misuse 
(see section 1.2.1). Their treatment-related objectives include:
•	 improving the availability of treatment services and related support;
•	 making better use of resources — utilising evidence based decision making, improving treatment 
outcomes and developing the skills of those working in the treatment sector and promoting joined 
up working across agencies; and 
•	 developing user-focused services
The strategy has been accompanied by shorter term implementation plans which outline performance 
measures for each of the key action areas, including supporting substance misusers to improve their 
health and to aid and maintain recovery. 
A Recovery Framework was launched in February 2014,72 which is supported by the Recovery Group 
for Wales. Two courses have been designed by partner organisations in the Recovery Group for Wales 
to facilitate this process, namely: Embracing Recovery and Recovery Framework: Theory to Practice. 
The main priority of the Recovery Group for Wales is to ensure the principles of the framework are 
embedded throughout Wales. Establishing recovery-oriented systems of care; peer-led recovery 
community support; and implementing best practice across Wales continue to be prioritised. 
Northern Ireland 
The current Northern Ireland (NI) strategy, New Strategic Direction for Alcohol and Drugs (NSD) Phase 
2, 2011-2016 (Department of Health Social Services and Public Safety Northern Ireland, 2011b) has a 
number of treatment-related priorities including: 
•	 developing a regional commissioning framework for treatment;
•	 targeting those at risk and vulnerable; and 
•	 workforce development
5.2.2 Quality Standards
The Care Quality Commission 
The Care Quality Commission (CQC) is an independent body charged with monitoring, inspecting and 
regulating health and social care services in England. In July 2015 the CQC launched an inspection 
handbook for service providers.73 This was developed after a series of pilots conducted in early 2015 
and details how inspections will be planned and arranged, what evidence will be gathered and through 
what means, and how services will be judged and rated, as well as the potential outcomes, including the 
consequences and enforcements for those rated ‘requires improvement’ or ‘inadequate’.
72 See: http://gov.wales/topics/people-and-communities/communities/safety/substancemisuse/policy/
treatmentframework/?lang=en 
73 See: http://www.cqc.org.uk/content/provider-handbooks?page=1
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Scotland 
Local Delivery Plans
The Local Delivery Plan (LDP) Standard (formerly Health Improvement, Efficiency and Access Treatment 
(HEAT) Standard) for drug and alcohol treatment waiting times expects that 90% of people receive access 
to appropriate drug and/or alcohol treatment within three weeks of referral to support their recovery 
(Information Services Division, 2015a). Getting people into treatment quickly for drug-related problems 
is a priority for the Scottish Government, as evidence suggests this is likely to result in improved client 
outcomes. The HEAT Standard was initially introduced as a target and had been exceeded by March 
2013. It then became a HEAT Standard for 2013/14 and beyond. 
Data is published on a quarterly basis at national, Health Board and ADP level. The most recent statistics, 
published in June 2015, indicate that in January – March 2015, 95% of the 11,114 people who started 
their first drug or alcohol treatment waited three weeks or less (LDP Standard) (Scottish Government, 
2015a). This ambitious Standard therefore continues to be exceeded at national level.
For drug treatment, 94.1% of the 4,136 people who attended an appointment for drug treatment between 
January and March 2015 waited three weeks or less, a slight increase from 93.7% in the previous quarter.
For alcohol treatment, 95.5% of the 6,978 people who started alcohol treatment between January and 
March 2015 waited three weeks or less, a slight decrease from 95.7% in the previous quarter.
5.2.3 Guidelines for treatment
In September 2007 the Drug Misuse and Dependence: UK Guidelines on Clinical Management 
(Department of Health England and the devolved administrations, 2007) were published, to be used as 
a guide by all clinicians working in drug misuse treatment, particularly those providing pharmacological 
interventions.
The guidelines include the following key principles underlying appropriate care of drug misusers:
•	 drug misusers have the same entitlement as other patients to the services provided by the National 
Health Service (NHS);
•	 the General Medical Council’s statement that: “The investigations or treatment you provide or 
arrange must be based on the assessment you and the patient make of their needs and priorities, 
and on your clinical judgement about the likely effectiveness of the treatment options. You must 
not refuse or delay treatment because you believe that a patient’s actions have contributed to their 
condition. You must treat your patients with respect whatever their life choices and beliefs”;
•	 it is the responsibility of general practitioners to provide general medical services for drug misusers. 
Health Authorities, Primary Care Trusts in England, local health boards in Wales and health boards in 
NI and Scotland all have a duty to provide treatment for drug misusers, to meet local population needs. 
This should include interventions to reduce drug-related harm, such as hepatitis B vaccinations and 
needle exchange provision, together with evidence-based drug treatment;
•	 every doctor must provide medical care to a standard which could reasonably be expected of a 
clinician in his or her position. An increasing number of clinicians are trained and supported to 
provide drug treatment under the terms of a contract negotiated with their local commissioners; and
•	 the focus for the clinician treating a drug misuser is on patients themselves. However, the impact 
of their drug misuse on other individuals and on communities should be taken into consideration.
In 2014 PHE, on behalf of the departments of health in England, Scotland, Wales and Northern Ireland, 
held a consultation regarding whether these guidelines could benefit from being updated, despite much 
United Kingdom Drug Situation 2015 edition Page 79
of the content remaining current.74 The majority of responses received to the consultation, through focus 
groups and in writing, were in favour of an update, and consequently a review of the evidence is currently 
being conducted. Updated guidelines are expected to be published in early 2016. 
NICE have produced a range of guidelines, technical appraisals and pathways relating to best practice and 
standards of care in the treatment of substance misuse. Interventional procedures apply to all countries of 
the UK. Clinical guidelines and technology appraisals apply to those using the NHS in England and Wales 
only and are usually disseminated after local review in Northern Ireland. Public health guidance applies to 
those using the NHS in England only and is often disseminated after local review in other UK countries.75
The key NICE guidelines76 relating to substance misuse treatment are: 
•	 CG51 (2007) Drug misuse — psychosocial interventions (National Institute for Health and Care 
Excellence, 2007b);
•	 CG52 (2007) Drug misuse — opioid detoxification (National Institute for Health and Care 
Excellence, 2007a); 
•	 CG120 (2011) Psychosis with coexisting substance misuse: Assessment and management in adults 
and young people (National Institute for Health and Care Excellence, 2011); 
•	 PH4 (2007): Interventions to reduce substance misuse among vulnerable young people (National 
Institute for Health and Care Excellence, 2007c); 
•	 PH52 (2014): Needles and syringe programmes (National Institute for Health and Care 
Excellence, 2014b); 
•	 PH49 (2014) Behaviour change: individual approaches (National Institute for Health and Care 
Excellence, 2014a); 
•	 QS23 (2012) Drug use disorders (National Institute for Health and Care Excellence, 2012); and 
•	 TA114 (2007) Methadone and buprenorphine for the management of opioid dependence (National 
Institute for Health and Care Excellence, 2007d)
Turning Evidence into Practice
Throughout 2014 and 2015 PHE has issued a series of briefings entitled Turning Evidence into Practice,77 
which provide advice to commissioners and services on a range of topics including:
•	 helping service users to access and engage with mutual aid;
•	 helping service users to engage with treatment and stay the course;
•	 biological testing in drug and alcohol treatment;
•	 optimising OST; 
•	 preventing drug-related deaths;
•	 improving hepatitis C treatment; and
•	 image and performance enhancing drugs
74 See: https://www.gov.uk/government/consultations/drug-misuse-and-dependence-uk-guidelines-on-clinical-management 
75 See: https://www.nice.org.uk/about/what-we-do
76 See: www.nice.org.uk 
77 See: http://www.nta.nhs.uk/2015.aspx
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All of these briefings are drawn from published evidence, guidance and expert consensus and provide 
both an overview of the topic as well as prompts for commissioning effective services. 
Project NEPTUNE
The Novel Psychoactive Treatment UK Network (NEPTUNE),78 an independent charity funded by the 
Health Foundation, conducted a systematic review of the evidence on club drugs,79 focusing particularly 
on their acute and long-term harms and convened a group of UK experts to provide clinical consensus 
on their treatment. This evidence was then used to develop Guidance on the clinical management of 
acute and chronic harms of club drugs and novel psychoactive substances (Abdulrahim & Bowden-
Jones, 2015), which was published in March 2015.80 
The guidance is aimed specifically at clinicians in specialist drug treatment services, hospital emergency 
departments, general practice/primary care and sexual health clinics. It is designed to increase the 
confidence and skills of clinicians in the detection and identification of club drugs and new psychoactive 
substances (NPS). 
New psychoactive substances toolkit
In November 2014, PHE published a toolkit81 to help LAs and NHS England respond to NPS use and 
associated problems in their area. The toolkit provided advice, resources and points for consideration 
across multiple factors including tackling supply and use, prevention, NPS interventions and treatment, 
NPS in prisons and competence in working with NPS users. 
5.2.4 Evaluations and reviews
Advisory Council on the Misuse of Drugs review of opioid substitution therapy
In 2014 the Inter-Ministerial Group on Drugs commissioned the Advisory Council on the Misuse of Drugs 
(ACMD) to investigate: 
•	 whether or not evidence supported the case for time limiting OST;
•	 if so what would a suitable time period be and what would be the risks and the benefits; and
•	 if time limiting OST is not supported, how can OST be optimised to maximise recovery outcomes 
for service users
The ACMD produced two reports in response to the commission. The first, published in November 2014 
(Advisory Council on the Misuse of Drugs, 2015a), concluded that time limiting OST could result in:
•	 the majority of clients relapsing in to heroin use; and
•	 significant unintended consequences such as increases in drug-driven crime, heroin overdose 
deaths and spread of blood-borne viruses (BBVs)
It is also possible that such a restriction could be subject to medico-legal challenges.
The second paper, published in October 2015, made six recommendations for how OST can be 
optimised. These are:
78 See: http://neptune-clinical-guidance.co.uk/
79 The term ‘club drugs’ is used here to refer to a group of psychoactive substances typically used in dance venues, house 
parties, music festivals and sometimes in a sexual context 
80 See: http://neptune-clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf
81 See: http://www.nta.nhs.uk/uploads/nps-a-toolkit-for-substance-misuse-commissioners.pdf
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•	 the Government and LAs should protect the investment in recovery-oriented drug treatment and 
recovery systems;
•	 LAs should strive for a culture of stability and quality improvement in drug treatment;
•	 the Government should implement a national quality improvement programme for recovery-oriented 
OST and ensure implementation of evidence-based practice;
•	 LAs should ensure all local drug treatment and recovery systems have enough community and 
residential abstinence pathways and ongoing recovery support;
•	 discrimination and stigmatising of those in medication assisted recovery should be tackled at all 
levels; and 
•	 further research should be undertaken to build the UK research evidence on recovery-oriented 
treatment and interventions for heroin users
5.3 Organisation and provision of drug treatment
5.3.1 Outpatient drug treatment system
Main providers
In the UK, community-based specialised drug treatment centres are the most common providers of 
substance misuse services. Specialist services account for 89% of community-based treatment units 
reporting to the NDTMS in England (n= 906). General Practitioners (GPs) prescribing OST medications 
in a shared care arrangement report to NDTMS through the specialist service providing the shared 
care component. Some GPs prescribing in isolation do not report to NDTMS, so there is some under 
reporting. As such, the number of ‘General/Mental health care’ services is underreported in ST24.
Specialised drug treatment centres are predominantly public services, commissioned and funded by 
local government. The contracts to deliver drug treatment services commissioned by LAs are often 
held by third sector organisations (i.e. registered charities). Some of these organisations (such as 
Addaction82) specialise solely in substance misuse, whilst others (for example, Turning Point83) deliver 
contracts for Mental Health services and services for people with learning disabilities. Specialist drug 
treatment services are also provided in the NHS by Mental Health Trusts.
Low-threshold agencies 
TDI data is not supplied for low-threshold services in the UK. However, there are various services 
providing such interventions including Criminal Justice Intervention Teams (CJITs) and Liaison and 
Diversion services84 (see sections 2.4.2 and 2.4.3 respectively); needle and syringe programmes (NSP) 
(see section 6.6.1); and information, advice and harms reduction services.
Prisons
There are 141 prisons across the UK (123 in England and Wales, 15 in Scotland and three in Northern 
Ireland). The majority of prisons offer some form of treatment for substance misuse. However, prison 
drug treatment reporting is not yet fully integrated with community datasets and, at present, only NI 
prison treatment data is included in TDI figures. The 2014/15 Her Majesty’s Inspector of Prisons survey 
reported that 28% of male and 41% of female new arrivals at prison stated they had substance misuse 
needs (Her Majesty’s Inspectorate of Prisons, 2015). The provision of treatment in prisons is covered in 
section 8.5.2.
82 See: http://www.addaction.org.uk/ 
83 See: http://www.turning-point.co.uk/ 
84 See: http://www.england.nhs.uk/wp-content/uploads/2014/04/ld-op-mod-1314.pdf
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Client utilisation
Almost all clients treated in the UK receive treatment in a community setting, including some who receive 
treatment in the community before or after attending a residential unit. The treatment system in the UK 
was greatly expanded during the early 2000s in order to address the demand for services following 
the heroin epidemic of the 1990s. The majority of clients accessing the treatment system in the UK 
(both outpatient and inpatient) cite heroin as a problematic drug (see ST34). Comparisons with Problem 
Drug Use estimates suggest that in England around 56%85 of the problem opioid and/or crack using 
population access community treatment services. Other commonly cited substances include cannabis 
and cocaine.
5.3.2 Inpatient drug treatment system
Main providers
Inpatient and residential facilities account for 11% of all substance misuse treatment units in England. 
Inpatient units provide assessment, stabilisation and/or assisted withdrawal with 24-hour cover from 
a multidisciplinary clinical team who have had specialist training in managing addictive behaviours. In 
addition, the clinical lead in such a service comes from a consultant in addiction psychiatry or another 
substance misuse medical specialist. The multi-disciplinary team may include psychologists, nurses, 
occupational therapists, pharmacists and social workers. Inpatient units are for those alcohol or drug 
users whose needs require supervision in a controlled medical environment. These units are often based 
within hospitals but can also be attached to residential rehabilitation services, or may be standalone. 
Inpatient detoxification interventions may also be delivered on a general ward within a hospital. 
Residential rehabilitation services are primarily run by voluntary and private sector organisations. 
They offer structured programmes that may include psychosocial interventions, individual and group 
therapy, education and training, and social and domestic skills. There is a broad range of different types 
of residential rehabilitation available, and services differ widely in terms of their philosophy, intensity, 
inclusion criteria, programme content and duration. 
In early 2014, PHE conducted a survey of both providers of residential rehabilitation and substance 
misuse commissioners in England, in part to assess the impact of changes to the commissioning 
structure that occurred in April 2013 (Public Health England, 2014d). Nearly three quarters (70%) of 
providers stated that adult social care was their largest funding source. Other sources of funding 
reported by providers included the public health grant (42%), local authority supporting people funding 
(20%) and private clients (50%). 
The commissioning of inpatient services in NI was reviewed and revised in 2014 and the new regionally 
networked and managed system has been embedded during 2015.
Another non-hospital based residential setting in the UK is a recovery house. A recovery house is a 
residential living environment, in which integrated peer support and/or integrated recovery support 
interventions are provided for residents who were previously, or are currently, engaged in treatment to 
overcome their drug and alcohol dependence. The residences are also referred to as dry-houses, third-
stage accommodation or quasi-residential.
85 Based on latest available estimates for prevalence of opioid use and/or crack cocaine use: 293,879 from 2011/12 
(Hay et al., 2014)
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Client utilisation 
The proportion of the overall treatment population who receive treatment in inpatient/residential settings 
is low compared to those who receive it on an outpatient basis. In England, 1.6% of the total treatment 
population were reported as having been treated in an inpatient unit and 1.3% in a residential service or 
recovery house (with some clients having been treated in both). It should be noted that residential services 
in England are not required to report treatment information on private clients to NDTMS, and as a result 
the number of clients treated in residential settings is underreported in TDI and other treatment statistics. 
The average cost of inpatient treatment is £158.36 daily compared with £99.57 for residential 
rehabilitation.86 Given that the average time spent in residential rehabilitation is 13 weeks, this equates 
to an average of £9,000 for every treatment episode commissioned by local authorities. As such, clients 
accessing rehabilitation will usually be required to meet certain admission criteria including:
•	 being abstinent from drugs and alcohol following detoxification; 
•	 a commitment to becoming substance free; 
•	 a desire to leave treatment; and 
•	 having been assessed as capable of achieving abstinence and prepared to do so
Clients are usually also required to complete a period of community treatment prior to rehabilitation and 
may return to community services for further support after exiting inpatient facilities. 
The NICE clinical guideline CG51 (2007)87 recommended that residential rehabilitation be used for the 
“most complex users”. As such, clients accessing residential rehabilitation will usually have: 
•	 not benefited from previous community-based psychosocial treatment; 
•	 longer and more entrenched drug and alcohol misusing careers; 
•	 a range of problem substances; 
•	 more significant housing problems; and
•	 co-morbid physical and/or mental health problems
In addition, residential rehabilitations treat a higher proportion of clients who are: 
•	 using both heroin and crack; 
•	 injecting drugs;
•	 polydrug users; and
•	 offenders
In 2013/14 in England 3,935 clients accessed support through residential rehabilitation, as reported by 
the NDTMS (Public Health England, 2014d). Clients in residential rehabilitation consistently made up 
about two per cent of all those reported as being in drug treatment.
86 Based on the New Economy Unit Cost Database, see: http://neweconomymanchester.com/stories/832-unit_cost_database 
87 See: https://www.nice.org.uk/guidance/cg51/chapter/1-Guidance
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5.4 Access to treatment
5.4.1 Changes to the Treatment Demand Indicator and reporting 
The TDI records the number of clients presenting to a treatment centre in a particular year, but does 
not provide information on clients who remain in treatment without starting a new treatment episode.88 
Data presented are from the NDTMS in England, the SDMD in Scotland, the WNDSM89 in Wales and 
the NIDMD in Northern Ireland. Data are presented for the UK as a whole unless otherwise stated.90 
Continuous national data are available from 2003/04.
From the reporting year 2014, the UK has changed the period it reports from financial to calendar year 
primarily to align with other European Union (EU) member states91, and the TDI methodology underwent 
significant change.92 Due to changes in the TDI protocol, data for 2013 and 2014 calendar years are not 
directly comparable to previous national reports. 
In 2014, 100,456 clients presented to treatment in the UK.93 Similarly to previous years, 76.3% were male 
and 35.5% had never received treatment previously.
5.4.2 Treatment centres
A total of 1,104 treatment centres reported through national treatment monitoring systems in the UK 
during 2014. Of these, 81% provided outpatient services (n= 894), 10.5% provided inpatient services 
(n= 116) and 6.3% were general practitioner (GP) services (n= 70).
Table 5.1 shows that 86% of all clients presenting to drug treatment in the UK during 2014 were treated in 
outpatient centres. Opioid users make up a larger proportion of clients within inpatient and GP services 
than within outpatient services.
5.4.3 Characteristics of treated clients
The following data outlines the characteristics of clients seeking treatment in the UK and is based on 
data from ST34 and TDI.
Source of referral
As in previous years, the most common source of referral amongst clients starting a new episode of 
treatment in 2014 was self-referral (40.0%), with referral from the criminal justice system (CJS) the next 
most common referral source (26.3%). Despite the association between opioid use and crime, the 
proportion of opioid clients referred to treatment through the CJS was about the same as the proportion 
of cannabis users (27.9% and 26.3% respectively).
Those presenting to treatment for the first time were more likely to have been referred by a GP than those 
previously receiving treatment (9.3% and 6.3% respectively). Those who had previously received treatment 
were more likely to have a criminal justice referral than first ever treatments (28.7% and 22.2% respectively).
88 See: http://www.emcdda.europa.eu/html.cfm/index65315EN.html 
89 Data from Wales include less structured treatments
90 Percentages quoted are valid percentages
91 Northern Ireland and Scotland continue to report financial year
92 See: http://www.emcdda.europa.eu/publications/manuals/tdi-protocol-3.0 
93 Excluding Greater Glasgow and Clyde and Tayside
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Table 5.1: Primary drug by centre type in the United Kingdom, 2014
DRUG OUTPATIENTS INPATIENTS GP* OTHER TOTAL
 n % n % n % n % n %
Amphetamines 2,509 2.9 31 2.2 30 1.5 1 0.08 2,673 2.8
Benzodiazepines 1,164 1.3 45 3.2 123 6.0 231 18.3 2,102 2.2
Cannabis 23,260 26.9 64 4.6 133 6.5 598 47.5 25,278 26.0
Cocaine† 8,521 9.9 110 7.9 58 2.8 154 12.2 9,154 9.4
Crack cocaine 2,865 3.3 118 8.5 53 2.6 0 0 3,082 3.2
Opioids 44,439 51.4 984 70.5 1,553 75.9 262 20.8 50,592 52.1
Other 3,715 4.3 44 3.2 95 4.6 14 1.1 4,187 4.3
Sub Total 86,473 100 1,396 100 2,045 100 1,260 100 97,068 100
Not Known 154  5  5  0  3,388  
Total 86,627 86.2 1,401 1.4 2,050 2.0 1,260 1.3 100,456 100
*data are for England only
†includes cocaine powder and cocaine unspecified
Source: ST34
Primary drugs used
In 2014, around half of all treatment presentations in the UK were for primary opioid use (52.1%), with just 
over one quarter (26.0%) for primary cannabis use. However, the pattern is markedly different between 
those who report that they have been previously treated and those who do not, with cannabis being 
the most frequently reported primary drug amongst first ever presentations (46.6% compared to 14.8% 
of those reporting previous treatment). Almost one-quarter (23.2%) of new treatment presentations 
reported primary opioid use, compared to over two-thirds (68.0%) of previously treated clients. This is 
indicative of heroin clients being more likely to drop out of treatment and to subsequently re-present, or 
to relapse after completing a treatment episode and to seek treatment again as a result. 
In 2013/14 in England 79% of clients in contact with treatment services were using opioids, a substantially 
higher proportion than the 52.1% of treatment entrants who cited this. This difference in proportions is 
largely due to opioid clients typically spending longer in treatment than those presenting with other drugs.
Conversely, cannabis clients accounted for just nine per cent of clients in treatment in England in 2013/14 
but 26% of treatment entrants. This is explained by the relatively short time cannabis clients spend in 
treatment, leading to a higher turnover of clients when compared to those accessing support for opioid use.
Whilst new treatment entrants were more than twice as likely to report a primary substance of powder 
cocaine when compared to previously treated clients (13.7% and 6.4% respectively), they were less 
likely to report a primary substance of crack cocaine (2.2% and 3.8% respectively) indicating that crack 
users are also more likely to have multiple episodes. First time treatment entrants were also more likely to 
report the primary use of stimulants other than cocaine (7.2%), and benzodiazepines (2.9%), compared 
to those who had been previously treated (3.9% and 1.7% respectively).
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Secondary substances
Crack cocaine
The number of primary heroin clients entering treatment reporting secondary use of crack cocaine has 
been increasing since 2003/04, and in 2014 accounted for 41.1% of all primary heroin presentations (a 
rise from 37.9% in 2013). In 2013/14 almost one-third (32%) of clients in treatment in England were opioid 
and crack users (Public Health England, 2014a).
Alcohol
Primary powder cocaine clients were most likely to report secondary alcohol problems (40.2% of all 
clients). Other frequent secondary citations of alcohol occurred alongside cannabis (30.9%) and crack 
cocaine (30.6%). Overall, 21.7% of all clients presenting to treatment in 2014 reported a secondary 
alcohol problem.
The proportion of primary heroin presentations reporting a problem with alcohol increased from 8.9% in 
2007/08 to 15.6% in 2013 where it has remained stable, accounting for 15.5% in 2014. It is uncertain if 
this reflects an increase in prevalence of alcohol problems amongst this group or whether it is due to an 
increased awareness of the importance of alcohol issues amongst treatment providers and a change 
in recording practices. Given the prevalence of secondary alcohol problems amongst the general 
treatment population, and that research evidence that suggests higher levels of alcohol problems 
amongst methadone users than the treatment data suggests (33%) (Sebanjo, Wolff, & Marshall, 2007), 
alcohol problems may be under-reported amongst this group.
Benzodiazepines
The number of presentations to treatment in the UK in 2014 reporting a secondary benzodiazepine 
problem (n= 6,033) was over two and a half times greater than the number of presentations reporting a 
primary benzodiazepine problem (n= 2,102). A large percentage of primary benzodiazepine users also 
reported secondary problems with other drugs; cannabis being the most frequently reported secondary 
drug (22.0% of primary benzodiazepine users, n= 444). A large number of primary benzodiazepine 
users also cited problems with alcohol (11.2%; n= 227).
Age
The mean age of treatment presentations in 2014 was 31.9 years (+/- 10.7 years). However, those who 
had never previously received treatment tended to be younger (27.5 years +/- 11.4 years). Of all clients 
accessing treatment, males tended to be older than females (32.2 years +/- 10.7 years and 31.1 years 
+/- 10.9 years respectively), but the ages across genders were more similar in new treatment entrants 
(27.5 years +/- 11.1 years in males and 27.6 years +/- 12.2 years in females). 
Of all clients accessing treatment in 2014, those accessing treatment for heroin, crack cocaine and 
benzodiazepines tended to be older (36.1 years +/- 8.3 years, 36.6 years +/- 9.3 years and 36.3 years 
+/- 13.2 years, respectively) than those accessing treatment for cannabis, MDMA and volatile substances 
(23.3 years +/- 10.7 years, 22.2 years +/- 7.7 years and 23.6 years +/- 12.4 years, respectively). This 
pattern was seen irrespective of gender or treatment history. 
Since 2003/04 the percentage of primary heroin users entering treatment who are over the age of 
40 years has more than trebled, increasing from 10% to 32.5% in 2014; this is reflective of the static 
population of an ageing cohort.
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Age of first use
Among all those entering treatment, the average age of first use of a drug was 20.2 years (+/- 7.9 years). 
This was similar for males (20.0 years +/- 7.7 years) and females (20.6 years +/- 8.4 years), and was 
also similar among those who were new to treatment as well as those who had previously received 
treatment. In general, the age of first use of cannabis and volatile substances was lower than for other 
drugs (14.6 years +/- 4.1 years and 16.1 years +/- 7.7 years for all those in treatment). This was similar 
regardless of gender and history of previous treatment.
The age of first use for barbiturates for all those entering treatment was 20.6 years (+/- 10.2 years). 
However, this varied from 14.0 years (+/- 1.4 years) for those new to treatment to 25.0 years (+/- 11.5 
years) for those having previously received treatment. This was similar regardless of gender. 
Injecting status
The majority (59.9%) of clients presenting to treatment reported that they had never injected drugs 
with 15.9% reporting current injecting.94 Previously treated clients were three times more likely to report 
currently injecting than new treatment clients (see Table 5.2). Primary opioid users account for 92.1% 
of current injectors, with amphetamine users accounting for 2.5%. Heroin users were also most likely 
to inject, with nearly two-fifths (38.3%) of treatment entrants citing injecting as their primary route of 
administration. Although accounting for small numbers, a high proportion of methamphetamine users 
(46/157 [29.3%]) were recorded as injectors.
Table 5.2: Injecting status amongst all clients entering treatment in the United Kingdom, 2014
INJECTING STATUS
NEW TREATMENT 
CLIENTS
PREVIOUSLY TREATED 
CLIENTS
ALL CLIENTS
n % n % n %
Ever injected, but not currently 2,380 8.2 19,133 31.7 21,891 24.2
Currently injecting (in last month) 1,928 6.7 12,368 20.5 14,381 15.9
Never injected 24,644 85.1 28,841 47.7 54,096 59.9
Sub Total 28,952 100 60,432 100 90,368 100
Not known/missing 6,055 3,187 10,088
Total 35,007 63,529 100,456
* Data on current injecting are not available for Wales as the item asks for ever injected (which has been mapped to ever but 
not currently) and never injected.
Source: ST34
5.4.4 Treatment Demand Indicator trends
All treatment entrants
Due to the introduction of a new methodology for calculating TDI, differences between 2013 data 
and previous years should be interpreted with caution. Both the increase in proportion of cannabis 
presentations and the decrease in opioid presentations from 2011/12 to 2013 will have been exaggerated 
by the introduction of the new TDI protocol and should not be treated as one time series. 
94 Data on current injecting are not available for Wales as the item asks for ever injected (which has been mapped to ever 
but not currently) and never injected
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Since 2003/04, the percentage of primary cannabis presentations steadily increased from 10.7% of all 
presentations through to 22.4% in 2011/12 (the last year of the previous protocol). There has also been 
a decrease in the percentage of all clients accessing treatment for primary opioids from a peak of 71.4% 
in 2003/04 to 56.4% in 2011/12 (see Table 5.3).
Presentations for primary crack cocaine increased from 5.4% in 2003/4 to 6% in 2008/09. However, they 
have since declined and accounted for 3.2% of the treatment cohort in 2014.
Table 5.3: The percentage of all drug treatment presentations by primary drug in the United Kingdom, 
2003/04 to 2014
DRUG 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2013 2014
Amphetamines % 3.7 3.6 3.5 3.8 3.5 3.2 3.2 3 2.8 2.6 2.8
Benzodiazepines % 2.1 2.4 1.9 1.8 2 1.9 2 2.1 2.5 2.6 2.2
Cannabis % 10.7 14.1 15.8 15.6 16.4 17.1 19.6 20.3 22.4 26.8 26.0
Cocaine* % 4 4.9 5.8 6.9 8 8.5 7.6 7.4 8 9.4* 9.4*
Crack cocaine % 5.4 5.6 5.8 5.8 5.9 6 4.5 4.8 4.6 3.5 3.2
Opioids % 71.4 67 65.1 63.7 61.9 61.2 60.8 59.3 56.4 50.3 52.1
Other % 2.7 2.5 2.1 2.4 2.4 2.1 2.6 3 3.4 4.8 4.3
Not known % 7.2 11 7.3 4.7 3.5 3.9 3.7 4 3.8 2.6 3.5
Total n 99,763 117,781 128,446 128,208 132,003 139,390 127,993 119,652 113,814 101,753† 100,456
*includes cocaine powder and cocaine unspecified
†figures are not directly comparable to previous years due to changes in TDI protocol
Source: ST34
New treatment entrants
Despite recent rises in the percentage of first ever treatment presentations for cannabis, between 2013 
and 2014 the proportion fell from 48.6% to 46.6%. Conversely, whilst the overall percentage of primary 
opioid clients has been decreasing from a peak of 57.8% in 2003/04 to 33.4% in 2011/12, it showed a 
slight increase between the first two years of the new protocol from 19.7% in 2013 to 23.2% in 2014 (see 
Table 5.4). 
By 2011/12 (under the old protocol), the proportion of new treatment entrants citing primary cannabis had 
overtaken that for primary opioids and this remained the same in 2013 and 2014 using the new protocol. 
The new protocol gives a better indication of treatment demand because it does not double count those 
transferred between agencies within a continuous treatment journey, which is disproportionately the case 
for opioid users.
Comparisons of clients accessing treatment across the UK
While England and Wales have seen decreases in the number of referrals to treatment since 2006/07, 
NI saw sharp increases between 2006/07 and 2011/12 followed by three years of decreases 
(Figure 5.1).95 In 2013/14 the number of clients referred to treatment in NI had fallen to a level lower than 
that seen in 2010/2011. Conversely, Scotland saw decreases in the number of referrals to treatment 
between 2006/07 and 2011/12 followed by two years of increases in 2013 and 2014. 
95 Data indexed to 2006/07
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Table 5.4: The percentage of first time drug treatment presentations by primary drug in the United 
Kingdom, 2003/04 to 2014
DRUG 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2013 2014
Amphetamines % 5.1 4.1 3.9 4.3 4.4 3.8 3.3 3.6 3.3 2.8 3.4
Benzodiazepines % 2.3 3.1 2.5 1.9 2.9 2.5 3 3.1 3.9 3.8 2.9
Cannabis % 18.6 22.1 24.8 24 27.2 28 32.5 32.4 37.1 48.6 46.6
Cocaine* % 5.8 7.7 9.1 10.5 13.3 15.1 12.4 11.4 12.9 14.6* 14.7*
Crack cocaine % 6 6.6 6.7 6.1 6.3 6.7 4.6 4.6 4 2.4 2.2
Opioids % 57.8 52.3 50 45.7 42.5 41 40.4 40 33.4 19.7 23.2
Other % 4.6 3.9 3.3 3.1 3.5 3.1 3.8 4.9 5.4 8.1 7.0
Not known % 3.5 8.0 6.6 4.2 3.4 3.0 4.3 5.4 5.6 2 2.7
Total n 29,865 42,497 49,625 47,165 46,601 45,048 44,924 47,566 43,110 35,229† 35,007
*includes cocaine powder and cocaine unspecified
†figures are not directly comparable to previous years due to changes in TDI protocol
Source: ST34
Opioids are the most commonly cited primary drug group for those entering treatment in England 
(52.1%), Scotland (56.9%) and Wales (57.6%); however, this group accounts for only 22.7% of those 
accessing treatment in NI. 
Figure 5.1: The number of new presentations to treatment in England, Wales, Northern Ireland and 
Scotland, 2006/07 to 2014 (data indexed to 2006/07)
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5.5 Clients in treatment
Data on clients in treatment for substance misuse are available from England, Wales and Scotland. In 
Northern Ireland, a census of those in treatment on a certain day is carried out every two years with the 
most recent carried out in 2014.
5.5.1 Data from the National Drug Treatment Monitoring System in England
In 2013/14 there were 193,198 individuals over the age of 18 in drug treatment in England; a slight 
decrease from the previous year (n= 193,575) and a continuation of the decreasing trend in numbers in 
treatment that started in 2009/10 (Public Health England, 2014a). This reduction is principally driven by 
decreases in the number of new treatment journeys for opioids and/or crack cocaine. Between 2005/06 
and 2013/14, decreases in treatment presentations for opioids and/or crack have occurred in all age 
groups except those over 40 (see Figure 5.2). These decreases mirror reductions in estimates of the 
prevalence of problem drug use (PDU) and suggest an ageing cohort of opioid and/or crack cocaine 
users. In contrast, the number of new journeys for cannabis, which has increased every year since 
2005/06, continued rising from 11,280 in 2012/13 to 11,821 in 2013/14.
Most clients in contact with treatment were using opioids (79%). Cannabis was the primary drug for nine 
per cent of clients and powder cocaine for five per cent of clients (Public Health England, 2014a).
Figure 5.2: The number of new treatment presentations for opioids and/or crack cocaine by age group 
in England, 2005/06 to 2013/14
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Young people in treatment in England
The number of young people (aged 17 years and under)96 attending specialist substance misuse services 
for drugs or alcohol during 2013/14 was 19,126, down from 20,032 in 2012/13 (a 4.5% decrease) (Public 
Health England, 2014g). This decrease is in line with decreases in self-reported alcohol and drug use 
among young people (Fuller, 2015). Of the young people entering specialist services during the year, 
99% waited less than three weeks from the point of referral to the first appointment, with the average wait 
of just under two days (Public Health England, 2014g).
Cannabis remains the most cited primary drug for which young people present to treatment in England. 
Despite a decline in self-reported cannabis use, the proportion of young people presenting to specialist 
services in 2013/14 for cannabis increased to 71% compared to 68% in 2012/13 (Public Health England, 
2014g). In 2013/14, the number of young people citing heroin as their primary substance fell to a historic 
low of 160, continuing the decreasing trend since 2005/06 and mirroring the adult treatment data. 
Following five years of decreasing powder cocaine presentations (806 in 2007/08 to 245 in 2012/13), the 
figure remained stable in 2013/14 at 254 (see Figure 5.3). A decrease in the number of presentations 
for amphetamines was observed; 591 in 2013/14 from 755 in 2012/13. The number of presentations for 
solvents also continued to fall from 163 in 2013/14 to 134 in 2013/14. 
Figure 5.3: The numbers of under-18s in treatment for the primary problematic use of individual class A 
drugs in England, 2005/06 to 2013/14
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Club drug users in treatment in England
‘Club drugs’ is a collective term for a number of different substances, including GHB/GBL, ketamine, 
ecstasy, methamphetamine and mephedrone, typically used by young people in bars and nightclubs, 
at concerts and parties. 
Between 2011/12 and 2012/13 there was a steep increase in the number of clients aged 18 or over 
presenting to treatment for any club drug, from 2,675 to 3,536 (Public Health England, 2013). This figure 
has remained stable in 2013/14 (n= 3,543) (Public Health England, 2014a) and represents five per cent 
of those presenting to treatment in 2013/14. 
96 NDTMS records clients aged nine upwards
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Between 2012/13 and 2013/14 the numbers presenting to treatment for each of the five substances, with 
the exception of ecstasy, increased. Presentations for ecstasy have fallen to 964, nearly half the number 
presenting in 2005/06 (n= 1,872). Conversely, presentations for mephedrone have almost doubled since 
being added to the NDTMS in 2010/2011, rising from 839 to 1,641 in 2013/14. Ketamine presentations 
have risen by approximately 40% between 2010/2011 and 2013/14, from 675 to 944. Despite these 
rises in numbers entering treatment, self-reported use in the last 12 months among adults aged 16 to 
59 for both mephedrone and ketamine was 0.5%, with the majority of users (71% and 70% respectively) 
reporting taking drugs just “once or twice a year” (Home Office, 2015f). 
Figure 5.4: The number of new treatment presentations for club drugs in England, 2005/06 to 2013/14
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5.5.2 Data from the Scottish Drug Misuse Database
In 2012/13, 11,861 individuals had an initial assessment for specialist drug treatment, equivalent to 
a European Age-sex Standardised Rate (EASR) of 222 per 100,000 population (Information Services 
Division, 2014a). The overall EASR has fluctuated since 2006/07, reaching a maximum of 246 in 2007/08, 
but has been stable at approximately 220 per 100,000 of the population since 2009/10 (see Figure 5.5). 
Similar to the pattern observed in English data, since 2006/07, an increasing proportion of individuals 
from older age groups have been assessed for specialist drug treatment each year. In 2006/07, half 
(51%) of the individuals were aged 30 and over, compared with two-thirds (66%) in 2012/13.
In the majority of Scottish Health Boards, the proportion of individuals reporting heroin as their main illicit 
drug used in the past month decreased between 2011/12 and 2012/13. In almost all Health Boards, 
fewer younger people reported heroin use at their initial assessment. Again, this is in line with the trend 
reported over recent years (in 2006/7, 58% of those under the age of 25 reported using heroin, falling to 
34% in 2011/12). There was no change in injecting behaviour in the majority of health boards between 
2011/12 and 2012/13, but the percentage of people who reported injecting in the previous month fell 
notably across most Health Boards between 2006/7 and 2012/13.
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Figure 5.5: Clients entering treatment in Scotland, 2006/07 to 2012/13, European Age-sex Standardised 
Rate per 100,000 of the population
200
205
210
215
220
225
230
235
240
245
250
2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13
Source: (Information Services Division, 2014a)
5.5.3 Data from the Welsh National Database for Substance Misuse
In 2013/14, the number of new referrals to treatment citing drugs97 in Wales was 11,142, a decrease 
from 11,393 in 2012/13 (Welsh Government, 2014b).98 The distribution of males/females has remained 
broadly consistent across the years; 72% of all clients referred were male and 28% female in 2013/14. 
The number of clients citing problematic use of opioids has slightly increased to 5,010 in 2013/14 from 
4,931 in 2012/13, with heroin remaining the most cited drug at treatment referral, accounting for 39% 
of all referrals for which drugs were specified as the main problematic substance. Cannabis (24%) and 
cocaine (7%) were the next most common primary drugs cited at referral.
5.5.4 Data from the Northern Ireland Drug Misuse Database
In NI in 2013/14, a total of 2,574 clients presented to services for problem drug misuse; nine per cent 
lower than in 2012/13 (2,824 clients) (Department of Health Social Services and Public Safety Northern 
Ireland, 2013). The number of clients presenting to treatment has increased from 1,409 in 2003/04.
5.5.5 Data from Northern Ireland treatment census
On 1 September 2014 a census was done of those receiving treatment for alcohol or substance misuse 
in Northern Ireland. Findings show that there were 4,662 people in treatment in NI for either drugs only 
or a combination of drug and alcohol (Department of Health Social Services and Public Safety Northern 
Ireland, 2015a). Sixty-six per cent of clients in treatment for drugs only were male and 13% were under 
18. Between 2007 and 2014 the proportion of clients in treatment for both drugs only and for drugs 
and alcohol has risen from 20% to 31% and from 18% to 24% respectively. However, this figure rose 
when age and gender were accounted for, with 42% of males and 36% of females under 18 years old in 
treatment for drugs only. 
97 Where there is a known substance type
98 Figures will not match referenced figures as they exclude alcohol as a primary drug type
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5.5.6 Opioid Substitution Treatment 
In the UK OST can be prescribed and managed by any GP, although the vast majority is received through 
structured treatment services where clients are encouraged to also engage in other forms of treatment 
such as psychosocial intervention, counselling and/or groups. Both methadone and buprenorphine are 
recommended in NICE guideline TA11499 as treatment options for people who are opioid dependent. 
Methadone currently remains the most commonly prescribed drug for OST. 
England
Data show that the number of opioid users in prescribing treatment increased from 98,991 in 2005 to 
152,828 in 2010. It has since stabilised and in 2014 OST was prescribed to 146,875 clients in England, 
a slight decrease from the 147,640 recorded in 2013 (see Figure 5.6). 
In 2014 two-thirds (66%) of those entering treatment in the UK with a primary drug of opioids, who had 
previously been treated, had received OST in the past. 
Figure 5.6: Trends in numbers of clients in England receiving opioid substitution treatment, 2005-2014
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Wales
In Wales there was a steep increase in the total number of OST clients between 2005 and 2011, from 
275 to 2,208.100 This was followed by a fall in 2012 to 1,925 and a slight rebound in 2013 to 1,995 clients 
where it remained stable to 2014 (n= 1,993) (see Figure 5.7). 
During 2014 two-thirds of clients in OST (n= 1,278) were prescribed methadone, whilst the remaining 
third (n= 715) received buprenorphine. However, the number of clients receiving buprenorphine has 
been steadily increasing over the last decade from 46 in 2004 (ST24). 
99 See: https://www.nice.org.uk/guidance/ta114
100 Due to a change in the Welsh dataset and a number of duplicate records being deleted from the database these figures 
will not match those reported in previous years 
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Figure 5.7: Trends in numbers of clients in Wales receiving opioid substitution treatment, 2005-2014
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In almost all NHS Health Boards, methadone was currently prescribed in over half of assessments where 
a prescription drug was reported. Diazepam was the second most commonly prescribed drug reported 
at assessments for drug treatment in 2012/13. 
In 2014/15, there were over 531,100 OST items dispensed in the community; some 439,800 of these 
were for methadone treatments. Overall the number of OST items dispensed decreased by 3.2% 
compared to 2013/14. Methadone dispensing decreased by 5.4% and has been decreasing year-on-year 
since 2010/11.
Prescription cost analysis shows that the prescribing of drugs other than methadone for the treatment of 
opioid dependency has been steadily increasing. For example, the number of items dispensed for the 
combined drug buprenorphine and naloxone (Suboxone®) increased by over 28% between 2012/13 
and 2013/14.
5.5.7 Treatment outcomes
The Treatment Outcomes Profile (TOP) is a clinical tool that enables clinicians and drug workers to keep 
track of the progress individuals make through their treatment journey.101 It measures drug use and gives an 
early indication about clients’ progress in overcoming problems with work, education or housing through 
a set of 20 questions.102 TOP was introduced in England in 2007 and has also been used in Wales since 
2009. In Scotland, from 2008 an enhanced, web-based SDMD follow-up reporting system was introduced 
to collect information on individuals throughout their treatment, not just at initial assessment. TOP data from 
England and Wales is not comparable due to differences in reporting methodology.
101 A TOP assessment is completed at treatment entry and then should be completed every three months and on treatment exit.
102 See: http://webarchive.nationalarchives.gov.uk/20150408180724/http://www.dtmu.org.uk/sph-files/top/TOP-form-v1.1-
Aug%202008.pdf 
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Treatment Outcomes Profile data in England
Table 5.5 shows the mean number of days use of a drug reported at treatment start and review and 
the percentage of clients reporting abstinence of that drug at treatment review in England (Public Health 
England, 2014a). The mean days use103 of a drug at treatment start was highest for cannabis (22 days), 
followed by opioids (21 days), amphetamines (16 days), crack cocaine (11 days) and cocaine powder 
(10 days). 
Table 5.5: Self-reported drug use by Treatment Outcome Profiles and the percentage of abstinent 
clients at treatment start and review in England
DRUG
MEAN DAYS USE OF DRUG AT 
TREATMENT START
MEAN DAYS USE OF DRUG AT 
TREATMENT REVIEW
PERCENTAGE OF CLIENT 
ABSTINENT AT TREATMENT REVIEW
Opioids 21.4 6.3 48%
Crack 11.1 3.8 60%
Powder cocaine 9.7 2.2 65%
Amphetamines 15.7 6.2 51%
Cannabis 22.1 11.3 36%
Source: (Public Health England, 2014a)
English data revealed that users of both opioids and crack cocaine reduced their days of illicit opioid use 
by less than opioid only users (mean days use of drug at treatment review was eight days compared to 
six days out of the last 28 days) (Public Health England, 2014a). Users of cocaine powder and users of 
crack cocaine only were most likely to be abstinent at review (65% and 60% respectively) with cannabis 
users least likely to be so (36%).
Treatment Outcomes Profile data in Wales
Based on TOP data in Wales, for those with a main problematic substance of heroin, the average number 
of days of heroin use fell from 24.5 to 9.3 (-61.8%), with 59.1% having not used heroin at all in the 28 
days prior to the exit TOP (Welsh Government, 2014b). Reductions were greater in clients citing use of 
powder cocaine, where the average number of days of powder cocaine use fell from 10.3 to 2.9 (a 72% 
reduction). Reductions were also seen in clients who used cannabis from 24.9 days to 15.2 (a 39.0% 
reduction), with 32.5% not having used cannabis at all in the 28 days prior to the exit TOP. Finally, the 
change in frequency in the use of amphetamines between start and exit TOPs fell from 21.8 to 11.3 days 
(a 48.3% reduction), with 67.9% having not used amphetamines at all in the 28 days prior to the exit TOP.
Clients leaving treatment successfully in England in 2013/14
The number of clients leaving treatment successfully in England has levelled off following an increasing 
trend since 2005/06 (Public Health England, 2014a). The number of clients discharged as ‘treatment 
completed’104 remained stable between 2012/13 and 2013/14 at 29,025 and 29,150 respectively (45% of 
clients exiting treatment) (see Figure 5.8). Successful completions as a percentage of the total number 
of people in treatment remained at around 15% in 2013/14 and 2012/13. Since 2005, approximately 
one-third (33%) of people who have come into treatment have been successfully completed and have 
not since returned.
103 Self-reported use in the 28 days prior to starting treatment.
104 This is determined by clinical judgement that the client no longer has a need for structured treatment, having achieved all 
the care plan goals and having overcome dependent use of the drugs that bought them into treatment.
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Figure 5.8: The proportion of clients leaving treatment free from dependency in England, 2005/06 to 2012/13
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Young People
In 2013/14 12,510 individuals under the age of 18 exited treatment, 79% of whom did so in a planned way 
and no longer required specialist treatment (Public Health England, 2014g).
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6. Drug-related infectious diseases and other 
drug-related harms
6.1 Introduction
People who use drugs are at risk of both fatal (Hickman et al., 2003) and non-fatal overdose (Gossop, 
Griffiths, Powis, Williamson, & Strang, 1996); experiencing periods of elevated overdose risk in the 
immediate period after leaving inpatient treatment and prison (Cornish, Macleod, Strang, Vickerman, 
& Hickman, 2010; Farrell & Marsden, 2008); and experiencing greater risk of contracting blood-borne 
viruses (BBVs) through injecting drug use (Judd et al., 2004).
The United Kingdom (UK) Government and devolved administrations have a number of policy and 
guidance documents outlining best practice for responses to the health correlates and consequences 
of drug use (often referred to as harm reduction). Generally, harm reduction is the combination of work 
aimed at reducing the number of drug-related deaths and BBVs and other infections, with the wider 
goals of preventing or reducing drug misuse and encouraging stabilisation in treatment and support for 
recovery. Principles of harm reduction aim to reduce the risky behaviour of those active drug users, who 
are either unwilling or unable to abstain. Each of the UK and devolved administration drug strategies 
include harm reduction objectives such as reducing drug-related harm and the prevention and control 
of drug-related infectious diseases. 
In Wales, the 10-year substance misuse strategy, Working Together to Reduce Harm. The Substance 
misuse strategy for Wales 2008-2018 (Welsh Assembly Government, 2008a) was published in 2008, 
setting out a national agenda for tackling and reducing the harms associated with substance misuse. 
In 2014, Public Health Wales (PHW) issued guidance on Diagnostic Testing for Hepatitis C, Hepatitis B 
and HIV (Public Health Wales, 2014) aimed at those who work in substance misuse services. Additionally, 
the Blood Borne Viral Hepatitis Action Plan for Wales 2010-2015 (Welsh Assembly Government, 2010) 
was published in 2010 with the key aims of reducing the transmission of hepatitis infections in Wales; 
increasing the diagnosis of current infections; and improving the provision of treatment and support to 
infected individuals. The Action Plan was followed by the new Together for Health – Liver Disease Plan 
published by the Welsh Government in May 2015 (Welsh Government, 2015a) which sets out priorities 
to improve treatment services and prevent liver diseases relating to alcohol, obesity and viral hepatitis. 
The Scottish Government launched the HIV Action Plan in Scotland, December 2009 to March 2014 
(Scottish Government, 2009b) in November 2009. The plan aimed to reduce the number of transmissions 
occurring in Scotland through increased prevention, increased early diagnosis and the improvement of 
the treatment and care of those living with the virus. The five year framework, the Sexual Health and 
Blood Borne Virus Framework 2011-2015 (Scottish Government, 2011), integrated the aforementioned 
program with sexual health and hepatitis and set out the Scottish Government’s agenda in relation to 
sexual health, HIV, hepatitis C and hepatitis B until 2015. The framework adopts an outcomes-based 
approach anchored by effective shared ownership and joint working with a strong focus on challenging 
inequalities. Quality standards applicable to all HIV services (Health Improvement Scotland, 2011) and 
quality indicators applicable to all hepatitis C services (Health Improvement Scotland, 2012) were also 
published in Scotland. 
In England, the Drug Strategy 2010, Reducing Demand, Restricting Supply, Building Recovery: 
Supporting people to live a drug free life (Her Majesty’s Government, 2010) includes a key best practice 
delivery outcome that all drug services are commissioned to prevent drug-related deaths and prevent 
the spread of BBVs. Public Health England (PHE) routinely publishes guidance on best practice and 
reports annual surveillance on a range of key indicators associated with BBVs in the UK. In April 2014, 
PHE launched its ‘Big Ambitions’, which include tuberculosis (TB).105
105 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/319696/Business_plan_11_June_pdf.pdf
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In Northern Ireland, responses to health correlates and consequences of drug misuse are broadly covered 
by the overarching strategy for alcohol and drugs misuse, the New Strategic Direction for Alcohol and 
Drugs Phase 2, 2011-2016 (Department of Health Social Services and Public Safety Northern Ireland, 
2011b). One of the overall aims of the new strategic direction is to reduce drug-related harm and ensure 
continued support to further develop appropriate harm reduction approaches and strategies.
6.2 Main drug-related infectious diseases 
6.2.1 HIV and viral hepatitis 
HIV
The overall prevalence of HIV seen amongst people who inject drugs (PWID) in 2014 was similar to 
that seen in recent years. The prevalence of HIV amongst the current and former PWID taking part 
in the Unlinked Anonymous Monitoring (UAM) Survey across England, Wales and Northern Ireland in 
2014 was one per cent (95% CI, 0.07%-1.4%) (Public Health England, 2015l). Between 2004 and 2013, 
prevalence varied between 1.1% and 1.6% (Public Health England, 2015l) (see Figure 6.1). In 2014 the 
HIV prevalence was 1.1% (95% CI, 0.22%-3.4%) in Wales and 0.65% (95% CI, 0.01%-3.9%) in Northern 
Ireland (Public Health England, 2015l). In England, the HIV prevalence was one per cent (95% CI, 0.69%-
1.5%) in 2014, not significantly different from 2004 when the prevalence was 1.4% (95% CI, 1.0%-2.0%) 
(Public Health England, 2015l).
HIV prevalence amongst “recent initiates” to injecting drug use (those who first injected during the 
preceding three years) is an indicator of recent HIV transmission. The prevalence amongst the recent 
initiates participating in the UAM Survey across England, Wales and Northern Ireland was 0.41% (95% CI, 
0.01%-2.5%) in 2014 (Public Health England, 2015l). This is similar to that found in recent years, indicating 
that HIV transmission amongst PWID is ongoing within the UK albeit at a low level (see Figure 6.1).
There were 131 new HIV diagnoses associated with injecting drug use reported in the UK during 2014; 
17 of these diagnoses were reported from Scotland (Public Health England et al., 2015). There were also 
33 reported HIV diagnoses that were associated with sex between men, for which injecting drug use was 
also reported as a risk (Public Health England et al., 2015).
In the Greater Glasgow and Clyde area of Scotland, there has been a recent increase in the number of 
HIV infection diagnoses where the risk factor is injecting drug use. On average, 115 new diagnoses of 
HIV infection are made annually in the Greater Glasgow and Clyde area, with the majority of these being 
acquired through sexual transmission. The number of new diagnoses thought to be transmitted through 
injecting drug use is on average about ten per annum. By the end of August, there had been 36 new 
diagnoses with this risk so far in 2015. The cause of this increase is currently under investigation, but the 
increase is thought to be due to an outbreak. Three key messages have been issued as part of the local 
response: if injecting, use clean, fresh equipment and never share; use a condom for sex; and take an 
HIV test.106
Hepatitis C 
PWID are the group with the highest prevalence of hepatitis C in the UK. Around 90% of the hepatitis C 
infections diagnosed in the UK will have been acquired through injecting drug use. During 2014, 14,149 
hepatitis C infections were diagnosed across the UK (Public Health England et al., 2015). There has 
been a marked increase in the annual number of new diagnoses throughout the UK over the last decade, 
reflecting the increased availability and easier access to voluntary confidential testing (VCT).
106 See: http://www.nhsggc.org.uk/about-us/media-centre/news/2015/06/hiv-infections-increase/
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Figure 6.1: The prevalence of antibodies to HIV amongst all participants and recent initiates* in the 
Unlinked Anonymous Monitoring Survey of people who inject drugs: England, Wales and Northern 
Ireland, 2004 to 2014
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*A recent initiate is someone who first injected during the preceding three years
Source: (Public Health England, 2015l) 
The prevalence of hepatitis C infection amongst PWID remains relatively high. The overall prevalence of 
antibodies to hepatitis C (anti-HCV)107 amongst the current and former PWID participating in the UAM 
Survey across England, Wales and Northern Ireland was 49% (95% CI, 47%-51%) in 2014 (Public Health 
England, 2015l). This proportion has remained relatively stable over the last decade (see Figure 6.2). In 
2014, in Northern Ireland anti-HCV prevalence was 32% (95% CI, 25%-39), which is lower than in England 
(50%, 95% CI, 49%-52%) and Wales (50%, 95% CI, 44%-56%) (Public Health England, 2015l). While in 
England and Northern Ireland the hepatitis C prevalence amongst the participants in the UAM Survey has 
remained relatively stable over time, in Wales there has been an increase from 19% recorded in the period 
2003–05 (Public Health England, 2015b). In England there were very marked regional variations from 29% 
in the north east region to 66% in the north west region (Public Health England, 2015b).
In Scotland, the estimated prevalence of antibodies to hepatitis C was 57% among current and former 
PWID surveyed at services providing injection equipment across mainland Scotland in 2013/14. This 
compares to 52%, 55% and 53% who tested positive in 2008/09, 2010 and 2011/12, respectively (Public 
Health England et al., 2015).
The level of hepatitis C transmission among PWID in the UK appears to have changed little in recent 
years. The prevalence of antibodies to hepatitis C amongst recent initiates has also been fairly stable. 
Amongst those in this group participating in the UAM survey from across England, Wales and Northern 
Ireland, prevalence was 19% (95% CI, 15%-25%) in 2014 (Public Health England, 2015l). Over the last 
decade the prevalence in this group has ranged between 18% and 24% (Public Health England, 2015b). 
Incidence of hepatitis C infection among PWID in England, Wales and Northern Ireland is currently 
estimated to be between five to 16 infections per 100 person years of exposure (Public Health England, 
107 Anti-HCV is a marker of previous or current hepatitis C infection
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2015f). In Scotland, the incidence of hepatitis C infections among PWID was estimated to be 10 infections 
per 100 person years of exposure during 2013/14; this compares with an incidence of 13 infections per 
100 person years found during 2008/09 (Public Health England, 2015f).
Figure 6.2: The prevalence of anti-HCV amongst all participants and recent initiates* in the Unlinked 
Anonymous Monitoring Survey of people who inject drugs: England, Wales and Northern Ireland, 2004 
to 2014
50%
40%
30%
20%
10%
0%
2004 2005 2006 2007 2008 2009
Anti-HCV Prevalence: Recent Initiates OnlyAnti-HCV Prevalence: All Participants
2010 2011 2012 2013 2014
An
ti-
H
C
V 
Pr
ev
al
en
ce
Survey Year
*A recent initiate is someone who first injected during the preceding three years
Source: (Public Health England, 2015b) 
Hepatitis B
In 2014, 14% (95% CI, 13%-16%) of the current and former PWID who took part in the UAM Survey in 
England, Wales and Northern Ireland had antibodies to hepatitis B core antigen (anti-HBc, a marker of 
previous or current hepatitis B infection) (Public Health England, 2015l). This prevalence has remained 
relatively stable in recent years, but it is lower than the level seen ten years ago when prevalence was 
28% (see Figure 6.3) (Public Health England, 2015l). The prevalence of anti-HBc varied by country: 
Northern Ireland, 7.1% (95% CI, 3.9%-12%; prevalence was 13% in 2004); Wales, 11% (95% CI, 7.9%-
15%; prevalence was nine per cent in 2003-05); and England, 15% (95% CI, 14%-17%; down from 29% 
in 2004) (Public Health England, 2015b, 2015l).
The samples collected by the UAM Survey of PWID during 2014 that had anti-HBc detected were also 
tested for hepatitis B surface antigen (HBsAg), a marker of current infection. In 2014, of the samples 
from the UAM Survey of PWID with anti-HBc, four per cent (95% CI, 2.5%-6.3%) had HBsAg detected 
indicating current infection; this represents 0.58% (95% CI, 0.36%-0.93%) of all the PWID surveyed in 
England, Wales and Northern Ireland that year (Public Health England, 2015l).
The available data on reports of acute hepatitis B infections indicate that currently few of these are 
among PWID, with most UK acquired cases associated with sexual activity. These findings indicate 
that current hepatitis B infection is now rare among PWID, probably reflecting the impact of the marked 
increased in the uptake of the hepatitis B vaccine among PWID (Public Health England et al., 2015).
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Figure 6.3: The prevalence of anti-HBc amongst all participants and recent initiates* in the Unlinked 
Anonymous Monitoring Survey of people who inject drugs: England, Wales and Northern Ireland, 2004 
to 2014
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Source: (Public Health England, 2015l) 
6.2.2 Blood borne viral infections amongst people who inject image and performance enhancing drugs
Following a pilot UAM Survey of people who inject image and performance enhancing drugs (IPEDs) that 
was undertaken during 2010/11 (Hope et al., 2013), the first biennial monitoring survey was performed 
in 2012/13 (Public Health England, 2014b). The participants were principally recruited through needle 
and syringe programmes (NSP) across England and Wales over an 18 month recruitment period.108 
The participants provided a dried blood spot (DBS) specimen that was tested anonymously for HIV, 
hepatitis C and hepatitis B (the main tests used were for antibodies to HIV, hepatitis C and the hepatitis B 
core antigen). Behavioural and demographic information was collected using a short subject completed 
questionnaire.
During the 2012/13 sampling period 249 individuals took part in the IPED survey from across England 
and Wales. Of these, two per cent (95% CI, 0.74%-4.9%) had HIV (compared with 1.1% in PWID using 
psychoactive drugs), 2.8% (95% CI, 1.2%-5.9%) anti-HBc (compared with 16% in those PWID using 
psychoactive drugs), and 3.6% (95% CI, 1.8%-7.9%) had anti-HCV (compared with 49% in those PWID 
using psychoactive drugs) (Public Health England, 2014f). Though the prevalence of antibodies to both 
hepatitis B and C were lower than the prevalence found in people who inject psychoactive drugs, the 
prevalence of HIV was similar in both groups. 
The prevalence of BBV infections amongst IPED injectors in Scotland and Northern Ireland is currently 
not known. A pilot survey of IPED injectors is currently under way in Northern Ireland. In Scotland, 
among those who had injected image and performance drugs only during the last six months, 5.1% had 
antibodies to hepatitis C in 2013/14.
108 An 18 month recruitment period was used, instead of 12 months in the main UAM Survey of people who inject 
psychoactive drugs, due to the cyclic nature of some of the forms of drug use among this target population
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6.3 Other drug-related infectious diseases
6.3.1 Tuberculosis
In total there were 6,520 cases of TB reported in England in 2014 (Public Health England, 2015k). Amongst 
the cases with known information on the four ‘social risk factors’ monitored among TB cases in England: 
3.3% (201/6,031) had either a history of, or currently had, a problem with drug use; 3.3% (198/5,988) of 
alcohol misuse; 3.4% (206/6,062) of homelessness; and 3.3% (192/5,903) of imprisonment. A total of 
9.4% of cases (538/5,708) had at least one of these social risk factors. A higher proportion of the UK born 
TB cases had at least one social risk factor when compared to non UK-born cases (15.0% versus 7.2%).
6.3.2 Infections due to spore-forming bacteria
Illnesses caused by the toxins produced by a number of spore-forming bacteria, such as botulism, 
tetanus or anthrax, continue to cause problems among people who inject drugs. The spores produced 
by these bacteria are found in the environment, and may end up in drugs, such as heroin, through 
contamination. There were three cases of botulism among people who inject drugs during 2014, and 
the last two were the first cases of the largest cluster of botulism cases among this group seen so far 
in Europe. Between 2000 and 2013, there had been a total 167 cases of botulism amongst people who 
inject drugs in the UK (Public Health England et al., 2015).
The recent cluster involved a total of 40 cases over a six month period between December 2014 and 
May 2015. Seventeen (42%) cases were confirmed by detection of the toxin in blood or detection of 
Clostridium botulinum type B in wound material. Molecular typing of the organism from 14 of the cases 
indicated a common source, and all cases had injected heroin sourced from the same Scottish city. 
Awareness-raising materials, highlighting the symptoms of botulism, were distributed widely among 
people who use drugs, healthcare professionals, and frontline workers in addictions and injecting 
equipment provision services (Figure 6.4). A pragmatic risk reduction approach was taken, advising 
users to make sure they injected their drugs into a vein, smoked drugs as an alternative to injecting, or if 
possible stopped use altogether (Public Health England et al., 2015).
There were no cases of tetanus or anthrax reported among people who inject drugs in the UK during 
2014 (Public Health England et al., 2015).
6.3.3 Other injection-related bacterial infections
Severe illnesses among people who inject drugs due to hygiene-related bacterial infections, including 
those caused by Staphylococcus aureus and Group A streptococci, continue to occur. Data from 
the mandatory enhanced surveillance of meticillin-sensitive S. aureus (MSSA) and meticillin-resistant 
S. aureus (MRSA) bacteraemias indicate that in 2013, of those with risk factor information, 80% of the 
MSSA bacteraemias were associated with injecting drug use, as were 4.8% of the MRSA bacteraemias. 
Severe Group A streptococci infections have also been reported among people who inject drugs. There 
has recently been a large outbreak of soft tissue infections among people who inject drugs in Edinburgh 
(Public Health England et al., 2015). Though a number of different organisms were detected, Group 
A streptococci infections, and in particular one less commonly seen type of S. pyogenes, was often 
detected in the cases. Those involved had injected a range of drugs including a new psychoactive 
substance. Many cases required prolonged hospital admission and extensive surgical intervention 
(Health Protection Scotland, 2015).
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Figure 6.4: Botulism health warning ‘postcard’ distributed to people who use drugs
Source: Scottish Drugs Forum www.sdf.org.uk / NHS Greater Glasgow and Clyde
In 2014, over one-quarter, 31% (95% CI, 29%-33%) of PWID participating in the UAM Survey in England, 
Wales and Northern Ireland reported that they had experienced an abscess, sore or open wound, all 
indicating symptoms of injecting-site infection, during the preceding year (Public Health England, 2015l). 
This was similar to the level seen in recent years. The proportion of people reporting symptoms increased 
with age, from 24% amongst those aged under 25 years to 33% amongst those aged 35 years and over, 
with more women (37%) reporting symptoms than men (29%) (Public Health England, 2015b). Among 
those attending needle and syringe programmes in Scotland during 2013/14, 28% reported that they had 
experienced an abscess, sore or open wound during the last year (Public Health England et al., 2015).
Among the participants in the 2012/13 UAM sub-survey of people who inject IPEDs, 16% reported that 
they had ever experienced symptoms of injecting-site infection, with the proportion highest among the 
25 to 34 age group (22%) (Public Health England, 2014b).
6.4 Behavioural data: infection risks 
The extent and patterns of infections over time reflect changing patterns of risk. Risk will be impacted 
by the extent of service provision, particularly the provision and uptake of harm reduction and health 
protection interventions such as NSP, opioid substitution treatment (OST), vaccination, and diagnostic 
testing services. The provision of these services is widespread in the UK and provision and uptake have 
both improved across the UK over the last decade (see section 6.6). 
6.4.1 Sharing of injecting equipment: people who inject psychoactive drugs
The level of needle and syringe (direct) sharing reported by participants in the UAM Survey in England, 
Wales and Northern Ireland has declined from 28% (95% CI, 26%-30%) in 2004 to 17% (95% CI, 
15%-19%) in 2014 (Public Health England, 2015l) (Figure 6.5). Throughout the 2004 to 2014 period, 
direct sharing levels were higher among women than men; in 2014, 21% (95% CI, 17%-26%) of women 
reported direct sharing compared with 15% (95% CI, 14%-18%) of men (Public Health England, 2015l). 
Direct sharing was found to vary across England (16%), Wales (22%) and Northern Ireland (17%) (Public 
Health England, 2015b). In England regional variations were reported, ranging from 12% (95% CI, 5.5%-
22%) in the east of England in 2014 to 23% (95% CI, 17%-30%) in the south-west of England (Public 
Health England, 2015l).
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Sharing of any of the injecting equipment asked about in the UAM Survey (i.e. needles, syringes, 
mixing containers, or filters; direct and indirect sharing) was reported by 38% of those participating 
in the survey in 2014; this was not significantly different from the previous year (Public Health 
England, 2015b). Sharing of any of this equipment was reported by 38% of the participants in England 
(regional range: 31% to 55%), by 41% in Wales, and by 30% in Northern Ireland in 2012 (Public Health 
England, 2015b).
In Scotland, data from the Scottish Drug Misuse Database (SDMD) indicates sharing of needles/syringes 
among those injecting drugs in the past month was generally low (less than 10%), ranging from two per 
cent to nine per cent between NHS Health Boards and remaining constant with the values reported in 
2011/12 (Information Services Division, 2014a). However, the percentage of injectors reporting having 
shared needles/syringes in the past, but not in the previous month was higher (ranging from 18% to 44% 
between NHS Health Boards), remaining broadly similar to the previous year.
Among the injectors reporting sharing of injecting paraphernalia in the past month the percentages were 
low, with similar variation between NHS Health Boards (ranging from four per cent to 12%). Similar low 
values of injectors reporting recent sharing of paraphernalia since 2010/11 and decreasing from a higher 
percentage in 2006/07 (44%) were reported in all NHS Health Boards.
Figure 6.5: The percentage of current injectors* in the Unlinked Anonymous Monitoring Survey of 
people who inject drugs reporting needle and syringe sharing: England, Wales and Northern Ireland, 
2004 to 2014
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6.4.2 Sharing of injecting equipment: people who inject image and performance enhancing drugs
Among the participants in the 2012/13 UAM sub-survey of people who inject IPEDs, only 13% (95% CI, 
9.3%-18%) reported ever sharing any injecting equipment (Public Health England, 2014f).109 Sharing 
levels were slightly higher amongst those aged 25 to 34 years than amongst the other age groups in 
the 2013 sub-survey110 with 10% of those aged under 25 years reporting sharing compared with 16% of 
those aged 25 to 34 years and 12% of those aged 35 years and over (Public Health England, 2014b).
6.4.3 Sharing of injecting equipment: people who inject new psychoactive substances
There have been recent concerns about increased injection of stimulants, and in particular the 
emergence of the injection of new psychoactive substances (NPS), including mephedrone and other 
synthetic cathinones. These drugs are injected more frequently than opioids and compulsive re-dosing 
has been reported. In England, Wales and Northern Ireland, 5.9% of those surveyed as part of the UAM 
Survey in 2014 reported that they had injected mephedrone during the preceding month and 8.9% 
had injected this drug at some point during the preceding year. Those currently injecting mephedrone 
were more likely to report sharing needles, syringes and other injecting equipment than those currently 
injecting other substances
Figure 6.6: Injecting risk behaviours among those currently* injecting in England, Wales & Northern 
Ireland: 2014
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The recent cluster of Group A streptococci infections among PWID in the Edinburgh included those 
injecting the NPS ethylphenidate. The recent emergence of injection of this fairly short-acting stimulant 
probably played a role in the extent of this cluster, of often severe illnesses (see section 6.3.3). In south-
west Wales, an increase in infections and other harms has been associated with the emergence of the 
injection of synthetic cathinones, including mephedrone. The changes in injection practice associated 
with the use of these stimulants probably markedly increased risk (Public Health England et al., 2015).
109 Needle, syringe or vial
110 Age was not provided by all participants to the sub-survey
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6.4.4 Condom use and sexual behaviour in people who inject drugs
In 2014, over two-thirds (68%, 95% CI, 66%-70%) of the PWID participating in the UAM Survey across 
England, Wales and Northern Ireland reported having anal or vaginal sex during the preceding year, 
and this level has changed little over time (Public Health England, 2015l). Of those who had sex in the 
last year, 40% (95% CI, 38%-42%) reported having had two or more sexual partners during that time. 
Of these individuals, only 22% (95% CI, 19%-25%) reported always using condoms for anal and vaginal 
sex. This suggests increased efforts are required to improve the use of condoms in PWID (Public Health 
England, 2015l).
Among the participants in the 2012/13 UAM sub-survey of people who inject IPEDs, nine-tenths (92%, 
95% CI, 87%-95%) reported having anal or vaginal sex during the preceding year, suggesting this cohort 
are more sexually active than participants in the main UAM Survey of PWID (Public Health England, 
2014b). Within the 92% of those who had sex in the previous year, 54% (95% CI, 47%-60%) reported 
having had two or more sexual partners during that time and of these, only 13%, (95% CI, 8%-21%) 
reported always using a condom; a smaller proportion than in the main UAM Survey of PWID (Public 
Health England, 2014f).
6.4.5 Men who have sex with men
There are on-going concerns about the injection of methamphetamine and mephedrone among some sub-
groups of men who have sex with men (MSM), many of whom are HIV positive. These drugs are typically 
being used by these men during sex in a practice known as chemsex, with injecting equipment often 
shared while condoms are not always being used. Although the scale of this behaviour remains unclear, 
specialist Lesbian, Gay, Bisexual and Transgender (LGBT) drug services are continuing to see an increase 
in the number of MSM who report injecting these drugs. The use and injection of these drugs has also been 
reported to be a factor in the increased transmission of a number of sexually transmitted infections (STIs) 
(Bourne, Reid, Hickson, Torres Rueda, & Weatherburn, 2014; Kirby & Thornber-Dunwell, 2013).
The number of diagnoses of STIs reported in MSM has risen sharply in recent years. Recent figures show 
that syphilis diagnoses increased by 46% in the past year (2,375 to 3,477) and gonorrhoea diagnoses by 
32% (13,629 to 18,029) (Public Health England, 2015e). Since 2009 there has been a steady increase in 
diagnoses of STIs in HIV-positive MSM, and the population rate of acute bacterial STIs is up to four times 
that of HIV-negative MSM or undiagnosed MSM. This pattern is indicative of rapid STIs transmission 
occurring in dense sexual networks of HIV-positive MSM (Malek et al., 2015). In addition, in recent years 
the number of new HIV diagnoses among MSM has increased steadily, rising from 2,860 men in 2010 to 
3,360 men diagnosed HIV positive in 2014 (55% of all new diagnoses) (Public Health England, 2015g). 
This trend reflects both high levels of on-going HIV transmission and increases in HIV testing. There is 
also an increased risk of hepatitis C infection among MSM, which has been associated with having HIV 
and with chemsex. Data from the Hepatitis C in the UK, 2015 report shows that newly acquired hepatitis 
C infection in England among MSM is on-going but declining. Among the HIV-positive MSM population 
transmission of hepatitis C is predominantly due to sexual transmission. In England the estimated 
incidence of infection in this population declined significantly over the four years up to 2013, and was 2.3 
per 1,000 person years in 2013 (Public Health England, 2015f).
In November 2015 PHE published a briefing aimed at commissioners and providers of drug and alcohol 
services in order to highlight issues related to MSM and chemsex in particular. The document contains 
background information and recent data as well as case studies and prompts intended to support 
commissioners and providers of drug and alcohol services to meet the needs of MSM participating in 
chemsex (Public Health England, 2015i).
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6.5 Other drug-related health correlates and consequences
6.5.1 Non-fatal overdoses and drug-related emergencies
The NHS Data Model and Dictionary defines an emergency admission as one that occurs “when 
admission is unpredictable and at short notice because of clinical need”. A drug-related acute 
emergency hence arises when medical care is sought while the patient is under the influence of drugs 
(not primarily alcohol). Based on this definition, data on drug overdoses and drug-related emergencies in 
the UK are provided using hospital inpatient data and International Statistical Classification of Diseases 
and Related Health Problems 10th Revision (ICD-10) codes. However, it is difficult to assess the full extent 
of non-fatal overdoses and drug-related emergencies due to the use of illicit drugs. This is because the 
ICD-10 coding system includes some legally available drugs such as codeine, which can be purchased 
without prescription at pharmacies. Conversely, ICD-10 codes do not include NPS. Also, data from 
hospitals are only available for those who are admitted to hospital and stay as an inpatient. Evidence 
shows that less than one-third of individuals attending hospital with acute recreational drug toxicity are 
admitted to hospital, and even those admitted may not be assigned an appropriate ICD-10 code (UK 
Focal Point, 2011, 2014; Wood, Conran, & Dargan, 2011).
Discharge information is based on the patient’s first episode within a continuous spell of treatment. 
A continuous inpatient stay is an unbroken period of time that a patient spends as an inpatient. 
In 2013/14, hospital inpatient data showed that there were 41,628 inpatient discharges recording 
poisoning by drugs in the UK, a nine per cent increase since 2012/13 (Table 6.1). As in previous years, 
over half (62.1% or 25,856) were due to ‘other opioids including morphine and codeine’. Discharges 
linked to other opioid poisonings have increased each year from 2008/09 when there were 17,902. 
Heroin poisoning accounted for 7.7% (3,193) of discharges, cocaine for 6.7% (2,778) and methadone for 
3.7% (1,527). Methadone poisoning discharges fell in 2013/14 to 1,527 from 1,543 in 2012/13 and from 
1,833 in 2011/12. Almost all drug poisonings were emergencies (99%).
The latest Global Drug Survey 2015 revealed that for the third year running synthetic cannabinoids 
were more likely to leave people needing emergency medical treatment than any other drug group — 
with 3.5% of last year users reporting having sought emergency treatment in the last year (an increase 
from 2.5% the previous year). In the previous 12 months, 0.9% of respondents had sought emergency 
medical treatment after taking MDMA and one per cent after using cannabis (Global Drug Survey, 2015).
6.5.2 Enquiries to the National Poisons Information Service
The National Poisons Information Service (NPIS) is a service commissioned by PHE on behalf of the 
UK health departments. It provides information and advice for NHS healthcare professionals on the 
diagnosis, treatment and care of poisoned patients across the UK via its 24 hour telephone advice 
service and its online database TOXBASE©.111 In order to provide better toxicosurveillance of drug misuse 
and a more comprehensive mechanism to describe recreational drug use, from 2014/15 the NPIS has 
changed its approach to the way telephone enquiries are recorded to capture all calls referring to drugs 
of misuse including prescription medicines, which are described as ‘recreational’ during the telephone 
enquiry.112 These changes are aimed at facilitating the detection, monitoring and review of emerging 
substances that are causing clinical harm. Consequently, the telephone data reported here for 2014/15 
cannot be directly compared to the data published in previous reports (Public Health England & National 
Poisons Information Service, 2015). In 2014/15, the NPIS reported 1,722 telephone enquiries related to 
286 drugs of misuse. This represented 3.7% of all NPIS telephone enquiries. In the same year the NPIS 
also reported 69,537 online accesses on TOXBASE related to 598 drugs of misuse, representing 4.4% 
of all TOXBASE activity. For the 61 specific substances reported on in 2013/14, there was a 3.5% overall 
increase in telephone calls and a 6.7% increase in TOXBASE accesses in 2014/15. The most commonly 
accessed TOXBASE entries and subjects of telephone enquiries were stimulants including MDMA, 
111 See: http://www.npis.org/toxbase.html 
112 Until 2013/14 the NPIS provided data on telephone enquiries about 61 drugs of misuse. From 2014/15 that number has 
risen to 286 drugs of misuse
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branded products113 and opioids. In relation to individual drug groups, when enquiries on synthetic 
cannabinoid receptor agonists (SCRAs) and branded products thought to contain these substances 
were combined, SCRAs registered the largest increase in telephone enquiries and TOXBASE accesses 
with a 144% and a 151% increase respectively compared to 2013/14 (Public Health England & National 
Poisons Information Service, 2015).
Table 6.1: Inpatient discharges recording poisoning by drugs in the United Kingdom, 2008/09 to 2013/14
DRUG 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14
n % n % n % n % n % n %
Other opioids 
including morphine 
and codeine
17,902 57.2 19,266 62.9 21,509 63.5 22,102 61.0 22,472 58.6 25,856 62.1
Heroin 3,053 9.8 3,155 10.3 2,500 7.4 2,453 6.8 2,338 6.1 3,193 7.7
Cocaine 2,627 8.4 1,986 6.5 2,247 6.7 2,139 5.9 2,226 5.8 2,778 6.7
Methadone 1,493 4.8 1,533 5.0 1,954 5.8 1,833 5.1 1,543 4.0 1,527 3.7
Total 31,319 100.0 30,618 100.0 33,889 100.0 36,255 100.0 38,342 100.0 41,628 100.0
Emergencies 30,991 99.0 30,311 99.0 31,794 93.7 35,897 99.0 37,908 99.0 41,178 99.0
Source: Personal communication – Public Health England, Department of Health, Social Services and Public Safety Northern 
Ireland, Information Services Division Scotland, Public Health Wales
6.6 Prevention and control of drug-related infectious diseases: harm reduction services
A range of services are provided across the UK that contribute to the prevention of infections amongst 
PWID. This section considers the key services involved in such prevention, other than OST and drug 
treatment, which are considered elsewhere (see section 5.5.6). Additionally, this section outlines the 
availability and uptake of diagnostic and treatment services for key infections.
Data indicate that the prevalence of HIV and hepatitis C infection among PWID in the UK has been 
broadly stable over the last decade, and the extent of current hepatitis B infection is very low and has 
probably declined over the last decade. These patterns reflect the extensive provision of interventions, 
such as needle and syringe programmes, and the increase in hepatitis B vaccination. Though service 
levels have been expanded or maintained over the last decade, further improvements to intervention 
coverage are probably needed. These will probably need to be sustained over many years if levels of 
hepatitis C, in particular, are to be reduced.
6.6.1 Needle and syringe programmes
Needle and syringe programmes (NSP) are provided throughout the UK in a variety of settings, principally 
through pharmacies and specialist services. These provide a range of injecting equipment and also advice 
on safer injecting practice. In addition, many offer other services including testing for BBVs, vaccinations, 
injection site care and referral into other specialist drug treatment and sexual health services. There are also 
a small number of mobile syringe exchanges, usually attached to a local treatment provider, and in Wales 
there is a single vending machine which can also be used to obtain syringes.
113 With this terminology NPIS refers to enquiries where the substances are difficult to classify because their chemical 
constituents are sometimes unknown and may change over time. It generally refers to the so-called ‘legal highs’. Spice/
synthetic cannabinoid data previously included branded products but, from 2014/15, these are now reported independently
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In April 2014, the National Institute for Health and Care Excellence (NICE) updated its public health guidance 
Needle and Syringe Programmes (National Institute for Health and Care Excellence, 2014b). The new 
guidance makes recommendations on NSP, including those provided by pharmacies and drug services for 
adults and young people who inject drugs (including those under 16), with specific recommendations for 
users of IPEDs (for example, anabolic steroids for bodybuilding or injected tanning agents).
The vast majority (89%) of the participants in the UAM Survey of PWID from across England, Wales and 
Northern Ireland reported that they had used a NSP in 2014 (Public Health England, 2015b).
England
Data from the UAM Survey of PWID showed that in 2014 the vast majority (85%) of participants who 
injected psychoactive drugs in the previous year reported using a NSP, while only five per cent had never 
used a NSP (Public Health England, 2015f). Of those who had injected in the preceding four weeks, just 
under half (48%) reported receiving more needles than they required from a NSP.114 Just less than one-
third (29%) of participants who had injected in the preceding four weeks had injected with a used needle 
that they had attempted to clean. These findings may indicate that, in England, the majority of PWID are 
accessing NSP; however, equipment provision needs to be increased.
NSP are not currently provided in prisons. A recent audit of hepatitis C services in a representative 
sample of English prisons suggested that disinfection tablets for sterilising injecting equipment were 
available in 81% of English prisons. These tablets were accessed in a variety of ways: 53% of prisons 
made them available via dispensers, 41% of prisons distributed them directly via prison officers, and 
12% of prisons distributed them via healthcare staff (Public Health England, 2015f).
Scotland
There were 299 injection equipment provider outlets, of which 218 (73%) were pharmacy-based, reported 
to be operating in Scotland in 2013/14. This is an increase from 188 outlets in 2004/05 (Figure 6.7).
Over four million needles/syringes115 were estimated to have been distributed to PWID in Scotland during 
2013/14, based on data reported by 85% (255/299) of the injection equipment provider outlets. Accounting 
for the under-reporting in 2013/14, this is higher than the 3.6 million needles/syringes reported to have 
been distributed to PWID in Scotland during 2004/05, and similar to the number of needles/syringes 
(in the range 4.4 to 4.7 million per year) reported to have been distributed in recent years (2007/08 to 
2012/13). The number of injecting paraphernalia items distributed to PWID has increased in recent years, 
with notable rises in the provision of filters and spoons/cookers between 2008/09 and 2009/10 and more 
recently in the provision of sterile water between 2012/13 and 2013/14. In 2013/14, the items distributed 
included: 2,864,000 filters, 2,810,000 spoons/cookers and 1,019,000 vials of sterile water.
114 This data should be interpreted with caution as some people receive more needles to pass to friends – known as 
secondary distribution
115 This estimate was calculated based on the data reported by 85% (255/299) of the injection equipment provider outlets. 
It will therefore not match data provided in ST10
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Figure 6.7: Injection equipment provider outlets operating in Scotland between 2004/2005 and 2013/2014
Agency basedPharmacy based
In
je
ct
io
n 
eq
ui
pm
en
t p
ro
vi
de
r o
ut
le
ts
Years
2004/05 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14
350
300
250
200
150
100
50
0
 
Source: (Public Health England, 2015f)
Wales
The provision of NSP, and other harm reduction services, in Wales is monitored using the Harm Reduction 
Database (HRD). In 2014/15 the HRD was active in 47 statutory and voluntary sector NSP sites across 
Wales, including five mobile services and four hostels. The 207 community pharmacies providing NSP 
services were linked to the HRD in April 2014 (Public Health England, 2015f). Data from the HRD indicates 
a total of 25,409 unique individuals accessed NSP services (including community pharmacy) from April 
2014 to March 2015 (Public Health England, 2015f). Of these, 51% reported primary use IPEDs; 37% 
opioids; 9.4% stimulants (crack, amphetamine, etc.); and 1.5% new psychoactive substances (NPS) 
(Public Health England, 2015f).
In 2014/15 a total of 3,141,442 syringes were distributed in Wales. Fifty-four per cent (n= 1,693,980) 
of syringes were distributed through pharmacy-based NSP, whilst specialist agencies distributed 46% 
(n= 1,446,280) and 1,182 were accessed through a syringe vending machine (>1%) (ST10). 
In specialist agencies there were 9,725 unique clients who generated 47,626 client contacts, and 
pharmacy-based NSP distributed to 18,593116 clients over 87,314 transactions (ST10). The primary drug 
type profile of those accessing NSP via specialist agencies was: 45% IPED; 43% opioid users; 8.3% 
stimulants (crack, amphetamine etc.); and 2.1% NPS. Amongst people who had injected psychoactive 
drugs (all substances excluding IPEDs), 80% were male (Public Health England, 2015f). 
116 Due to multi-site access the total number of unique NSP clients accessing either or both specialist and pharmacy based 
services is 25,409 clients.
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Northern Ireland
In Northern Ireland, NSP were available in 18 locations, including three outreach services. The number 
of packs dispensed by needle exchange schemes has increased year-on-year since 2007/08, reaching 
28,284 in 2013/14. Specific packs are available for people who inject IPEDs and the number of packs 
issued for this use is rising (Public Health England, 2015f). In 2013/14, of the 15,483 visits to the NSP 
where the person disclosed what they would use the needles for, 58% were for injecting IPEDs (Public 
Health England, 2015f). In 2013/14 there were 241,370 needles distributed during 22,742 client contacts, 
predominantly (98%) through pharmacy-based NSP and the remaining two per cent via specialist agencies.
6.6.2 Hepatitis B vaccination
Hepatitis B is a vaccine-preventable infection that can cause long-term liver disease and liver cancer. 
The UK has a targeted vaccination programme focused on the population groups most at risk, 
including PWID.
The proportion of the PWID participating in the UAM Survey who reported having taken up an offer of the 
hepatitis B vaccination has increased markedly over time, rising from 56% (95% CI, 54%-58%) in 2004 
to 76% (95% CI, 75%-78%) in 2011. In 2014, uptake had dropped slightly to 72% (95% CI, 71%-74%; 
self-reported data) (Public Health England, 2015l) (Figure 6.8). Uptake of hepatitis B vaccination was 
comparable in England, Wales and Northern Ireland, (range: 72%-78%).
Among the participants in the 2012/13 sub-survey of people who inject IPEDs, the level for uptake of 
the hepatitis B vaccination was lower, with 40% (95% CI, 34%-47%) of those injecting IPEDs reporting 
this compared to 76% (95% CI, 75-78%) of those in the main UAM Survey sample of people injecting 
psychoactive drugs (Public Health England, 2014f). 
In Scotland, among those attending needle and syringe programmes during 2013/14, 74% reported 
uptake of the hepatitis B vaccine (Public Health England, Health Protection Scotland, Public Health 
Wales, & Public Health Agency Northern Ireland, 2014; Public Health England et al., 2015).
Figure 6.8: Uptake of hepatitis B vaccination amongst participants in the Unlinked Anonymous 
Monitoring Survey of People Who Inject Drugs: England, Wales and Northern Ireland, 2004-2014
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6.6.3 Hepatitis C diagnosis and treatment 
In the UK, public health programmes related to hepatitis C focus on four key action areas: prevention 
of new infections; increasing awareness of infection; increasing testing and diagnosis; and getting 
diagnosed individuals into treatment and care.
Hepatitis C prevention strategies primarily focus on injecting drug use, as this is presently the most 
important risk factor for acquisition of the virus in the UK. Reducing the number of individuals who 
begin injecting drugs, encouraging injectors to stop injecting, reducing risky behaviour, such as sharing 
needles and syringes, in those who continue to inject, and the early diagnosis and treatment of those 
who become infected with hepatitis C, are all components of the prevention programme.
Data from the UAM Survey of people who inject psychoactive drugs in England, Wales and Northern 
Ireland shows a significant increase over the past decade in the self-reported uptake of voluntary 
confidential testing (VCT) for hepatitis C among survey participants, with the proportion of survey 
participants ever tested rising from 67% (95% CI, 65%-69%) in 2004 to 82% (95% CI, 80%-83%) in 
2010. The level has been stable since then and was 83% (95% CI, 82%-85%) in 2014 (Public Health 
England, 2015l). This stabilisation may suggest that there is saturation among the pool of easy-to-access 
individuals and/or a reduction in awareness raising activity.
The proportion of participants who answered the questions on the uptake of VCT for hepatitis C, reporting 
that they were aware of their hepatitis C infection was 52% (95% CI, 50%-55%) in 2014. This indicates 
that around half of the hepatitis C infections in this population remain undiagnosed. However, this varied 
across England, Wales and Northern Ireland (Table 6.2) (Public Health England, 2015l).
Table 6.2: Uptake of voluntary confidential testing for hepatitis C and the proportion of clients aware of 
hepatitis C infection in England, Wales, Northern Ireland and combined, 2014
UPTAkE OF HEPATITIS C VOLUNTARY 
CONFIDENTIAL TESTING
PROPORTION AWARE OF 
HEPATITIS C INFECTION
England 83% 52%
Wales 85% 48%
Northern Ireland 88% 68%
England, Wales and Northern Ireland 83% 52%
Source: (Public Health England, 2015b) 
Among the participants in the 2012/13 sub-survey of people who inject IPEDs, 32% (95% CI, 26%-38%) 
reported ever having a VCT for HCV (Public Health England, 2014b). The reported level of the uptake of 
VCT for HCV in this group was much lower than that reported among participants in the main survey of 
people who inject psychoactive drugs in the same year (82%, 95% CI, 81%-84%).
In Scotland, among 2,331 PWID interviewed at services providing injection equipment during 2013/14, 
88% reported having been tested for hepatitis C in the past with 45% having been last tested during 
the previous year (Public Health England, 2015f). When those who reported a previous hepatitis C 
diagnosis (prior to 12 months ago) were excluded, the percentage of respondents who had been tested 
for hepatitis C during the last year has been steadily increasing and was 52% in 2013/14 compared to 
40%, 45% and 49% in 2008/09, 2010 and 2011/12 respectively (Public Health England, 2015f).
Across the UK, alternative testing technologies, in particular the use of dried blood spot (DBS) testing, 
are continuing to contribute to the increased uptake of hepatitis C testing among PWID. In England 
Sentinel surveillance data indicate that the number of people tested by venepuncture has fallen by 25% 
between 2013 and 2014 whereas the rate of DBS testing has increased by 23% during that period (Public 
Health England, 2015f). In Wales, in individuals thought to have been tested via Substance Misuse 
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Services or in prisons, it is estimated that the numbers tested via DBS increased by 12% between 2012 
and 2013 with over 1,800 individuals tested in 2013; there were over 1,600 DBS tests undertaken in these 
settings in Wales during 2014.
Mathematical modelling work indicates that successfully treating hepatitis C infections among PWID, 
alongside provision of NSP and drug treatment services, could reduce transmission of hepatitis C and 
so harm. Among the participants from the UAM Survey of PWID who had received a positive diagnosis 
and were aware of their hepatitis C status, 69% in England and 73% in Wales reported that they had 
seen a specialist doctor or nurse about their infection (Public Health England, 2015f). Of the English 
participants, 18% reported receiving any kind of medication related to their infection.
Data collection systems to provide information on the numbers of individuals commencing treatment for 
hepatitis C infection have been under development in Wales. It is estimated that in 2011 and 2013 over 
700 individuals commenced treatment (Public Health England, 2015f). In England ways of monitoring 
numbers being treated are being developed. Although there is much uncertainty, the current available 
data suggest that over 4,000 people with hepatitis C are being treated each year (Public Health England, 
2015f). The number of chronically infected people who began hepatitis C antiviral therapy in Scotland 
increased to 1,273 in 2014/15 (Public Health England, 2015f). For Northern Ireland the available data, 
collected from the Regional Hepatology Unit in Belfast, indicate that since January 2004, 420 people 
have commenced treatment for hepatitis C (Public Health England, 2015f).
6.6.4 HIV diagnosis and treatment
Amongst PWID, the self-reported uptake of VCT for HIV among the UAM Survey of PWID which recruits 
across England, Wales and Northern Ireland has increased significantly since 2004; 63% (95% CI, 61%-
65%) in 2004 to 77% (95% CI, 75%-78%) in 2014 (Figure 6.9) (Public Health England, 2015l). In 2014, 
VCT was comparable across genders; 76% of males and 79% of females self-reported testing. Sixty-
three per cent of those under 25 self-reported VCT compared to 74% of those aged 25-34 and 79% of 
people over 35 years of age. In 2014, of the participants in the UAM Survey who had antibodies to HIV, 
85% (95% CI, 66%-94%) reported awareness of their infection.
Figure 6.9: Uptake of voluntary confidential HIV testing amongst participants in the Unlinked Anonymous 
Monitoring Survey of people who inject drugs: England, Wales and Northern Ireland, 2004-2014
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In Scotland, among those attending needle and syringe programmes during 2013/14, 78% reported 
having ever had a VCT for HIV. In 2008-09, 68% of those surveyed in Scotland had reported uptake 
(Public Health England et al., 2014).
Among the participants in the 2012/13 sub-survey of people who inject IPEDs (Public Health England, 
2014c), 41% (95% CI, 35%-47%) reported ever having a VCT for HIV which is significantly lower than 
self-reported levels in the main UAM Survey of people who inject psychoactive drugs (76%, 95% CI, 
74%-78%). 
The number of HIV-infected people seen for HIV treatment and care in the UK who had acquired 
their infection through injecting has increased over the past decade, with 1,654 seen in 2014 
(Public Health England et al., 2014). In 2014, 418 people who acquired their HIV-infection through 
injecting, and who were seen for care, had CD4 counts of 350 cells/mm3 or less (the recommended 
level to start anti-retroviral therapy). Among those seen for HIV treatment and care with CD4 counts 
of 350 or less in 2014, 87% of those who had acquired their infection through injecting were on 
anti-retroviral therapy, this is similar to the level found in other groups. Following revision to the 
guidelines in 2015, anti-retroviral treatment is now recommended for all those with HIV; in 2014, 90% 
of those seen for care who had acquired their HIV infection through injecting drug use were on anti-
retroviral therapy.
6.7 New developments 
6.7.1 Scotland 
In September 2015 new clinical guidelines for the treatment of HCV in adults were published (Dillon, 
Hayes, Barclay, & Fraser, 2015). Developed in collaboration with Health Improvement Scotland and 
NHS Scotland, the guidelines provide recommendations to Health Boards, Area Drug and Therapeutics 
Committees and clinicians regarding the efficacy of available drugs for treating the different genotypes 
of HCV. The guidelines also take the cost of different drugs into account and recommend the most cost-
effective regimen where efficacy is not statistically different. This is to ensure that the maximum number 
of patients can be treated.
6.7.2 Wales  
Liver Disease Delivery Plan for Wales (2015-20)
In May 2015 Welsh Government published their new Together for Health – Liver Disease Plan which will 
succeed the existing Blood Borne Viral Hepatitis Action Plan for Wales. Encompassing liver disease 
relating to alcohol, obesity and viral hepatitis, the liver disease plan sets out Wales’ on-going key service 
issues, priorities and assurance measures in preventing disease and improving treatment services. 
The plan is split into six key themes:
•	 preventing liver disease and promoting liver health;
•	 timely detection of liver disease;
•	 fast and effective care;
•	 living with liver disease;
•	 improving information; and
•	 targeting research
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The plan calls for partnership working across the NHS and the wider public and voluntary sectors; 
moreover, it requires Health Boards to develop liver disease plans and to report progress on an annual 
basis to ensure delivery of the desired aims.
6.7.3 Northern Ireland
In Northern Ireland a pilot project is being undertaken during 2015 in some pharmacy needle exchange 
sites to survey people using IPEDs. This survey will involve unlinked anonymous survey methodology, 
using a subject-completed questionnaire and collection of a DBS for BBV testing. It aims to provide a 
greater insight into risk and harm among individuals who use IPEDs in Northern Ireland.
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7. Drug-related deaths 
7.1 Introduction 
Data on drug-related deaths submitted to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) by the United Kingdom (UK) are based on three different definitions. The EMCDDA definition 
refers to deaths caused directly by the consumption of at least one illicit drug.117 The UK Drug Misuse 
Definition (DMD),118 originally adopted to measure the impact of the former UK Drug Strategy (Home Office, 
2002), is where the underlying cause is drug abuse, drug dependence, or poisonings where any of the 
substances scheduled under the Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971) are involved. 
The definition used by the Office for National Statistics (ONS) is much wider and includes legal drugs.119 
There are three General Mortality Registers (GMRs) in the UK: figures for England and Wales are both 
reported through a single GMR held by ONS. Due to this, combined figures for England and Wales are 
routinely reported in this chapter. It should be noted that trends may differ between the two countries as 
well as between regions within each country.
The UK DMD has been adopted by the GMRs across the UK and is a subset of the ONS definition. 
Information on deaths is also available from a Special Mortality Register (SMR).120 
In the UK, based on the DMD, the number of deaths registered increased each year from 2004 (n= 1,932) 
to a peak in 2008 (n= 2,607). This was followed by year on year decreases in the number of drug-related 
deaths between 2008 and 2012. However, over the last two years there has been an increase of almost 
30% from 2,283 deaths registered in 2012 to 2,936 in 2014. Among deaths where heroin was mentioned 
on the death certificate, there has been a long-term trend towards other substances (including alcohol) 
being mentioned alongside heroin, and away from heroin being the only drug mentioned. 
There has been growing concern regarding the harmful effects of new psychoactive substances (NPS) 
across the UK. In March 2015 the synthetic stimulant 4,4’-dimethylaminorex (4,4’-DMAR) became 
controlled as a class A drug after it was associated with 37 deaths across the UK. The Prisons and 
Probation Ombudsman (PPO) also reported on an increased number of deaths in prison related to NPS 
between April 2012 and September 2014 (Prisons and Probation Ombudsman, 2015).
7.2 Drug-related deaths and mortality of drug users
7.2.1 Changes to methodology 
In England and Wales, there are significant delays in registration of drug-related deaths - as of 2014, 
the median delay was between five and six months. Scotland is subject to different legislation around 
registration of deaths and experiences only minimal delays. This is problematic for reporting figures based 
on registration year at UK level, as this combines up-to-date data from Scotland with generally delayed 
data from England and Wales. Consequently, UK figures under the EMCDDA definition are, from 2015 
reporting year onwards, counting deaths from England and Wales according to year of occurrence. As 
such, 2013 is the latest available reporting year by this definition, as this is the most recent year where it 
can be assumed that the large majority of relevant deaths in England and Wales have now been registered 
(it is probable that a substantial proportion occurring in 2014 were not registered by the end of 2014). For 
the ONS and DM definitions, the figures continue to represent registrations in the most recent year (2014).
117 These deaths are known as ‘overdoses’, ‘poisonings’ or ‘drug-induced deaths’. See: http://www.emcdda.europa.eu/
themes/key-indicators/drd 
118 Formerly known as the Drug Strategy Definition (DSD) and originally adopted to measure progress against an aim in a 
former UK Drug Strategy (Home Office, 2002).
119 For ONS definitions See: ONS (2013) http://www.ons.gov.uk/ons/publications/re-reference-tables.
html?edition=tcm%3A77-314585 
120 The National Programme on Substance Misuse Deaths (NPSAD) publishes data from inquests into drug-related deaths 
reported by coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Procurators Fiscal in 
Scotland and the Scottish Crime and Drug Enforcement Agency (SCDEA).
United Kingdom Drug Situation 2015 editionPage 118
A further methodological change in this year’s reporting is that deaths with an underlying cause of death 
recorded as the International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) codes X44, X64 or Y14 alongside relevant T-codes have been incorporated into UK 
figures reported using the EMCDDA definition. Due to historical coding practice in England and Wales, 
this has substantially increased the number of deaths counted under this definition. Also, due to changes 
in reporting, the small number of deaths registered in England and Wales where the person was not 
resident in either country are no longer included. For each definition, the time series back to 2004 has 
been updated to take into account these changes (see ST06).
7.2.2 Overdose deaths
Using the EMCDDA definition, the total number of drug-related deaths occurring in the UK during 2013 
was 2,449, a 12% increase from 2012 (n= 2,178) (ST06) and the highest number reported to date. 
Using the slightly different definition of drug misuse, and reporting based on year of registration, there 
were 2,936 drug-related deaths registered in the UK in 2014 (up from 2,551 in 2013). Using the much 
wider ONS definition, there were 4,174 drug-related deaths registered in the UK in 2014 (up from 3,742 
in 2013). 
Overdose deaths recorded in each General Mortality Register
In 2013, a total of 1,868 drug-related deaths were reported under the EMCDDA definition for England 
and Wales – this is 76% of the UK total. In Scotland, 516 deaths (21%) were reported and 65 (3%) for 
Northern Ireland. The combined England and Wales total saw an 18% increase in the number of drug-
related deaths compared to 2012, while Scotland experienced a fall of 6%, and Northern Ireland a rise of 
48%. As a result, deaths from England and Wales make up a greater proportion of the UK total than in 
2012 (up from 73%) and deaths from Scotland a smaller proportion (down from 25%).
Age and gender
Of the deaths occurring in 2013 meeting the EMCDDA definition, almost three-quarters (74%, n= 1,812) 
were males and one-quarter (n= 637) were females (ST05). This proportion is similar across the UK, 
ranging from 72% males in Northern Ireland to 75% males in Scotland. The number of deaths amongst 
males in the UK has increased by 14% between 2012 and 2013 and by 7% amongst females.
In 2013, the average age of those dying was 41.6 years, with males tending to be about five years 
younger than females (40.5 years and 45.1 years respectively). The average age at death has increased 
from 37.6 years in 2004. The average age was lower in Scotland than for the UK as a whole (40 years), 
particularly for women (42 years).
Overall, the largest proportion of deaths occurring in the UK in 2013 occurred in the 40 to 44 years age 
group (433, or 18% of deaths) and deaths in this age group increased by 21% from the previous year 
(n= 358). Compared to 2008, the number of drug-related deaths decreased for all age groups below 
the age of 40 and increased for all age groups above this point. An increase was seen in all age groups 
in 2013 compared to 2012, with the exception of the 20-24 years age group.
Intentionality 
Three-quarters of deaths reported in the UK using the EMCDDA definition for 2013 (72%, 1,769 deaths) 
were accidental self-poisonings (ST05). There were 268 deaths reported as intentional self-poisonings 
and 270 deaths as poisonings of undetermined intent (11% each). The remaining six per cent of deaths 
are reported as mental and behavioural disorders due to psychoactive substance use (‘F‘ codes). A 
higher proportion of deaths are reported as ‘undetermined intent‘ in Scotland than in England and Wales 
(17% vs nine per cent), and a much higher proportion again in Northern Ireland (35%). Northern Ireland 
also has a higher proportion of deaths reported using the ‘F‘ codes than the UK as a whole (18%), with 
only 28% reported as accidental poisonings.
United Kingdom Drug Situation 2015 edition Page 119
7.2.3 Toxicology of overdose deaths
Headline figures for the United Kingdom
Across the UK under the EMCDDA definition for 2013, there were 2,160 deaths counted which featured 
an opioid (ST05). This was 88% of the UK total. Ten per cent involved non-opioid drugs without an 
opioid, while two per cent of the total did not have any drug specified. The proportion with opioid use has 
remained broadly similar since 2004 (ST06), while the proportion with non-opioid drugs without an opioid 
has risen from six per cent. The proportion with no drug specified has fallen from six per cent.
The proportion of deaths featuring an opioid reported through each GMR in 2013 was highest in Scotland 
(93%), followed by Northern Ireland (91%), with England and Wales lowest (87%). Almost all cases with 
no drug specified were in England and Wales, where 11% featured non-opioid drugs without an opioid.
Table 7.1: Mentions of selected drugs on death certificates, England and Wales 2004 to 2013 (EMCDDA 
definition)
DATE OF DEATH YEAR
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
All EMCDDA def 1706 1739 1684 1911 1788 1865 1537 1597 1586 1868
Opioids 1475 1467 1384 1581 1503 1636 1360 1427 1368 1624
Heroin 799 782 777 894 798 909 609 559 608 792
Methadone 204 231 290 349 399 375 401 490 392 366
Tramadol 14 29 20 28 37 37 84 163 178 237
Cocaine 151 186 181 231 214 156 108 120 138 174
Amphetamines 86 96 92 102 94 48 57 78 114 126
Ecstasy 51 46 48 50 39 4 9 25 40 37
Benzodiazepines 140 125 128 164 184 245 216 248 244 287
Opiates % 86% 84% 82% 83% 84% 88% 88% 89% 86% 87%
Heroin % 47% 45% 46% 47% 45% 49% 40% 35% 38% 42%
Methadone % 12% 13% 17% 18% 22% 20% 26% 31% 25% 20%
Tramadol % 1% 2% 1% 1% 2% 2% 5% 10% 11% 13%
Cocaine % 9% 11% 11% 12% 12% 8% 7% 8% 9% 9%
Amphetamines % 5% 6% 5% 5% 5% 3% 4% 5% 7% 7%
Ecstasy % 3% 3% 3% 3% 2% 0% 1% 2% 3% 2%
Benzodiazepines % 8% 7% 8% 9% 10% 13% 14% 16% 15% 15%
Source: ST05
Detail of substances mentioned/implicated from each General Mortality Register within the United Kingdom
Each of the three GMRs in the UK are subject to annual reporting which reports by substances mentioned 
or implicated in greater detail than is currently available at UK level.
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England and Wales
The most recent figures for England and Wales cover 2014 registrations (Office for National Statistics, 
2015) reported using the DMD and the broader ONS definition. There were 952 registrations of deaths 
where heroin/morphine was mentioned, which represented a 24% increase on registrations in 2013 
and a 64% increase from 2012 (however, deaths registered in 2011 to 2012 were notably lower than the 
preceding years). Heroin/morphine deaths accounted for 45% of deaths under the DMD, and heroin 
was the only drug mentioned in 23% of drug misuse deaths (492 deaths). Methadone was mentioned 
in 394 cases (19%), which was a similar number to the previous two years and lower than a peak of 486 
in 2011. Methadone was the only drug mentioned in 132 deaths (six per cent of the total). Tramadol, 
which recently became a controlled drug within the UK (UK Focal Point, 2013), accounted for 240 deaths 
(11%), the highest number reported to date and an increase of nine per cent on 2013. In total, 1,786 
deaths featured at least one opioid, disregarding those included as part of a paracetamol compound.
Benzodiazepines were mentioned in 372 deaths registered in 2014 in England and Wales, 18% of the 
total under the DMD, and an increase of nine per cent on 2013. However, only 22 of these cases did 
not also mention another drug. Cocaine was mentioned in 247 deaths (12%), an increase of 46% on 
2013. Similarly, the number of mentions of amphetamines rose to 151 (seven per cent of deaths), a 
26% increase on 2013. For both cocaine and amphetamines, the number of mentions in deaths was 
more than double that reported in 2011. Mentions of NPS continued to rise, increasing slightly to 67 
(three per cent of deaths), although ONS noted that analysis of the trends based on the year the death 
occurred suggested that NPS deaths fell in 2013 after successive rises in 2011 and 2012. The majority 
of NPS deaths were accounted for by mentions of cathinones (principally mephedrone) and GHB/GBL. 
Around one-third of deaths registered in 2014 where at least one opioid was mentioned also had a 
mention of alcohol (576 deaths, 32%), rising to 36% for deaths where heroin/morphine or methadone 
were mentioned.
When broken down by substance, there were distinct differences in the age profile among deaths 
registered in England and Wales in 2014. The majority of deaths where NPS, cocaine or amphetamine 
were mentioned occurred in people under 40 years of age, while the reverse was true for deaths where 
opioids or benzodiazepines were mentioned.
Scotland
Statistics for drug-related deaths in Scotland registered in 2014 were published in August 2015 (National 
Records of Scotland, 2015). For this report, drug-related deaths are identified by National Records 
of Scotland (NRS) requesting further information on all deaths involving drugs or persons known, or 
suspected, to be drug-dependent, or where the information on the death certificate is vague or suggests 
that there might be a background of drug abuse. This corresponds closely to the UK drug misuse 
definition. There were 613 such deaths registered in Scotland in 2014.
In 2014, there were 535 deaths in Scotland where an opioid was implicated. This was 87% of all drug-
related deaths, an increase of 16% on 2013 (461 deaths). In 209 of these cases, only opioids (and 
possibly alcohol) were implicated in the death. Within the opioid category, heroin/morphine was the 
most commonly implicated drug, with 309 deaths (50% of all deaths), followed by methadone with 214 
deaths (35%). Deaths where heroin/morphine was implicated increased by 40% in 2014 rising from 
221 in 2013. Benzodiazepines were implicated in 121 deaths in 2014 (20%), falling by 38% from 2012. 
Cocaine was implicated in seven per cent of deaths, with ecstasy and amphetamines, reported distinctly, 
at two and four per cent respectively. Alcohol was implicated in 106 drug-related deaths (17%). NPS were 
implicated in 62 cases; benzodiazepine–type NPS were the only NPS present. There were only seven 
cases where NPS were implicated without any other substance.
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Northern Ireland
Tables for drug-related deaths registered in 2014 in Northern Ireland were published in September 
2015.121 These are reported according to the DMD and ONS definitions. In contrast to the rest of the UK, 
benzodiazepines were the most commonly mentioned substance group, being mentioned in 45 deaths 
registered in 2014 (51% of deaths counted under DMD) and 365 deaths registered between 2004 and 
2014 (59%). Again in contrast to the UK as a whole, tramadol was the most commonly mentioned opioid 
drug, in 22 deaths registered in 2014 (25%), followed by codeine (excluding compounds), mentioned in 
20 deaths (23%). Heroin/morphine was mentioned in 11 deaths (13%).
7.2.4 Mortality cohort studies
Pierce et al. carried out a national record linkage study of 198,247 opioid users in England identified 
via drug treatment and criminal justice sources between April 2005 and March 2009, linking to mortality 
records (Pierce, Bird, Hickman, & Millar, 2015). They identified 3,974 deaths from all causes within the 
cohort, a rate almost six times what would be expected in a sample of the general population with the 
same distribution age and gender (standardised mortality ratio of 5.7, with 95% confidence intervals (CI): 
5.5-5.9). Of these deaths, 1,715 (43%) were drug-related poisonings. The authors found that risk of drug-
related poisoning was greater for males than females (crude mortality rate of 35 per 10,000 person years 
(PY) for men compared to 23 for women), that risk increased with age, and that the difference in risk 
between males and females narrowed considerably with age. The study also found that the opioid users 
in the cohort were at elevated risk of mortality from other causes of death, including infectious disease, 
respiratory disease, circulatory disease, liver disease, suicide, and homicide.
In a follow-up study, 151,983 opioid users treated for opioid dependence in England between April 
2005 and March 2009 were identified in order to assess risk of drug-related poisoning (DRP) (Pierce, 
Bird, Hickman, Marsden, et al., 2015). Differences in risk were considered according to the type(s) of 
treatment received, as well as modifying factors such as patient characteristics, route of referral, and 
treatment completion. The study found that there were 1,499 DRP deaths in the cohort, a rate of 3.4 
per 1,000 PY (with 95% CI: 3.2-3.6). Risk when enrolled only in a psychological intervention was found 
to be double that observed during periods receiving opioid agonist pharmacotherapy with or without 
psychological support (adjusted hazard ratio of 2.07, with 95% CI: 1.75 to 2.46). Increased risk of DRP 
death outside of treatment was greater for: men; illicit drug injectors; and those reporting problematic 
alcohol use.
White et al. carried out a longitudinal cohort study which explored risk of opioid poisoning in relation 
to periods of treatment for opioid use in England (White et al., 2015). This study used a counterfactual 
model which used estimated annual prevalence of opioid use, treatment data and mortality data to 
establish risk of opioid poisoning prior to treatment, during treatment and after treatment. It was then 
possible to estimate the number of opioid poisonings prevented by treatment. The authors found that 
220,665 opioid users had been in treatment in England at some time between April 2008 and March 
2011. There were 741 opioid poisonings during treatment, a rate of 0.2 per 100 PY, increasing to 0.4 per 
100 PY after treatment (268 deaths). Prior to treatment the risk was higher still at 0.8 per 100 PY (2,722 
deaths). Using a counterfactual method, the authors estimated that an average of 880 opioid poisonings 
(with 95% CI: 702 to 1,084) were prevented by treatment services in England annually.
Bird et al. (2015) explored the impact of Opioid Substitution Treatment (OST) provided to prisoners 
in Scotland on drug-related death risk following prison release (Bird, Fischbacher, Graham, & Fraser, 
2015). The study found that between 1996 and 2002, prior to the introduction of prison-based OST, there 
were 305 drug-related deaths in the 12 weeks following prison release, a rate of 3.8 per 1,000 prison 
releases (with 95% CI: 3.4-4.2), with 145 occurring in the first 14 days. Between 2003 and 2007, after the 
introduction of prison-based OST, this rate fell to 2.2 per 1,000 prison releases (154 deaths; with 95% 
CI: 1.8 to 2.5). Whilst the overall rate of Drug-Related Deaths (DRD) was significantly decreased, the 
proportion that occurred within 14 days post release did not appreciably change.
121 See: http://www.nisra.gov.uk/demography/default.asp30.htm
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7.3 Trends in drug-related deaths
7.3.1 Short-term trends
Using the revised figures under the EMCDDA definition, the figure of 2,449 drug-related deaths in 2013 
is the highest to date for the UK, exceeding the previous peak of 2,432 in 2009 (ST06). Due to the 
registration delays in England and Wales, the 2013 figure will be revised slightly upwards when the UK 
reports to the EMCDDA in 2016. Following the previous peak in 2009, there was a sharp fall in drug-
related deaths in 2010 (to 2,058, a decrease of 15% from 2009), with a small rise in 2011, a stable figure 
in 2012, and the increase of 12% observed for 2013.
It should be noted that figures for 2014 based on using year of registration indicate that the large increase 
in drug-related deaths in the UK for 2013 is very likely to have been followed by a further significant 
increase in 2014. This is evident in the figures submitted for the UK for 2014 registrations using the DMD, 
which show a 15% increase in registrations from 2013, and a 29% total increase from 2012. Figures 
published by ONS for England and Wales for 2014 registrations (Office for National Statistics, 2015) 
show a 15% increase using the DMD from 2013 and a 37% increase from 2012. In Scotland, where 
the registration delays are minimal and therefore registration year essentially equates to year of death, 
there was a reported 16% rise in 2014, to 613 deaths (National Records of Scotland, 2015). There is 
also an increase of 15% in deaths registered in Northern Ireland using DMD in 2014, to 90 deaths. It is 
therefore safe to conclude, with all the available information, that the increase reported for the UK for 
2013 probably represents the start of an increasing trend. However, ONS figures suggest that Wales 
may be an exception to the UK trend, with a reported 16% fall in deaths registered using DMD in 2014.
7.3.2 Long-term trends
The GMRs for England & Wales and Scotland have reported figures going back to deaths registered 
in 1993 and 1996 respectively. Figure 7.1 shows the trend from 2004 onwards using each definition. 
It should be noted that with the change to report by year of occurrence for the EMCDDA definition this 
now differs from the other two definitions which continue to be reported by year of registration. This can 
cause divergence between the definitions in individual years, such as in 2010 where a large fall can be 
observed in the EMCDDA definition which is less pronounced in the other definitions.
Figure 7.1: Drug-related deaths in the United Kingdom, 2004 to 2014 by definition
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In Scotland, there has been a general increasing trend in drug-related deaths since reporting began in 
1996 (National Records of Scotland, 2015). Figure 7.2 shows the annual figures, along with 3- and 5-year 
moving averages, to provide a better indication of the overall long-term trend.
Figure 7.2: Drug-related deaths registered in Scotland, 3- and 5-year moving averages, and likely 
range of values around 5-year moving average, 1996-2014
650
600
550
500
450
400
350
300
250
200
150
100
50
0
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Registered in year 3 year average 5 year average
Likely lower Likely upper
Source: National Records of Scotland, 2015
7.4 Complementary sources of data
7.4.1 National Programme on Substance Abuse Deaths (England, Northern Ireland, the Channel Islands 
and the Isle of Man) 
The National Programme on Substance Abuse Deaths (NPSAD) published their most recent report 
in September 2015 (Claridge & Goodair, 2015). This report covered drug-related deaths in England, 
Northern Ireland, the Channel Islands and the Isle of Man, occurring in 2013. Unlike previous NPSAD 
reports, Scotland and Wales are not within the scope of the report. The NPSAD report is based on a 
specific definition which may include deaths that are not normally within the scope of the drug misuse 
definition (DMD). Figures are also reported against the DMD used across the UK. NPSAD are notified 
of relevant deaths by coroners, and report that 75 of 92 coroners’ jurisdictions in England submitted 
responses in 2013, a coverage rate of 81.5%.
NPSAD reported 1,344 cases under their definition in England in 2013, with psychoactive drugs 
implicated in 1,237 cases (90%). This total was similar to that for 2012 (1,363); however, the figure 
for 2013 is likely to increase due to late registrations. The report found that there had been a marked 
increase in the proportion of these deaths where heroin/morphine was implicated, from 34% in 2012 
to 41% in 2013, which aligns with the recent increase in mentions of heroin/morphine reported via the 
England and Wales GMR. There was also an increase in the proportion of deaths where heroin/morphine 
was the sole drug implicated, from nine per cent to 11%.
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NPSAD also request information on which psychoactive drugs were prescribed. They found that 32.5% 
of individuals who died from a methadone-related death (n= 86) were known to have had the drug 
prescribed to them. This equates to 37% of those with a known prescribing status.
Information pertaining to drug abuse/dependence history was available for 1,067 individuals, of whom 
64% had a history. Those with a history of drug abuse/dependence were more likely to be male, to be 
younger, and/or experience accidental death, compared to those without such a history.
7.4.2 National Drug-Related Deaths Database (Scotland)
The fifth report from the National Drug-Related Deaths Database (NDRDD) in Scotland was published in 
April 2015, examining the personal circumstances of those who died a drug-related death in Scotland in 
2013 (Barnsdale, Gordon, & McAuley, 2015). The drug-related deaths in the NDRDD report are a sub-set 
of the 581 drug-related deaths published by NRS in August 2014 (National Records of Scotland, 2014).122 
In 2013, there were 448 cases identified as eligible for inclusion in the main NDRDD cohort (a decrease 
from 479 in 2012). As with previous years, around three-quarters (76%) were male. The proportion of these 
deaths where the individual was aged 35 and over has increased from half of deaths (50%) in 2009 to 
two-thirds (66%) of deaths in 2013, while the mean age increased from 34.4 in 2009 to 39.1 years in 2013. 
Nine out of ten individuals (88%) were known to be using drugs prior to death, and almost two-thirds 
(64%) had a known history of intravenous (IV) drug use. Over half (51%) had been prescribed an OST 
drug since 2009, including 31% prescribed an OST drug when they died (up from 21% in 2009). Over 
one-third (37%) had been prescribed an anti-depressant in the 30 days before death, with one-fifth (21%) 
recently prescribed diazepam and one-tenth (10%) recently prescribed gabapentin. Almost two-thirds 
(63%) had a psychiatric condition recorded, the highest reported so far.
Over half (53%) of those included in the cohort had been in contact with drug treatment services before 
they died. Seven in ten (71%) had been in contact with at least one service (drug treatment, hospital, 
police or prison) which may have identified them as being at risk of drug-related death.
In 68% of cases, more than one drug was implicated in the death. Diazepam was the drug most 
frequently found to be present (66% of cases, although down from 77% in 2009), but implicated in fewer 
than one-third of these cases (19% of all cases). The most commonly implicated drugs were heroin/
morphine (44%) and methadone (42%), with opioids implicated in 76% of cases.
7.4.3 Public Health England analysis
Public Health England (PHE) produced an analysis of trends in drug-related deaths in England using the 
DMD in July 2015 based on extracts of data received from the ONS (Public Health England, 2015j). This 
followed the reported rise in deaths registered in England using the DMD by the ONS for 2013 (Office for 
National Statistics, 2014) and a national summit on drug-related deaths in England held in January 2015. 
However, it predated the latest ONS bulletin (Office for National Statistics, 2015).
For this analysis, PHE reported figures based on year of death, highlighting that registration delays 
meant that later years were incomplete. The PHE analysis found that a large number of drug misuse 
deaths registered in 2013 had occurred in the same year (892 deaths), but that there had also been an 
increase in deaths registered after more than a year. It should be noted that the subsequently published 
data on 2014 registrations in England from the ONS indicated a further rise, and the PHE report commits 
to updating the analysis going forward.
The analysis also found that among deaths where heroin was mentioned on the death certificate, there 
was a clear long-term trend towards other substances (including alcohol) being mentioned alongside 
heroin, and away from heroin being the only drug mentioned. A data linkage exercise between drug 
poisoning data and drug treatment data was included in this report, showing that three-fifths (59%) 
of opioid misuse deaths in 2011 had received no treatment since at least 2006 (and possibly never). 
122  Since the latest NDRDD report was published, the NRS has published figures for 2014 (National Records of Scotland, 2015)
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This proportion had remained reasonably consistent over the full period studied (2008-2012). When 
considered in the context of prevalence estimates and treatment numbers, the analysis suggested that 
treatment had a significant protective effect for opioid users, supporting the findings of the previously 
mentioned White et al. (2015) study. However, it also suggested that there has been little change in the 
extent of the protective effect in recent years.
7.4.4 Relative safety of buprenorphine and methadone
Marteau et al. (2015) published an analysis looking at population-wide overdose risk emerging from 
the prescription of methadone and buprenorphine in OST in England and Wales (Marteau, McDonald, 
& Patel, 2015). For this analysis, drug-related deaths where methadone and buprenorphine were 
mentioned were presented as a rate of all prescriptions issued for these drugs, between 2007 and 2012. 
In this period there were 2,366 deaths where methadone was mentioned and 52 where buprenorphine 
was mentioned, with 17.3 million methadone prescriptions and 2.6 million buprenorphine prescriptions 
issued. This translates to rates of 0.137 deaths per 1,000 prescriptions of methadone and 0.022 per 
1,000 prescriptions of buprenorphine, or a relative risk ratio of 6.23 (with 95% CI: 4.79 to 8.10). Therefore, 
the authors assert that buprenorphine is six times safer than methadone in regard to overdose risk in 
the general population and suggest that clinicians should be aware of this increased risk, as well as 
recommending that tighter regulations are needed to prevent diversion.
7.4.5 Calls for legislative change around registration of deaths in England and Wales
In a correspondence to the Lancet in May 2015 on behalf of the Royal Statistical Society (RSS), Professor 
Sheila Bird reiterated a call for legislation to change the process of registration of deaths in England 
and Wales.123 Bird cited lengthy delays in relation to registration of drug-related deaths and suicides 
in particular, urging the Lancet and the Farr Institute of Health Informatics Research to join the RSS in 
lobbying the government on this issue.
7.4.6 Deaths from HIV/AIDS
Based on reports received up to the end of March 2014124, in England and Wales, there were 1,555 
AIDS deaths of people whose exposure category was recorded as either “injecting drug use” or “sex 
between men and injecting drug use”. This accounted for 7.9% of AIDS deaths recorded up to that date 
(n= 19,743). In Northern Ireland, there were 8 AIDS deaths of people who inject drugs (PWID) which 
accounted for between 6% and 7% of all AIDS deaths.125 In Scotland the percentage was much higher at 
45.1% of AIDS deaths (864 deaths, n= 1,915) (Public Health England, unpublished data).
7.4.7 Deaths from hepatitis C
Both hospital admissions and deaths from hepatitis C virus (HCV)-related end stage liver disease and 
hepatocellular carcinoma are continuing to rise in the UK (Public Health England, 2015f). Hospital 
admissions rose from 611 in 1998 to 2,658 in 2013, while deaths rose from 98 in 1996 to 424 in 2013. 
This increase is particularly notable in Scotland where liver-related deaths among people diagnosed with 
hepatitis C increased 3.2-fold from 43 in 1996 to 139 in 2013. However, in the last five years (2009-2013), 
the annual number of liver-related deaths has remained relatively stable. Linking records from Scotland’s 
National Hepatitis C Diagnoses Database to the national register of deaths showed that 851 (52%) of 
the total 1,638 liver-related deaths during 1996-2013 among people diagnosed with hepatitis C had any 
mention of hepatitis C on their death certificate. Among the 139 liver-related deaths in 2013, only 110 
(79%) had liver disease recorded as the underlying cause of death (alcoholic liver disease was the most 
prevalent underlying cause in 36). It is therefore likely that the total number of deaths recorded as HCV-
related end stage liver disease is an underestimate of the true situation.
123 See: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960920-5/fulltext?rss%3Dyes
124 Numbers for 2013 and 2014 are likely to increase as further reports are received; data presented are from reports 
received to the end of March 2014.
125 The total number of AIDS deaths in the period in NI was between 120 and 124. Due to suppression of statistics under five 
n could not be established precisely from published data. 
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7.5 New developments
7.5.1 Control of tramadol under the Misuse of Drugs Act 1971
Tramadol became a schedule 3 controlled drug under the Misuse of Drugs Act 1971 in June 2014 
(UK Focal Point, 2014), following advice from the Advisory Council on the Misuse of Drugs (ACMD), 
which expressed particular concern about the increasing number of deaths in the UK involving tramadol 
(Advisory Council on the Misuse of Drugs, 2013). ONS reported 240 deaths registered in 2014 in England 
and Wales where tramadol was mentioned (Office for National Statistics, 2015). Although this was the 
highest number yet recorded, due to registration delays it is not possible as yet to assess the effect of the 
control of tramadol on the number of deaths related to tramadol. Scotland reported a fall in drug-related 
deaths where tramadol was implicated from 64 in 2013 to 38 in 2014.
7.5.2 Deaths in Northern Ireland due to 4,4’-Dimethylaminorex and subsequent response
Cosbey et al. (2014) identified a total of 18 drug abuse deaths in Northern Ireland where the synthetic 
stimulant 44,4‘-DMAR was detected alongside other substances in toxicology samples (Cosbey et al., 
2014). The ACMD identified 37 deaths in total in the UK associated with 4,4‘-DMAR and recommended 
that this compound be controlled under the Misuse of Drugs Act 1971 as a class A substance. 4,4’-
DMAR became a class A drug in March 2015.
7.5.3 Deaths in prison
In July 2015, the PPO reported on 19 deaths which have occurred in prison between April 2012 and 
September 2014, where the prisoner was known or strongly suspected to have been using NPS-type 
drugs before their death (Prisons and Probation Ombudsman, 2015) (see section 8.7.1)
7.5.4 Preventing drug-related deaths
In April 2014, PHE published a briefing on Preventing Drug-related Death (Public Health England, 
2014e). The briefing contains practical advice for commissioners and services on preventing drug-
related deaths and additionally provides prompts to ensure best practice. 
In June 2014, the Welsh Government published Guidance for Undertaking Fatal and Non-Fatal Drug 
Poisoning Reviews in Wales (Welsh Government, 2014a). The guidance outlines the framework and 
procedures to undertake reviews of drug poisonings in Wales in line with the key aims within their 
substance misuse strategy (Welsh Assembly Government, 2008a). This document provides guidance 
for all stakeholders within Wales who have a remit for reducing fatal and non-fatal drug poisonings, and 
encompasses all stages of review including instigation, collaborative working with statutory bodies in data 
collection, establishment and implementation of recommendations/lessons learned and dissemination 
of information for action.
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8. Drug users in prison
8.1 Introduction
The link between substance misuse and crime is strong and represents a major challenge to the efforts 
to turn prisoners away from further criminal activity. Offenders do not necessarily want to stop taking 
drugs just because they have been imprisoned and so the demand for drugs in prisons is strong. For 
many prisoners they form a ‘lifestyle’ as well as a physical and psychological dependency. As such there 
is an unwelcome but deeply held desire for drugs in prisons: to maintain dependency; as recreation; 
to continue the ‘lifestyle’ or; to make money out of their supply. Drugs can have a number of different 
impacts in prisons. In addition to making rehabilitation more difficult, they can: present significant health 
risks; cause unpredictable and violent behaviour; put pressure on families and staff to supply them; and 
form the basis of a trade which involves debt, intimidation and violence.
From April 2011, the Department of Health (DH) assumed responsibility for funding both clinical and non-
clinical drug and alcohol treatment in all prisons and the community in England. The responsibility for 
commissioning substance misuse services was devolved to local partnerships in line with the key Patel 
Report recommendation that integrated and needs-led treatment services are best commissioned at a 
local level (Department of Health, 2010). In April 2013, as part of the new health and care changes set 
out in the Health and Social Care Act 2012 (Her Majesty’s Government, 2012b), National Health Service 
(NHS) England became responsible for commissioning health services in prisons and other secure 
accommodation in England. 
In May 2013, the Ministry of Justice (MoJ) published a new strategy, Transforming Rehabilitation: 
A strategy for reform (Ministry of Justice, 2013b), with the aim of reforming the criminal justice system 
(CJS) and reducing reoffending rates for prisoners. One of the proposed actions was to provide offenders 
with the support they need “through the prison gate”, offering continuous support, including treatment 
for substance misuse, from custody into the community.
In Wales, health services are the responsibility of the Welsh Government, with responsibility for 
commissioning devolved to local Health Boards. The National Offender Management Service (NOMS) 
retains responsibility for non-clinical substance misuse services for sentenced offenders. In Scotland, 
responsibility for the provision of health care services in prisons transferred from the Scottish Prison 
Service (SPS) to the NHS in November 2011. A range of health and substance misuse services are 
now provided within Scottish prisons by the respective local Health Boards. In Northern Ireland (NI), the 
South Eastern Health and Social Care Trust (SEHSCT) assumed responsibility to providing healthcare 
in prisons in 2008. 
Those in prison have access to a range of treatment services for substance misuse including clinical 
services such as detoxification and opioid substitution treatment (OST), structured psychosocial 
interventions, case management and structured counselling. Testing for HIV and hepatitis, and the 
vaccination against hepatitis B are also available. In Scotland, Take Home Naloxone (THN) is widely 
available for prisoners at risk of opioid overdose on release and is becoming increasingly available in 
England and Wales. 
There are a range of measures to prevent drugs entering prison including clearly-defined searching 
procedures covering all possible routes; passive and active drug dogs, with passive dogs available 
to all prisons; CCTV surveillance of all social visit areas and low-level fixed furniture; and comprehensive 
measures to tackle visitors attempting to smuggle drugs, including closed visits, visit bans and 
police arrest. 
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8.2 Prison service overview
8.2.1 Custodial estate
England and Wales
There are currently 123 prisons in England and Wales; 121 of which are currently in use. The majority are 
run by Her Majesty’s Prison Service, whilst 14 prisons are currently contracted out to private companies. Of 
the 121 prisons in use, 12 establishments are for female inmates, five are Young Offender Institutions (YOIs) 
and three are Immigration Removal Centres (IRCs) (National Offender Management Service, 2015b). 
Prisoners on remand are generally kept in separate establishments to those in which prisoners are held 
after being handed down a custodial sentence. When sentenced, adult male prisoners are assigned to 
the correct security category and allocated to an appropriate prison. Categorisation is based on the level 
of risk a prisoner might pose to the public or national security should they escape and the likelihood of 
their making attempts to do so, as set out in the Prison Service Instruction (PSI) 40/2011.126 
There are four different security categories: 
•	 Category A – Prisoners whose escape would be highly dangerous to the public, or the police, or 
the security of the state and for whom the aim must be to make escape impossible. Category A 
prisoners are subdivided further into Standard risk, High risk and Exceptional risk, based on their 
likelihood of escaping.
•	 Category B – Prisoners for whom the very highest conditions of security are not necessary but for 
whom escape must be made very difficult. 
•	 Category C – Prisoners who cannot be trusted in open conditions, but who do not have the resources 
and will to make a determined escape attempt. 
•	 Category D – Prisoners who present a low risk; can be reasonably trusted in open conditions and for 
whom open conditions are appropriate. 
Types of prison
There are multiple types of prison operating throughout England and Wales, designed to accommodate 
the different categories of prisoners whilst they are on remand and post-conviction (see Table 8.1). 
Young offenders
Offenders under the age of 18 are held in either a Secure Children’s Home (SCH), a Secure Training 
Centre (STC), or a Young Offender Institution (YOI). SCHs and STCs are for those aged under 18 years 
old only, while YOIs hold offenders up to the age of 25. Typically those aged less than 15 years old will 
be held in a SCH and those over 15 will be held in either a YOI or STC. For female young people only 
those aged 17 years or older are normally placed in a YOI. There are eight YOIs holding young males in 
England and Wales and three female young person units in England, which are attached to adult prisons. 
From April 2013 to March 2014, most young people under the age of 18 held in custody in England were 
in YOIs (68%), 22% were in STCs and the remaining 11% were in SCHs (Public Health England, 2015d). 
Young offenders are classified as suitable for either closed or open conditions according to PSI 41/2011.127 
126 See: http://www.justice.gov.uk/offenders/psis/prison-service-instructions-2011 
127 See: http://www.justice.gov.uk/offenders/psis/prison-service-instructions-2011 
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Table 8.1: Types of prison in England and Wales
TYPE OF PRISON DESCRIPTION
Local
There are 31 local prisons, which serve the courts and receive remand and post-conviction 
prisoners, before their allocation to other establishments. They hold many short-term prisoners 
including remand prisoners, those awaiting allocation to training prisons and may hold a small 
number of immigration detainees.
Training
May be open or closed and offer courses and training as part of prisoner rehabilitation. 
A number of category ‘C’ training prisons have also been identified as “resettlement prisons”.
Open
Accommodate category ‘D’ prisoners, as well as indeterminate and longer-sentenced prisoners 
who are coming toward the end of their sentence and who have gradually worked their way down 
the categories. Open prisons are part of the resettlement programme to reintegrate prisoners 
back into society.
Resettlement
Established under Transforming Rehabilitation: A strategy for reform (Ministry of Justice, 
2013), resettlement prisons are expected to hold category ‘C’ prisoners who will engage with 
resettlement providers in the last three months of their sentence. Offenders released from these 
prisons are expected to leave with a package of support in place, delivered by one of the new 
Community Rehabilitation Companies (CRCs), enabling better linkage with local settlement 
services and improved family contact.
High Security
There are two types of high security prison: dispersal prisons and local prisons. Core locals 
primarily serve the courts and the majority of their population are those described in the local 
prisoner section (i.e. those on remand or awaiting sentence), as well as short-term sentenced 
category ‘B’ and ‘C’ prisoners from the local area. The dispersal prisons serve to spread the 
category ‘A’ population, ensuring that the most dangerous prisoners are not concentrated in a 
single establishment, thereby reducing the risks involved in holding them. There are eight high 
security prisons in England and Wales. 
Female
Of the 12 female prisons, only two are closed training prisons; the rest have a combined local and 
trainer function. All female prisons have been identified as resettlement prisons.
Immigration Removal Centre
These establishments are holding centres for foreign nationals awaiting decisions on their asylum 
claims, or awaiting deportation following a failed application. They are operated on behalf of the 
Home Office by the MoJ’s NOMS.
Source: (National Offender Management Service, 2015b) 
Inmate profile 
There are approximately 100,000 unique admissions to the prison system in England and Wales within 
the year. The prison population on any given day is around 85,000 (Public Health England, 2015d). 
Approximately 81,000 inmates are male. In March 2015 the YOI population of under 18 year olds was 
1,004, consisting of 966 males and 38 females (Ministry of Justice, 2015c). 
Scotland
The Scottish Prison Service (SPS) has 15 prisons, including one open estate prison, Her Majesty’s Prison 
(HMP) Castle Huntly. Thirteen of the prisons are publicly managed and two prisons are operated by 
private sector companies under contract to the SPS. 
The available design capacity for prisons in Scotland is for 8,082 prisoners (personal communication – 
Scottish Prison Service). The average daily prisoner population during 2014/15 was 7,306 male and 425 
female inmates, totalling 7,731 (Scottish Prison Service, 2015).
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Northern Ireland
In NI there are three publicly run prison establishments, one of which includes a young offenders’ centre. 
There are two male prisons and one female prison. 
In March 2015 the prison population consisted of 1,726 inmates: 66 adult females, 1,546 adult males 
and 114 young offenders (three female and 111 male) (Northern Ireland Prison Service, 2015). 
8.2.2 Community
England and Wales
Under the new rehabilitation reforms, which commenced operation in early 2015, Community 
Rehabilitation Companies (CRCs) will be required to ensure that all sentence requirements or licence 
conditions/supervision requirements are delivered for the offenders they manage. This includes more 
punitive or restrictive elements of a Community or Suspended Sentence Order such as unpaid work 
or exclusion requirements, or specific licence conditions such as drug testing. CRCs will oversee the 
sentence of the court for each offender allocated to them to manage, and in doing so seek to rehabilitate 
offenders and reduce reoffending. These reforms will ensure that essentially every offender released 
from custody will receive statutory supervision and rehabilitation in the community. 
8.3 Strategy and co-ordination
8.3.1 Prison drug strategies
England and Wales
In December 2010 the MoJ published a Green Paper, Breaking the Cycle (Ministry of Justice, 2010), 
which proposed fundamental changes to the penal system based on the four principles of: protecting 
the public; punishing and rehabilitating offenders; transparency and accountability; and decentralisation. 
A key aim was to ensure prisoners were able to break the cycle of offending and incarceration through 
rehabilitation. 
A component of the report was to support offenders to recover fully from their addiction to drugs and/or 
alcohol whilst they were in prison. Proposed actions included working to reduce the availability of illicit 
drugs in prison, introducing pilots for Drug Recovery Wings (DRWs) in prisons, and to commence pilot 
payment by results schemes for providers who run the prison-based treatment services. 
In the same year, The Patel Report (Department of Health, 2010) was published which reviewed the prison 
drug treatment strategy and made a number of recommendations for the future. The ultimate aims of 
the drug strategy for prisons are that: offenders who use drugs cease their drug use in prison; that those 
who do not use drugs do not start to do so in prison; and that abstinence continues after release into the 
community. The Prison Service Drug Strategy (Department of Health, 2010) has two aims: 
•	 to reduce the demand for drugs in prisons; and 
•	 to reduce the supply of them
These aims are pursued through a combination of measures focusing on treatment, enforcement, 
and security:
•	 detoxification (clinical management of withdrawal);
•	 provision of integrated substance misuse services and interventions;
•	 mandatory drug testing to deter prisoners from misusing drugs;
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•	 information on patterns of drugs misuse, as well as identifying prisoners in need of treatment;
•	 communication and education to prisoners on the dangers associated with using drugs;
•	 voluntary or compact-based testing programmes;
•	 legislative and other mechanisms to enable an effective response to those who choose to abuse 
drugs; and 
•	 effective security measures aimed at supply reduction, including:
 – passive search dogs, which are available in all prisons, to detect visitors carrying drugs, and 
active search dogs, used to search goods and vehicles; 
 – strict measures to tackle visitors who smuggle or attempt to smuggle drugs. This includes, on 
suspicion of smuggling, ‘closed’ visits (i.e. through a glass screen) or visit bans, and arrest and 
prosecution where there is sufficient evidence; and
 – effective intelligence systems, targeting those trafficking drugs
In May 2013, the MoJ published a new strategy, Transforming Rehabilitation: A strategy for reform, 
(Ministry of Justice, 2013b), with the aim of reforming the CJS and reducing reoffending rates for 
prisoners. One of the proposed actions was to provide offenders with the support they need “through 
the prison gate” by offering continuous support, including treatment for substance misuse, from custody 
into the community. The strategy also called for new legislation which would make engagement with 
rehabilitation mandatory over a 12 month period for all prisoners released from short custodial sentences 
of up to two years. Upon release, offenders would be subject first to a standard licence period and 
then to an additional supervision period for the purpose of rehabilitation. Following release from prison 
offenders will be supervised by either a CRC, who supervise low to medium risk offenders, or through 
the National Probation Service, which supervises the highest risk offenders.
CRCs will be required to ensure that all sentence requirements or licence conditions/supervision 
requirements are delivered for the offenders they manage. This includes more punitive or restrictive 
elements of a Community or Suspended Sentence Order such as unpaid work or exclusion requirements, 
or specific licence conditions such as drug testing. CRCs will oversee the sentence of the court for 
each offender allocated to them to manage, and in doing so seek to rehabilitate offenders and reduce 
reoffending. These reforms will ensure that essentially every offender released from custody will receive 
statutory supervision and rehabilitation in the community.
Scotland 
The role of prison-based drug treatment programmes is highlighted in the 2008 Scottish Drug Strategy, 
Road to Recovery: A new approach to tackling Scotland’s drug problems (Scottish Government, 
2008c), as a means of assisting recovery. In the same year, the Scottish Government commissioned 
a task force to investigate health inequalities and published a new strategy, Equally Well (Scottish 
Government, 2008b). One of the key recommendations was for offenders who want to tackle their drug 
problems to be able to get access to addiction and health services within six weeks of release from 
prison. Improving the health and well-being of offenders was also cited as a means to reduce inequalities 
associated with violence and alcohol and drug problems. In 2010 a review of the strategy was conducted 
and it was agreed to continue offering Throughcare Addictions Services, which offer wraparound support 
to offenders with addiction issues being released from prison (Scottish Government, 2010c).
The Strategy framework for the management of substance misuse in custody (Scottish Prison Service, 
2010) reflects the aims and objectives of the Scottish Government’s national Drug Strategy. Over the past 
decade policy on managing prisoners with problematic substance misuse has moved from a punitive 
response to a therapeutic approach; offering a comprehensive integrated treatment service to support 
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recovery and community integration and to reduce reoffending. The Strategy focuses on robust security 
systems to divert, disrupt, detect and deter the supply of illicit substances and to support the provision 
of treatment services to encourage prisoners to reject the illicit drug culture.
In 2011 the responsibility and accountability for the provision of health services in prison, including 
substance misuse and mental health services, transferred to NHS Health Boards who provide a range 
of health and substance misuse services, broadly comparable to that available in the community. 
The emphasis is on recovery focused treatment options, including naloxone provision and improved 
Throughcare Services. An independent expert review of OST in Scotland, published in 2013, 
acknowledged the role that prison healthcare has to play in delivering OST to assist recovery (Drug 
Strategy Delivery Commission, 2013).
Northern Ireland
There is a real and concerted effort by the Northern Ireland Prison Service (NIPS) to address 
substance misuse based around a three strand approach: to restrict supply, to reduce demand and to 
assist recovery.
In March 2012 NIPS and the SEHSCT, who assumed responsibility for providing healthcare, including 
addiction services, in prisons in 2008, jointly published a Strategic Framework for the Reduction and 
Management of Substance Misuse in Custody. The framework reinforced the two organisations’ 
commitment to working in partnership to address misuse.
The purpose of the framework is to provide strategic direction and guidance in the management of 
prisoners with substance problems. The NIPS and the SEHSCT will take all reasonable measures to 
reduce the availability of illicit substances to prisoners; and to provide recovery-aiding services broadly 
equivalent to those available in the community, whilst recognising that prisoners require different routes 
to recovery.
The strategic aims are to:
•	 reduce the availability and supply of illicit substances;
•	 reduce the levels of substance misuse through recovery-based treatment programmes;
•	 ensure treatment programmes are integrated with, not separate from, a wide range of related prison-
based services; and
•	 develop substance misuse services to reflect the diverse needs of the prisoner population
In 2013 the Prison Service increased its focus on intelligence-led searching and there have been 
increased drugs finds in all three prisons. Both NIPS and SEHSCT are currently in the process of revising 
the substance misuse policy and strategy. The new SEHSCT Strategic Framework (July 2015) is currently 
in draft form. It aims to provide a template to ensure that substance misuse issues are recognised 
and that the challenges arising from a number of inspection reports, including joint CJINI/Her Majesty’s 
Chief Inspector (HMCI) and Regulation and Quality Improvement Authority (RQIA) inspections, and more 
recently, the publication of the Safety of Prisoners held by the Northern Ireland Prison Service (Criminal 
Justice Inspection Northern Ireland, 2014) report, are addressed. This can only be achieved through a 
multi-disciplinary, collaborative, partnership approach, not only involving staff from SEHSCT, Alcohol 
and Drugs: Empowering People through Therapy (AD:EPT) and NIPS, but also a significant range of 
other providers, including support from community and voluntary sectors organisations, for example, 
Alcoholics Anonymous and Narcotics Anonymous (NA).
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A draft strategy has been developed outlining how NIPS and the SEHSCT will work together to:
•	 understand the scale of the problem; 
•	 implement supply reduction methodologies which will prioritise disrupting supply routes before 
substances reach the end user; 
•	 provide clear engagement and treatment pathways for substance misusers; and
•	 ensure through care and continuity of treatment and support services on release from prison
In addressing concerns raised in a number of scrutiny reports, and incorporating the guidance of 
the Drug Strategy (Department of Health Social Services and Public Safety Northern Ireland, 2011b), 
the SEHSCT is committed to reducing the level of alcohol- and drug-related harm in NI prisons. To 
achieve this SEHSCT is committed to key underpinning principles including: being person centred, non-
judgemental and empowering; harm reduction; best practice; holistic care; equity and inclusion; shared 
responsibility; consultation, engagement and transparency; and an integrated approach.
8.3.2 Co-ordination of drug-related prison health responses
England
In England, the DH is responsible for determining the policy on substance misuse treatment and 
suitable approaches, including the balance between clinical treatment and psychosocial interventions. 
Substance misuse treatment services in custody are commissioned and funded by NHS England. 
NOMS and Public Health England (PHE) have a co-commissioning responsibility with NHS England 
to enable and support the efficient delivery of provision. The National Partnership Agreement for the 
Co-Commissioning and Delivery of Healthcare in Prisons in England (National Health Service England 
et al., 2015), a tripartite agreement between NHS England, PHE and NOMS, sets out respective roles, 
shared principles and development priorities as well as objectives to work together and address any 
issues arising from changes to the delivery environment. The agreement is overseen by the Prison 
Healthcare Board (England). In October 2014, the 35 former Probation Trusts were dissolved and their 
responsibilities were transferred to either the newly established National Probation Service within NOMS, 
or the CRCs. 
Wales
In Wales, health and delivery of its services within the public sector prisons are the responsibility of the 
Welsh Government, with responsibility for service provision devolved to local Health Boards. NOMS 
retains responsibility for its non-clinical substance misuse services for sentenced offenders. 
Resettlement in England and Wales
Key to successful drug treatment outcomes is continuity of treatment following release. The MoJ has 
been working closely with partners in health to help extend the focus of substance misuse treatment 
and recovery services in prison to plan and operate through the gate into the community. A network of 
89 resettlement prisons has been established under Transforming Rehabilitation: A strategy for reform 
(Ministry of Justice, 2013b), in order to provide support for prisoners within the last three months of their 
sentence who are returning to their home area. In addition, a comprehensive “end-to-end” approach 
to tackling addiction from custody to the community is being developed and tested in a number of 
resettlement prisons. DH funding has enabled NOMS, NHS England and PHE to test new pathway 
arrangements, develop products which can be used across the country, and capture learning by working 
closely with 10 resettlement prisons as early adopters in the north-west. The emphasis has been on 
joining up services in prison and on release.
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Scotland
In Scotland, responsibility for the provision of health care services in prisons transferred from the SPS to 
the NHS in November 2011. A range of health and substance misuse services are now provided within 
Scottish prisons by the respective local Health Boards. 
Northern Ireland
The provision of substance misuse services within NI prisons has undergone significant change in recent 
years. The transfer of responsibility for prison healthcare services to the SEHSCT, and recommendations 
from a number of independent reviews, surveys and inspections have influenced and reflected on a 
period of continued transition and change.
8.4 Drug use and problem drug use in prisons
8.4.1 Drug use prior to imprisonment
Surveying Prisoner Crime Reduction study in England and Wales
Light, Grant and Hopkins used data from the first wave of the Surveying Prisoner Crime Reduction 
(SPCR) longitudinal cohort study to explore substance use and gender differences (Light, Grant, & 
Hopkins, 2013). Eighty-one per cent of the cohort reported having taken illicit drugs at some point in their 
lives, with no difference between genders in this measure or for drug use in the last four weeks before 
custody (64% overall). Females were more likely than males to report ever using heroin (55% compared 
to 39%) and to report the use of Class A drugs in the four weeks prior to custody (58% compared to 
43%). Nineteen per cent of those who reported ever using heroin said that they had first done so in 
prison, with male heroin users (38%) more likely to report doing so than female heroin users (10%). Just 
under one-third of prisoners said their offending was always connected with their drug use, with females 
more likely to report this than males (50% and 28% respectively). Females were also more likely to report 
that they needed help with a drug problem on entry to prison (49% compared to 29% of males). A similar 
divergence was also found in the 2014/15 survey by Her Majesty’s Inspectorate of Prisons (HMIP) in 
which 28% of male and 41% of female new arrivals at prison stated they had substance misuse needs 
(Her Majesty’s Inspectorate of Prisons, 2015). 
Young adults (18-20 year olds) were less likely to report substance misuse needs compared to older 
prisoners (15% and 33% respectively) (Ministry of Justice, 2015b). The drugs used across age groups 
differed also, with young adults significantly more likely to report having used cannabis, cocaine, LSD 
or ecstasy in the year before custody, whilst older adult prisoners were more likely to report having used 
crack cocaine, heroin, illicit tranquilisers and illicit methadone. 
Addiction prevalence testing in Scotland
Data shows that of the 1,170 addiction prevalence tests (APTs) carried out on reception to prisons 
in Scotland during 2014/15, 70% were positive for illicit drugs, down from 77% in the previous year. 
Benzodiazepines and cannabis remained the most frequently detected drugs, being detected in 46% 
and 42% of tests respectively. This was a decrease in positive tests from the previous year for both drugs, 
when they were each detected in 50% of tests (see Table 8.2). The proportion of tests positive for opioids 
decreased significantly from 33% to 26%, the lowest figure recorded since APT began in 2007. Following 
an increase in the percentage of positive tests for cocaine last year, there was a small decrease this year, 
with the level remaining higher than that seen in 2012/13. 
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Table 8.2: Percentage of positive tests on reception to Scottish prisons, 2008/09 to 2014/15
 2008-09 2009-10 2010-11 2011-12 2012-13* 2013-14† 2014-15‡
Amphetamines 2 1 2 1 3 3 2
Barbiturates - 0 1 1 0 1 0
Benzodiazepines 49 38 53 48 47 50 46
Buprenorphine 3 0 2 3 9 9 7
Cannabis 42 28 40 35 45 50 42
Cocaine 6 6 8 9 9 13 11
Methadone 4 6 11 7 11 9 9
Opioids 36 36 36 34 31 33 26
All illicit drugs 71 56 73 70 72 77 70
*From http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2012-13-v2.pdf
†From http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2013-14.pdf
‡From http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2014-15.pdf
Source: (Scottish Government, 2010a, 2010b, 2012) 
The 2013 Scottish Prisoner Survey (Scottish Prison Service, 2014) results show that two in five 
respondents reported being under the influence of drugs at the time of their offence (39%), with around 
one-sixth reporting that they committed their offence to get money for drugs (16%).
8.4.2 Drug use inside prison 
England and Wales
Mandatory drug testing
Mandatory drug testing (MDT) was introduced as part of the Criminal Justice and Public Order Act 
(Her Majesty’s Government, 1994) and involves collecting urine samples from prisoners, which are then 
analysed for evidence of illicit drug use.128 It is used to estimate the level of drug use within prisons as 
well as to identify individual drug users, who can then be offered support and/or sanctioned. There are 
five ways in which drug testing can be undertaken under Prison Service Order (PSO) 3601:129 
•	 random testing — prisoners selected on a random basis;
•	 reasonable suspicion — prisoners selected where there is reason to believe they have misused drugs;
•	 risk assessment — prisoners selected where they are being considered for a privilege or position of 
trust (such as Release on Temporary Licence or a job);
•	 frequent test programme — prisoners selected because of their previous history of drug misuse; and
•	 reception testing — prisoners selected on a routine or occasional basis 
128 Each sample is analysed automatically for eight groups of drug: cannabis, opioids, cocaine, benzodiazepines, 
methadone, amphetamines, buprenorphine and barbiturates. NPS are not currently detectable. 
129 See: http://www.justice.gov.uk/offenders/psos 
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The target for Random Mandatory Drug Testing (RMDT), previously set at five per cent of the population 
in prisons with an average population in the previous 12 months of 400 or more inmates and 10% of the 
population for those with less than 400, was removed in 2011/12 although the information is still collected 
for management purposes. In England and Wales during 2014/15, the rate of drug misuse as reflected 
by those testing positive in MDT was 6.9% (National Offender Management Service, 2015a). This was a 
decrease from the rate for the previous year of 7.4% but similar to the rate observed in 2012/13 (seven 
per cent) (National Offender Management Service, 2014).
Whilst positive RMDT rates of just seven per cent were recorded in 2014, reasonable suspicion testing 
yielded a substantially higher rate of 30% (The Centre of Social Justice, 2015). However, levels of 
suspicion testing have dropped by 21% in the last two years. In 2014/15 59% of establishments did 
not consistently complete all requested suspicion MDTs in line with Prison Service requirements (Her 
Majesty’s Inspectorate of Prisons, 2015). 
Her Majesty’s Chief Inspectorate of Prisons Report
The HMIP Report 2014/15 included survey results showing that 32% of adult male respondents stated 
that illicit drugs were “easy” or “very easy” to obtain in their prison (Her Majesty’s Inspectorate of Prisons, 
2015). This rate varied depending on the type of establishment prisoners were held in, rising to 44% of 
respondents in Category C training prisons and falling to 18% of those held in high security prisons.
Furthermore, some prisoners stated they had actually developed problems with illicit drugs (seven 
per cent) or diverted medications (seven per cent) since entering prison (Her Majesty’s Inspectorate 
of Prisons, 2014). Over one-third (37%) of adult male prisons stated that the use of new psychoactive 
substances (NPS), specifically ‘Spice’ and ‘Black Mamba’, are of increasing concern (Her Majesty’s 
Inspectorate of Prisons, 2014). 
Surveying Prisoner Crime Reduction study 
Data from the second and third waves of the SPCR examined prisoners’ experience of prison and their 
outcomes on release (Ministry of Justice, 2014b). The findings suggested that whilst 40% of prisoners 
reported that they needed help for substance misuse, only 27% received support. A survey of longer-
sentenced prisoners130 found that 30% reported that they had used illicit drugs at some point during 
their sentence. The most commonly reported used drug was cannabis (22%), followed by heroin (14%). 
Seizures of drugs inside prisons
There were almost 4,500 seizures of illicit drugs in prisons in England and Wales in 2013/14, an increase 
of over 200 on the preceding year (DrugScope, 2015). 
In a press release from the MoJ,131 it was stated that there were 430 seizures of Spice132 in the first seven 
months of 2014 in prisons in England and Wales. This represented 132 more seizures of the substance 
than in the whole of 2013. 
In an effort to find out which NPS were being used in prisons, in 2014/15 893 samples were collected 
from prisons in the south-west and north-west of England and analysed by the Forensic Early Warning 
System (FEWS). The results showed that the vast majority (738) contained non-controlled NPS, most 
commonly synthetic cannabinoids (Home Office, 2015a). 
130 Those sentenced to between 18 months and four years. Base size 2,164.
131 See: https://www.gov.uk/government/news/new-crackdown-on-dangerous-legal-highs-in-prison 
132 This figure represents the number of seizures described exactly as “Spice” on the prison administrative data system. It is 
possible this figure will include seizures of other cannabinoids. 
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Scotland
Data shows that of the 616 APT tests carried out at prisoner liberation in 2014/15,133 29% were positive 
for illicit drugs. This was an increase from the previous year which had 25% positive returns. The drugs 
most commonly detected when leaving prison were buprenorphine (13%), cannabis (eight per cent) 
benzodiazepines (seven per cent) and opioids (six per cent). 
The 2013 Scottish Prisoner Survey (Scottish Prison Service, 2014) results show that two in five prisoners 
(38%) said that they had used illicit drugs in prison at some point. Of these, 82% said that their drug 
use had changed during their current period in prison. Almost two-thirds (63%) said that their drug use 
had decreased, whilst 14% said it had increased. Eight per cent of prisoners said they had used NPS in 
prison, with synthetic cannabinoids being the most commonly used (54%). Almost half of respondents 
reported that they had been assessed for drug use upon admission to prison (46%). 
The SPS 2014/15 annual report (Scottish Prison Service, 2015) shows that 901 male and 102 female 
inmates were disciplined for “administering, or allowing to be administered, a controlled drug to oneself”. 
This was an increase from 2013/14 when the figures were 790 and 79 respectively. 
Wales 
In Wales, the Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) project has 
been working in conjunction with the Welsh prisons to analyse and profile substance finds that do not 
have any evidential or forensic value. The main aim of this collaboration is to identify potential physical 
and mental health harm and trends in substances available within the Welsh prison estates. In addition, 
this work supports prison health care by allowing substance misuse teams and wider prison staff 
to address the challenges posed by those using drugs and by enabling the delivery of pragmatic 
and tailored harm reduction messages. These messages can then be passed in to community-based 
criminal justice services, helping to facilitate continuity of care and consistency of service provision. 
From November 2013 to September 2015 WEDINOS received 198 samples from three Welsh prisons. 
The most commonly identified substances were Synthetic Cannabinoid Receptor Agonists (SCRAs), more 
commonly known within the prison estate as ‘Spice’ and ‘Mamba’. Other drugs profiled include a range 
of image and performance enhancing drugs and a small number of stimulants and benzodiazepines.
Northern Ireland
In 2012/13 703 individuals presented to drug treatment in prisons in NI. Primary cannabis use was the 
most common reason for presentation (30.4%), followed by benzodiazepines (18.6%), heroin (11.5%) 
and cocaine (11.4%). The percentage of treatment presentations for primary cannabis and primary 
benzodiazepine users were less than those presenting to outpatient treatment in the community (40.1% 
and 26.5% respectively). Conversely primary cocaine and primary heroin users accounted for almost 
double the proportion of prison presentations than those in the community (5.4% and 5.2% respectively) 
(ST34, 2014).
Additionally, The Prisoner Quality of Life Survey 2012 found that 50% of respondents reported having 
emotional well-being/mental health issues; 44% reported having an alcohol problem when they came 
into prison; 39% had a problem with drugs when they came into prison, and 31% had a problem with 
prescription drugs (Roisin Broderick Scottish Prison Service Research Branch, 2013). Results from the 
survey also revealed that the most commonly drugs used were: cannabis (22%); benzodiazepines 
(16%); co-codamol (12%); tramadol (12%); ecstasy (11%); and Subutex® (buprenorphine; 11%).
The capturing of statistical information about substance misuse in NI prisons is currently being reviewed 
as part of the Prison Reform Workstream.
133 See: http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2014-15.pdf
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8.5 Drug-related health in prisons
8.5.1 Drug-related health problems
Blood-borne viruses
England
In April 2014 a new opt-out testing programme for blood-borne viruses (BBVs) was introduced in 11 
prisons across England. In the first six months there was a near doubling of BBV testing from 11% to 
22% of new receptions being screened in 8/11 prisons (Public Health England, 2015a). The proportion of 
those testing positive remained stable with 0.3% testing positive for HIV, 0.2% positive for hepatitis B and 
nine per cent testing positive for hepatitis C. It is hoped that opt-out BBV testing will be fully implemented 
across all prisons in England by 2016/17. 
Wales
BBV testing programmes and access to treatment are available in each prison in Wales. In 2014, 14% of 
prison receptions to Welsh prisons were tested for BBVs. This was a small increase from 13% of prison 
receptions undergoing testing in 2013. Data demonstrates that both venepuncture and dried blood spot 
methods are being used for testing. Improvements to data quality related to diagnosis and referral to 
specialist treatment centres are being made over 2015.
Scotland 
In 2009 the SPS commissioned a study into the prevalence and incidence of hepatitis C amongst 
prisoners (Scottish Prison Service, 2012). The hepatitis C virus (HCV) antibody prevalence among 
all prisoners who participated in the study (5,076 prisoners) was 19%, ranging from one per cent to 
34% across prisons. However, amongst injecting drug users (IDU) the prevalence rose to 53.1%, and 
amongst non-IDU it fell to 2.9%. 
HCV antibody prevalence was found to be higher among female prisoners who inject than male prisoners 
who inject, 65% and 52% respectively. HCV prevalence varies by age-group also: for those reporting 
injecting there was an increase from 14% HCV positive in those under 20 years old to 68% in those aged 
over 40 years old. 
Whilst the male population showed similar rates of HCV both in prison and in the community (52% and 
54% respectively), women had significantly higher prevalence in prison than in the community (65% and 
54% respectively).
From the study the estimated hepatitis C incidence rate was less than one per cent (or one per 100 
person years) among all prisoners, less than three per cent among prisoners with an injecting history and 
five to seven per cent among prisoners who had ever injected in prison (Scottish Prison Service, 2012).
Mental Health
The Rehabilitation for Addicted Prisoners Trust (RAPt), a prison treatment provider in England, conducts 
mental health screenings for all prisoners participating in their treatment programmes. They estimate that 
those accessing their treatment services have an average of 3.4 mental health problems.134 The most 
common disorders were trauma symptoms shown by 71% of participants, and depressive symptoms 
and eating disorders, both 67% (The Rehabilitation for Addicted Prisoners Trust 2015).
Anecdotal evidence suggests that the growing levels of NPS use in prisons is linked to a number of 
negative outcomes including an increase in disturbed and disruptive behaviour by prisoners, increasing 
levels of debt and heightened levels of intimidation and violence towards both staff and prisoners 
134 Based on a sample of 6590 inmates (6198 male and 392 female), who accessed treatment between 2006 and 2014. 
United Kingdom Drug Situation 2015 edition Page 139
(see section 8.7.1) (National Offender Management Service, 2015a). The Prisons and Probation 
Ombudsman (PPO) reported on 19 deaths which occurred between April 2012 and September 2014 
where the deceased was known, or highly suspected of, using NPS prior to death (Prisons and Probation 
Ombudsman, 2015).
8.5.2 Drug-related health responses
England and Wales
Drug treatment in prisons is based on an assessment of local need and designed to meet the 
requirements of low, moderate and severe drug misusers within the prison population — irrespective 
of age, gender or ethnicity — including the many that spend a comparatively short time in prison. Local 
commissioners have the discretion to commission services that accord with national clinical guidelines 
and that they judge are best oriented towards recovery (and consequential reductions in re-offending). 
However, in general, available interventions are: 
•	 clinical services including clinical responses to immediate needs — such as detoxification or 
maintenance prescribing of methadone or buprenorphine;
•	 a range of accredited and non-accredited rehabilitative programmes, structured psychosocial 
interventions and other evidence based approaches in prisons that are designed to address 
prisoners’ substance use, offending behaviour and contribute to their well-being. Offenders are 
often encouraged to learn and practise life skills that will help them on their recovery journey. These 
life skills, such as communication, healthy living and employment skills, will be vital for offenders 
sustaining a life free from substance use and crime. The variety of interventions allows the provision 
to meet the wide ranging needs of offenders and provide a more person-centred approach; and 
•	 case management/continuity, structured counselling — including motivational therapy, coping/
social skills training, behavioural self-control training, mutual aid (i.e. self-help) such as NA, life skills 
and family work 
Drug treatment services in prison are commissioned on the basis of equivalence with community based 
treatment and underpinned by evidence based clinical guidance. 
Treatment figures
Based on drug treatment data collected by the National Drug Treatment Monitoring System (NDTMS), in 
2013/14 there were a total of 43,372 OST interventions across prisons in England and Wales.135 Of these, 
68.5% of interventions were provided on an opioid maintenance basis and the remaining 31.5% were 
supplied for opioid reduction. 
Unfortunately our ability to provide the same data for 2014/15 has been compromised by the NDTMS 
shutdown between October 2014 and March 2015.
Harm reduction 
At present needle and syringe programmes (NSP) are not available within UK prisons. However, in 
March 2014 the Chief Medical Officer recommended that the viability and cost-effectiveness of running 
such programmes be explored (Department of Health, 2014). A recent audit of hepatitis C services in 
a representative sample of English prisons suggested that disinfection tablets for sterilising injecting 
equipment were available in 81% of English prisons (Public Health England, 2015f). These tablets were 
accessed in a variety of ways: via dispensers (53%); distributed directly via prison officers (41%); and via 
healthcare staff (12%) (see section 6.6.1).
135 See: http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/
Commons/2014-12-17/219264/
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Drug Recovery Wings
DRWs were piloted in five adult prisons from 2011, and a further six prisons in 2012, which also included 
women and young offenders. The piloting activity completed in 2014. A DH-funded independent evaluation 
of the DRW pilots is now underway and is due for completion in April 2016. It is for local health commissioners 
to decide if they wish to commission DRWs when considering how best to meet the needs of their 
population. A number of establishments in partnership with drug treatment providers have established their 
own local recovery wing or therapeutic community models outside of the original pilot areas.
Scotland
In Scotland the Better Health, Better Lives for Prisoners Framework (Brutus et al., 2012) was published 
in 2012 and aims to achieve better health outcomes for prisoners through delivery of policy, practice 
and environments that support health and well-being. The framework recommends work across a range 
of topics, delivered by a number of disciplines and involving prisoners in various capacities, including 
planning, feedback and peer support.
The framework proposes a vision of a healthy prison and offers a practical guide to achieve improved 
health outcomes and a reduction in health inequalities while also recognising and linking to offender 
outcomes relevant to health. The framework provides recommendations consistent with a “whole prison” 
approach to health improvement and is built around health promotion pillars which include tobacco, 
alcohol, and illicit drugs. Since its publication Scottish prisons have actively engaged in the framework 
on a number of initiatives including the introduction of peer mentors, workforce development and family 
engagement to support health and well-being. Improving health and well-being is now recognised as 
an integral part of purposeful activity within prisons, and work is ongoing to ensure a co-ordinated and 
sustainable approach. 
The framework is currently being developed for offenders in the wider community; this is expected to be 
published by the end of 2015.
Throughcare Addiction Service in Scotland
Data from Scotland show that around 1,320 individuals received assistance from the Throughcare 
Addiction Service136 on release from prison in 2012/13, a similar level to previous years and representing 
50% of all voluntary assistance cases (Scottish Government, 2014a). In Scotland, the Reducing 
Reoffending Change Fund137 has developed mentoring services for offenders to support them on their 
desistence journey. The mentors begin building a relationship with their mentee up to six months before 
their release; meet them at the prison gate on release; and work with them to support their reintegration 
back in to the community. The mentors can, therefore, support their mentee to keep appointments and 
attend for treatment as part of a holistic plan for release and reintegration (personal communication – 
Scottish Government).
The SPS provides a voluntary Throughcare Service for short term offenders with no statutory conditions 
placed on them. It aims to ensure that the transition from custody to the community is effectively managed 
in an approach that seeks to minimise the risk to the public, and to support a safe transition for service 
users back into the community. It does so by working collaboratively with the service users, families, 
colleagues and partner agencies to develop an asset-based individualised plan — “one person, one 
plan”. Throughcare Support Officers support offenders on their journey into desistance by working with 
them to prepare for and successfully make the transition from custody into the community, acting as 
an advocate on their behalf with partner agencies and encouraging their motivation to change through 
sustained engagement with key services.
136 The Throughcare Addiction Service commenced on 1 August 2005 and forms part of the voluntary aftercare service. 
It is delivered by a local authority criminal justice social worker who will work with the offender in the 6 week period prior 
to release from custody through the 6 week period post-release offering an intensive motivational service to help the 
offender address their addiction and link them to appropriate services.
137 See: http://www.gov.scot/Topics/Justice/policies/reducing-reoffending/change-fund 
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Northern Ireland
Opioid Substitution Treatment
Since October 2008, the SEHSCT has been responsible for the provision of addiction services to NIPS. 
Services across Maghaberry, Magilligan and Hydebank Wood prisons comprise a Clinical Addiction 
Team (for clinical treatments) and AD:EPT for all psychosocial interventions.
The Clinical Addiction Team provides OST within the prison setting. The staff adhere to the Northern 
Ireland Opioid Substitution Services Interface Protocol between Prisons and Health and Social Care 
Trust Community Addiction Services (April 2015). The purpose of this protocol is to ensure the seamless 
transition of patients between community OST services and prison, and the converse. This protocol is 
used to manage the community-prison interface in addition to the principles outlined in the Northern 
Ireland Primary and Secondary Care Opioid Substitute Treatment Guidelines.138 
The protocol provides best practice guidance but recognises providing treatment when transferring from 
prison to community (or vice versa) presents challenges, particularly when unplanned or unexpected 
transitions take place. Clinical decisions should be made in the patient’s best interests and should be 
balanced against risk to the patient; in some cases this may require an interruption in treatment until such 
times it can safely continue in the patient’s new location. 
Psycho-social Support/Counselling/Harm reduction
AD:EPT Drug and Alcohol service is delivered by Start360 across the three sites of the NIPS in partnership 
with the SEHSCT. AD:EPT is a comprehensive drug and alcohol service providing a range of services to 
people in custody who have problems associated with the misuse of substances.
Interventions provided by AD:EPT include:
•	 induction Programme;
•	 Addiction Severity Index (ASI) comprehensive assessment;
•	 1-2-1 Casework;
•	 1-2-1 Counselling;
•	 relapse Prevention Sessions;
•	 pre-Release work;
•	 harm Reduction;
•	 failed Drug Test (FDT);
•	 Building Skills for Recovery (BSR) behaviour change group programme;
•	 acupuncture; and
•	 naloxone training
AD:EPT works as part of a multi-disciplinary team in the prisons and in particular with the Clinical 
Addiction Team with the aim of delivering and promoting recovery by those who are presenting with 
problems associated with the misuse of substances. 
138 See: http://www.publichealth.hscni.net/publications/northern-ireland-primary-and-secondary-care-opioid-substitute-
treatment-guidelines-2013 
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Drug Recovery Unit Pilot
The Drug Recovery Unit (DRU) was commissioned in July 2014 by the NIPS to assess how a therapeutic 
substance misuse intensive programme might work within the prison environment. The DRU is an 
innovative approach to treatment for prisoners who misuse drugs or alcohol and is focused on harm 
reduction, freedom from drugs of dependence, and provision of services and advice in a central location.
This is provided through an intensive, full-time, structured programme delivered in an environment which 
exclusively houses prisoners committed to drug recovery.
The pilot was provided within the 15 bed Glen House Unit in Maghaberry, which is fully self-contained 
and isolated from the rest of the prison population. The programme was jointly facilitated by NIPS staff 
and drug and alcohol professionals from Start360, a voluntary sector provider. The DRU delivered an 
intensive programme seven days per week over a 12 week period and was built around the principles 
of the NOMS’s BSR programme which recently replaced Prisoners Addressing Substance Related 
Offending (PASRO) as best practice for addressing substance misuse.
The DRU commenced on 28 July 2014 and completed on 17 October 2014. All the participants went 
through an intensive assessment process, to identify need, dependency and motivation. This process 
highlighted that participants came from all areas of the prison, had varying degrees of dependency, and 
a protracted history of drug–related adjudications and Supporting Prisoner At Risk (SPAR) incidents 
relating to substance misuse. Of the 12 participants who commenced the programme, 11 participants 
completed (one participant left early in Week 10 after completion of the BSR programme).
The findings showed:
•	 11 of the 12 participants secured employment or education upon exit;
•	 all participants passed drug tests throughout the duration of the DRU;
•	 the GP reported a reduction in requests for medication;
•	 requested GP sessions reduced from 12 in the first few weeks to 2/3 in the last weeks;
•	 all participants successfully completed the NOMS accredited BSR programme;
•	 significant improvement in health and well-being;
•	 no drug–related SPARs;
•	 no drug–related adjudications;
•	 no failed drug tests; and
•	 a significant reduction in illicit drug use
Naloxone
Naloxone is a drug used to counter the effects of opioid overdose, such as heroin or morphine, 
specifically the life-threatening depression of the central nervous system, respiratory system and 
hypotension secondary to opioid overdose. Following release from prison, opioid users are at increased 
risk of opioid poisoning and there are initiatives in the UK to distribute THN kits to prisoners upon release 
to reduce the risk of fatal overdose. In October 2015 new legislation came into effect in the UK, making 
naloxone exempt from prescription only medicine (POM) requirements when it is supplied by a drug 
service commissioned by a local authority or the NHS. Although naloxone remains a POM, this will make 
naloxone easier to access by individuals who have previously used opioids (see section 2.2.1). 
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Scotland
There is a National Naloxone Advisory Group for Scotland which has been engaged with the Scottish 
Government to manage central funding allowing for continued service provision. The SPS and NHS 
Health Boards work in partnership to enable prisoners to undertake naloxone training whilst in custody 
and receive a naloxone kit on release.
There were 872 THN kits issued by prisons in Scotland in 2014/15 to persons at risk of opioid overdose 
(Information Services Division, 2015b). A further six kits were issued to either a service worker or a 
friend/family member of the person at risk. The total number of kits issued in Scottish prisons (n= 878) 
decreased by 18% in comparison to the number of kits issued in 2013/14 (n= 1,070), although the 
number remained higher than those distributed in 2012/13 (n= 747). 
There has been a steady decline in the percentage of all opioid-related deaths occurring within four 
weeks of prison release from the 2006-2010 baseline indicator of 9.8% to 3.1% in 2014. Performance 
against the baseline indicator will continue to be monitored to ensure that the percentage in the post-
naloxone period is estimated with sufficient precision.
The SPS is currently conducting a pilot by delivering training in naloxone administration to operational 
prison staff to provide them with the competence and confidence to administer intra-muscular naloxone 
to prisoners in emergency ‘first on the scene’ situations. Lessons learned from the ‘test site’ will be used 
to inform future roll out of the training across the prison estate.
Wales
Data from the Harm Reduction Database in Wales indicates that 20.5% (n= 116) of male unique 
individuals issued with THN between 1 April 2013 and 31 March 2014 were issued with THN upon 
release from prison. When compared to national Area Planning Board (APB) provision, prisons are 
amongst the highest distributors of THN within Wales (personal communication — Public Health Wales).
England
The availability of naloxone to prisoners in England has so far been limited. Naloxone has been made 
available to a limited extent in some prisons, and there are proposals to pilot its use as part of the end-
to-end approach to tackling addiction from custody into the community currently being tested in the 
north-west area (personal communication – Public Health England). A randomised trial of THN led by 
Kings College London (N-Alive) was initiated in early 2012 (UK Focal Point, 2012) but has now been 
discontinued. Naloxone distribution remains sporadic across England and its distribution is not required 
under treatment guidelines. However, new legislation in October 2015 will make naloxone more widely 
available (see section 2.2.1).
Northern Ireland
The New Strategic Direction (NSD) for Alcohol and Drugs Phase 2 2011-16 (Department of Health 
Social Services and Public Safety Northern Ireland, 2011b) required the Public Health Agency (PHA) to 
pilot a scheme for Distributed Naloxone and for this to be reviewed. NSD Phase 2 aims to reduce the 
number of drug–related fatalities including those within NI prison health care. The pilot of a THN initiative 
is being undertaken by a partnership between the PHA and the Health and Social Care Trusts in Northern 
Ireland. Community Addiction Teams and the NIPS began to give out THN kits in July 2012. 
The PHA service review, Take Home Naloxone programme in NI-Consultation with service users and 
service providers (March 2015, Dr Gillian W. Shorter & Mr Tim Bingham) highlighted some of the 
on-going challenges which include consideration of how to increase the training and take-up for those 
leaving prison, and reducing the time between departure and receiving their naloxone.
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The THN training in NI prisons is jointly provided by AD:EPT and the SEHSCT Clinical Addiction Team. 
Initially it was offered to those on substitution programmes but has since been expanded to anyone at 
risk. The training is usually conducted in groups of 8-10 participants; however, if possible, one to one 
training is available if there are barriers related to group participation.
To date the statistical data collected regarding the distribution of naloxone is limited. However, it is 
estimated that approximately 150 THN kits have been distributed to patients being discharged from 
prison health care.
8.6 Quality assurance of drug-related health prison responses
8.6.1 England
There are a number of indicators in the Public Health Outcomes Framework (PHOF) (see section 
5.2.1) related to people in contact with the CJS, one of which is the proportion of people assessed for 
substance dependence issues when entering prison who then require structured treatment and who 
had not previously received community treatment. The measure is designed to give local authorities an 
indication of the scale of treatment need unmet in the community. In 2012/13 the average proportion 
across England was 46.9% (Public Health England, 2015h). 
Up until March 2014 a broad set of indicators, known as the Prison Health Performance and Quality 
Indicators (PHPQIs), were used to monitor the quality of healthcare in prisons, as well as the performance 
of other contributing health and prison services. However, the PHPQIs were not outcome-focused and 
were qualitative measures that largely relied on self-assessment by local healthcare teams. Given this 
and the recent changes in the commissioning of healthcare services in places of detention, it was widely 
agreed that the PHPQIs needed reviewing and updating. To replace the PHPQIs a new set of Health and 
Justice Indicators of Performance (HJIPs) have been developed by NHS England, PHE and the NOMS 
(National Health Service England, 2014).
The new indicators are largely quantitative measures and include specific measures for drugs and 
alcohol. NHS England Area Teams will work with their commissioned providers to collect the HJIPs with 
the aim of:
•	 supporting effective commissioning of healthcare services in places of detention;
•	 enabling national and local monitoring of the quality and performance of healthcare in the secure estate;
•	 providing a tool for providers to review their performance and identify areas that need improvement;
•	 providing data for local health needs assessments (HNAs);
•	 providing assurance to commissioners and partners, including NOMS, that healthcare delivery in 
prisons is fit for purpose; and
•	 providing information for the Care Quality Commission (CQC) and the HMIP to support their 
inspection work
The framework has been agreed and is now up and running. Collecting complete and accurate data 
for 2014/15 has been challenging but an annual report will be published in late 2015. Data quality and 
completeness are expected to improve in 2015/16.
8.6.2 Wales
Across the public sector prison estate in Wales, standards of treatment provision will be matched against 
those set out above. In addition, the practice standards issued by the Royal College of Psychiatrists in 
relation to Mental Health services for prisoners will also be adopted.
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8.7 New developments 
8.7.1 New psychoactive substances
The presence of NPS within prison establishments is a significant and growing problem. Ten out of 16 
prisons who responded to the State of the Sector survey (DrugScope, 2015) reported an increase or 
significant increase in the use of NPS. Further, 13 prisons reported an increase or significant increase 
in the number of prisoners accessing treatment for help with the use of synthetic cannabinoids. In 
2014/15 the contents of 893 samples of substances thought to be NPS were collected from prisons 
and analysed by the FEWS. Of these samples 738 contained non-controlled NPS, the most commonly 
identified substances being 5F-AKB-48 and 5F-PB-22, which are both synthetic cannabinoids (Home 
Office, 2015a). 
The use of NPS has been linked to mental health problems and disturbed behaviour by prisoners, including 
violence. It is having an increasingly destructive impact on security and order in prisons, and the welfare of 
individual prisoners. Control and order is a fundamental foundation of prison life. Without it, staff, prisoner 
and visitor safety cannot be guaranteed and the rehabilitation of prisoners cannot take place. 
There is a wide-ranging programme of work being undertaken by NOMS to counteract NPS. This 
includes joint work with the Home Office on the re-classification of drugs to enable the control of most 
NPS substances and to make most NPS illegal to supply (see the Psychoactive Substances Bill, section 
2.2.3). This will allow prisons to press for the prosecution of those smuggling NPS into prisons or throwing 
them over walls (see Serious Crime Act 2015 below). Additionally, work is underway to develop new drug 
tests to detect NPS substances through the MDT programme.
The MoJ work closely with health partners to co-ordinate work on tackling the harm caused by NPS and 
other substance misuse, and to provide staff with the tools and information to tackle this issue in their 
work with offenders. There is an ongoing campaign to ensure that all prisoners are aware of the very 
serious risks that NPS bring. This has included a prison radio campaign, harm reduction posters, leaflets 
and a DVD, and focus groups and local initiatives in many prisons. 
In July 2015, the PPO reported on 19 deaths which occurred in prison between April 2012 and September 
2014, where the prisoner was known or strongly suspected to have been using NPS-type drugs before 
their death (Prisons and Probation Ombudsman, 2015). The PPO called for better education of both 
prisoners and prison staff regarding the signs that someone may be using NPS and the potentially 
harmful effects of such substances. 
Scotland
The SPS is currently developing a national strategy and action plan to respond to prisoners under 
the influence of NPS. This includes developing a protocol on the management of prisoners under the 
influence of NPS who are demonstrating challenging behaviour including ‘excited delirium’, and the roll 
out of a national NPS staff training programme. SPS is also working collaboratively with NHS Health 
Boards to support the development of a clinical response in line with the Project NEPTUNE guidance.
During 2015 the SPS in partnership with Crew, a third sector organisation who are experts in the field 
of NPS misuse delivered an NPS (training the trainers) training package to SPS staff, which will provide 
staff with the knowledge and skills to deliver awareness sessions to colleagues and prisoners on NPS.
8.7.2 Legislation
In January 2015 the Criminal Justice and Courts Act 2015 (Her Majesty’s Government, 2015a) provided 
additional powers to prison governors to test for non–controlled drugs, such as NPS, in MDT, and to impose 
stiffer penalties on those suspected of being involved in smuggling NPS into prisons. New sanctions include 
‘closed visits’ (no contact with partners or children), extended or further sentences, solitary confinement, 
forfeiture of prison wages and/or privileges and being moved to a higher security prison. 
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Further, in March 2015 the Serious Crime Act 2015 (Her Majesty’s Government, 2015b) was enacted 
which made it an offence to throw any article or substance in to a prison. Those found guilty could face 
up to 12 months in jail, or a fine or both for a summary conviction or up to two years in jail, or a fine or 
both for an indicted conviction.
The Offender Rehabilitation Act 2014 (Her Majesty’s Government, 2014) came into force on 1 February 
2015. At this time new providers became responsible for each of the 21 CRCs, who supervise low to 
medium risk offenders following their release. Throughout 2015 Payment by Results will be rolled out 
across these services, which will need to reduce both the number of offenders who reoffend and the 
number of further offences committed by each offender in order to achieve full payment. 
The Health Act 2006 (Her Majesty’s Government, 2006) brought in a total smoking ban in enclosed 
public places in England on 1 July 2007 (similar bans had already been implemented throughout the rest 
of the UK). Whilst prisons were exempt from this ban and prisoners remained able to smoke inside their 
cells, in January 2016 a full smoke free policy is to be implemented in all prisons in Wales and at four sites 
in England (HMPs Exeter, Channing Wood, Dartmoor and Erlestoke). This is part of a phased approach 
to make all prisons smoke free. E–cigarettes are available to buy in prisons and nicotine replacement 
therapy (NRT) products can be obtained on prescription through prison health services. Smoking will 
still be allowed outdoors.
8.7.3 Licence conditions
On 1 November 2014 two new licence conditions and supervision requirements, the Drug Appointment 
Condition and the Drug Testing Condition, became available to manage offenders in the community 
following their release through PSI 32/2014. The Drug Appointment condition requires those who have 
been receiving drug treatment in prison and whose use is associated with dependence to attend an 
appointment at a community treatment service upon release. Whilst the appointment is mandatory, 
entering treatment is not. This condition can be applied to any offender with drug misuse issues and is 
not limited to those misusing class A or B substances. 
The Drug Testing Condition should only be applied to offenders whose use of a specified class A or 
class B drug “caused or contributed to an offence of which the offender has been convicted or is likely 
to cause or contribute to the commission of further offences by the offender”. The decision of what to 
test for and how frequently is made by the offender’s case worker. Refusal by the offender to take a test 
constitutes a breach of the condition, whilst a positive test result should instigate consideration of a 
breach of the Good Behaviour Condition of their licence. 
8.7.4 Guidelines
A new toolkit designed to support prison healthcare and custody staff on tackling the growing NPS 
problem has been developed by PHE. This was published in January 2016, and will be supported by a 
training programme. 
Guidance on the clinical management of substance misuse in prisons is currently being reviewed and 
updated to reflect changing patterns of drug use and to keep pace with the learning from recent reviews 
of unclassified deaths in custody and emerging best practice. This work will pick up issues around opioid 
substitution therapy, including for example the use of methadone and Subutex® (buprenorphine), and 
also the use of naloxone, which may be provided by clinicians when someone leaves prison to mitigate 
the risk of overdose.
United Kingdom Drug Situation 2015 edition Page 147
9. Drug markets
9.1 Introduction
Most of the identified drug supply chains to the United Kingdom (UK) follow well-established trafficking 
routes. Heroin originates from Afghanistan and is transited through either Pakistan or Iran. Cocaine is 
produced in Colombia, Peru and Bolivia with Spain and the Netherlands being the main transit hubs 
within Europe for cocaine en route to the UK. The Netherlands is the most significant source for traditional 
synthetic drugs such as ecstasy and amphetamine, while China is where most new psychoactive 
substances (NPS) bought online originate. There is domestic production of high potency cannabis within 
the UK although most cannabis comes from abroad, with Africa and the Caribbean being the main 
sources for herbal cannabis, whilst resin mainly originates from Morocco and Afghanistan. Branded 
‘skunk’ is imported from the Netherlands. 
The restricting supply strand of the UK Drug Strategy 2010, Reducing demand, restricting supply, 
building recovery: supporting people to live a drug free life (Her Majesty’s Government, 2010) aims to 
make the UK an unattractive destination for drug traffickers. The Serious and Organised Crime Strategy 
(Her Majesty’s Government, 2013b) focuses, with regard to drugs, on: restricting the supply to the UK; 
engaging international partners to help disrupt OCGs smuggling illicit drugs through the UK’s borders; 
and ensuring the retrieval of the proceeds and assets from the crimes these groups commit. The strategy 
coincided with the launch of the new National Crime Agency (NCA).
Cannabis is the most commonly seized drug in the UK. Seizures of herbal cannabis increased in England 
and Wales alongside an increase in recorded cannabis possession offences following the introduction 
of cannabis warnings in England and Wales in 2004, although the quantity seized did not show a 
corresponding rise. Having risen steadily since 2004, the number of cannabis plant seizures dropped in 
2013/14, with the quantity of plants seized having already been falling since 2010/11 (perhaps indicative 
of the trend towards smaller production sites).
Having been low during both 2011 and 2012, heroin domestic resale purity has risen over the last two 
years and is now higher than in 2010. Cocaine powder purity has increased in recent years returning to 
levels seen around ten years ago. 
9.2 Supply to and within the country
The commentary provided below is based on correspondence with the NCA. 
9.2.1 Domestic production
Cannabis 
The production of the types of cannabis commonly referred to as ‘skunk’ continues to be widespread within 
the UK, with control by white British males most prevalent. Although the exploitation of persons subject 
to human trafficking and illegal immigration continues to occur, the representation of south–east Asian 
nationals within UK cannabis production sites is declining. OCGs are known to operate production sites 
and the supply of cannabis with other commodities (such as cocaine and MDMA/ecstasy) is also common.
The scale of commercial production sites ranges from those located in small dwellings to large scale 
converted commercial premises with the capacity for thousands of plants. Most production sites 
encountered by law enforcement are dwelling house conversions, commonly with rooms within a 
property being fitted for stages of production; ranging from seedling/cutting propagation, to developing 
plants and for those in final/harvest stages. Sophisticated lighting and ventilation systems are common, 
with UK-based outlets continuing to supply equipment ostensibly for legitimate horticultural purposes. 
Grow sites will also commonly provide a ‘drying room’ to prepare the harvested plants for distribution. 
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The most common yield per plant ranges from a dry weight of 28 grams to 84 grams, although there are 
many examples of plants capable of at least 200 grams. When measuring yield, only the bud/head of the 
plant is calculated, with the leaves being discarded. Although initial set up costs can run into thousands 
of Great British Pounds (GBP), cannabis production remains highly profitable to those doing so on a 
commercial scale, with rolling cycles. 
There remains a UK interest in production of ‘branded’ skunk (types developed in the Netherlands, 
designed to provide the user with a range of experiences and tastes); however, non-branded skunk 
remains most common. The branded options often achieve price premiums within a connoisseur and 
experimental market place.
The term ‘hydroponics’ is overused to describe cannabis production in the UK, with the majority of sites 
continuing to use a system involving the plants being potted/otherwise contained, with roots within a 
substrate. These are better described as ‘intensive grow sites’, due to the lighting and environmental 
systems creating ideal growing conditions for 10 to 12 week cycles. 
Amphetamine Sulphate
The conversion from base to sulphate is becoming an established trend in the UK, with only limited 
examples of production from precursors being encountered. British OCGs are importing liquid 
amphetamine oil and wet base into the UK to be converted into amphetamine sulphate. This requires 
much less expertise, chemicals and equipment than is required for production from precursors, but 
does offer degrees of control over quality and more diverse opportunities to conceal trafficking into the 
UK (utilising legitimate containers to conceal liquid rather than powder format amphetamine sulphate). 
This activity is most common in the north–east through direct links to supply sources in the Netherlands 
and Belgium.
9.2.2 Drug trafficking routes for imported drugs
Cocaine
Cocaine destined for the UK is produced in Colombia, Peru and Bolivia. Primary exit points from the 
region for UK-bound cocaine include Ecuador, Peru, Brazil, Venezuela and Guyana. Shipping out of 
Costa Rica and Panama is also encountered. Concealments within shipping freight, yachts, other 
maritime vessels, air freight and by air passengers remains common from this region.
Distribution from the Caribbean remains common, from islands including Trinidad and Tobago, those 
within the Eastern Caribbean, Jamaica and Dominican Republic. Activity involving air passenger couriers 
and yachts is commonly engaged by OCGs. 
West Africa remains a significant transit hub for cocaine destined for the UK, with countries including 
Ghana and Nigeria remaining significant. South Africa is also a key transit location with traffickers utilising 
the cover of air and sea facilitated trade routes and legitimate consignments. Cape Verde is a relevant 
maritime staging post for trans–Atlantic movement of cocaine towards the UK. 
Primary entry into Europe for UK-bound cocaine is via Spain, Belgium and the Netherlands, with north–
east, east, south–east and south coast ports being the most common access points to the UK from 
near–Europe. The Netherlands and Spain are the most influential hubs for onward distribution to the UK. 
Heroin
Heroin destined for the UK originates principally from Afghanistan, transiting through either Pakistan or 
Iran (depending upon the onward direction of travel). Some UK-bound heroin may also arrive into the 
European Union (EU) via Ukraine, having travelled north from Afghanistan through Central Asia. 
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Heroin that comes to the UK via Pakistan is sent directly by air freight and air passengers as well as via 
East Africa, having travelled south through the Indian Ocean. 
Heroin destined for the UK entering the EU from Turkey tends to transit via Iran, Iraq and smaller land 
mass countries to the north/east of Turkey. The Balkan Routes are the most common for heroin conveyed 
in goods vehicles entering the UK either direct from France via south coast ports or having entered and 
been redistributed in the Netherlands. 
The UK is most commonly accessed using ‘roll on-roll off’ haulage, commercial and private vehicles 
via south-east and north-east coast ports, with heroin concealed within vehicle structures, cavities and 
consignment loads. 
Amphetamine and MDMA/Ecstasy
The Netherlands is the primary source for traditional synthetic drugs imported into the UK, with points 
of entry via the north-east, east and south-east ports being most common, either direct from the 
Netherlands or via France. 
Cannabis (high potency/skunk)
The Netherlands remains the primary source for skunk cannabis imported into the UK, with points of entry 
via the north-east, east and south-east ports being most common, either direct from the Netherlands or 
via France. 
Cannabis (other herbal)
The most common sources include South Africa, West Africa and the Caribbean, and are most frequently 
imported directly into the UK via maritime freight vessels and containers. 
Cannabis (resin)
Morocco and Afghanistan are the primary sources for cannabis resin to the UK. Moroccan resin tends 
to travel through road routes via Spain and France, but with many examples of direct movement 
via maritime freight into the UK. The Netherlands is a hub for cannabis resin destined for the UK, with 
south-east ports being the primary UK access points. Afghan resin tends to follow traditional heroin 
routes into the UK. 
New psychoactive substances 
NPS are commonly ordered via the internet and then shipped into the UK from sources in China, or via 
European hubs, believed to be in use to hold larger consignments. These are broken down to supply 
individual on-line orders and most commonly despatched via the fast parcel system to the UK.
9.2.3 Drug trafficking within the country
The UK drug market is exploited by a very diverse demographic of drug dealers/distributors of a wide 
range of nationalities.
The cocaine trade is currently heavily influenced by Albanian-controlled organised crime, utilising other 
nationals to assist with trafficking logistics. British OCGs and those of other nationalities also continue to 
be involved. The heroin trade remains influenced by traffickers with Turkish and British Pakistani origin, 
but also by Albanian and White British OCGs. Nigerian and Ghanaian OCGs are influential concerning 
West Africa-based trafficking into the UK. 
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There are established markets in the UK for cocaine, heroin, crack cocaine, amphetamines, ecstasy/
MDMA powder, NPS and various types of cannabis. Crack cocaine and NPS wholesale batches tend to 
be relatively small (often under a kilogram (Kg) per transaction). Other substances are commonly traded 
in single, multiple, tens and even hundred plus Kg batches. 
Unit sizes commonly reflect traditional and long established unit weights of Kg, part (1/4 or 1/2) Kg, 
ounce (28 grams) and fractions of an ounce (1/2, 1/4, 1/8 and 1/16), then grams and part grams (0.1 and 
0.2). In many cases (for powder drugs) division and adulteration are combined to extend profit margin 
opportunities. 
Drugs are concealed in many ways during domestic distribution, although a recent increase in vehicle 
concealments (as those encountered at ports) has been noted. 
An established supply trend has developed involving urban gangs distributing user quantities of heroin 
and crack cocaine into country and coastal towns and cities from central hubs. These gangs acquire 
drugs from OCGs, send ‘runners’ out to establish markets in wider locations and then exploit young and 
vulnerable people to facilitate onward supply and safe houses. This activity is all facilitated via a ‘line’ 
often branded (with a nickname) to the gang in question. The ‘line’ is a trusted mobile phone number 
which is accessed by customers having been introduced by a runner. This facilitates a 24-hour demand 
and supply market, with the mobile phone commonly being isolated in an urban location, with runners 
able to respond to requests upon demand. By no means the only urban hub, London represents the 
most prolific.
9.3 Prices and purity
9.3.1 Market influences 
The value of the GBP against the United States Dollar (USD) and Euro is an important factor in drug 
market trends, as both cocaine and heroin are traded in these currencies en route to the UK and within 
distribution hubs accessed by OCGs supplying the UK. When the value of the GBP drops, no market 
adjustment is made by suppliers to UK/UK based customers, hence less spending potential following 
exchange and greater wholesale outlay leads to reduced profit margins. This has previously generated 
UK domestic wholesale price increases.
Substantial upstream cocaine seizures in Latin America, Caribbean, Caribbean Sea, Atlantic, West 
Africa and near Europe of major consignments destined for Europe and the UK have historically 
generated temporary shortages in some areas of the domestic market. This has combined with GBP 
market strength changes and also resulted in increases in UK wholesale prices. Wholesale suppliers 
counter this by bulking wholesale amounts (often re-pressing them into new diluted quality blocks) with 
cutting agents such as benzocaine, reducing retail quality through supply chains, but not increasing 
retail price.
9.3.2 Wholesale drug market prices
The Kg remains the most common wholesale trading weight for all solid and powder drugs with the 
exception of crack cocaine which is packaged following domestic conversion. As such, an ounce (28 
grams) has become the most frequently encountered trading unit, with each ounce capable of making 
280 x 0.1 gram ‘rocks’.
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Tablet and paper tab drugs, such as ecstasy and LSD, are most commonly traded in 1,000, 5,000 and 
10,000 unit batches at wholesale.
Common per Kg prices include:
•	 Cocaine £36,000 to £45,000
•	 Heroin £25,000 to £30,000
•	 Amphetamine £2000 to £4000
•	 Cannabis Resin £1000
•	 Cannabis Skunk £4000 (standard) to £8000 (for branded)
These prices reflect what is likely to be paid when acquiring a one Kg unit and take no account of the 
discount available for multiple unit consignments.
9.3.3 Street-level price data from law enforcement sources
Street/retail deals tend to be in one gram units for cocaine, amphetamine, MDMA, NPS, ketamine and 
high quality skunk cannabis, with other cannabis types typically being sold for 1/8th ounce (3.5 grams). 
Heroin and crack cocaine are commonly sold as ‘bags’ and ‘rocks’ respectively, in 0.1 gram and 0.2 
gram deals. 
Street-level price data from law enforcement sources suggest that the price of most drugs remained 
stable in 2014 (Table 9.1). However, the retail price of cannabis resin and sinsemilla both rose by over 
55% from £3.00 and £8.50 per gram in 2013 respectively to £5.20 and £15.20, respectively, in 2014. The 
price of ecstasy also rose between 2013 and 2014 from £3 to £5 per tablet, whilst the typical MDMA 
content per pill fell from 102g in 2012 to 90g in 2014.
9.3.4 Purity of drugs and composition of drugs/tablets in the domestic market
From forensic insight, the majority of adulteration tends to take place before the drug reaches the ‘street 
dealer’. Their means of profit-making will more often be division and reduction in deal size for the very 
small amounts. For example, if a street dealer buys quarter of an ounce of heroin (3.5 grams) and sells in 
0.08 gram, rather than 0.1 gram deals, this will provide 44 deals at £10, instead of 35 deals; an additional 
return of £90 from a very small amount.
Until 2007 drug purity data were provided by the Forensic Science Service (FSS). Following the growth 
of private forensic services, in 2008 and 2009 data were combined with data from the second largest 
provider, LGC Forensics. In December 2010 it was announced that the FSS was to be closed down by 
the end of March 2012 with the Serious Organised Crime Agency (SOCA) taking custodianship of the 
national drugs intelligence function. Data for 2010 onwards has been provided by SOCA/NCA from an 
expanded number of forensic agencies. The data are collected from tests conducted on police seizures 
within the domestic market including seizures of packages at one or two stages above street-level. As 
such, the mean purities reported for substances may be higher than if data were based on street-level 
seizures alone.
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Table 9.1: Law enforcement agencies: Typical price of street level illicit drugs in the United Kingdom, 
2006 to 2014
DRUG
PRICE PER GRAM ExCEPT WHERE OTHERWISE STATED
2006 2007 2008 2009 2010 2011 2012 2013 2014
ExCH. RATE: 
£1=€1.467
ExCH. RATE: 
£1=€1.4619
ExCH. RATE: 
£1=€1.2588
ExCH. RATE: 
£1=€1.1233
ExCH. RATE: 
£1=€1.1752
ExCH. RATE: 
£1=€1.1462
ExCH. RATE: 
£1=€1.2337
ExCH. RATE: 
£1=€1.2542
ExCH. RATE: 
£1=€1.2386
Amphetamines
£9.00 £9.00 £10.00 £10.00 £10.00 £10.00 £10.00 £10.00 £10.00
€13.20 €13.16 €12.59 €11.23 €11.75 €11.46 €12.34 €12.54 €12.39
Cannabis 
herb*
£2.68  £2.70 £2.85 £2.85 £2.82 £5.00 £5.00 £3.00 £2.90
€3.93 €3.95 €3.59 €3.20 €3.31 €5.73 €6.17 €3.76 €3.59
Cannabis 
resin*
£2.12 £2.82 £2.85 £2.85 £2.82 £5.00 £5.00 £3.00 £5.20
€3.11 €4.12 €3.59 €3.20 €3.31 €5.73 €6.17 €3.76 €6.44
Cannabis 
(sinsemilla)*
£6.21 £5.63 £7.15 £7.15 £10.00 £10.00 £8.50 £15.20
€9.08 €7.09 €8.03 €8.40 €11.46 €12.34 €10.66 €18.83
Cocaine 
powder
£49.00 £46.00 £40.00 £40.00 £40.00 £40.00 £40.00 £40.00 £40.00
€71.88 €67.24 €50.35 €44.93 €47.01 €45.85 €49.35 €50.17 €49.54
Crack cocaine†
£18.00  £65.00 £65.00 £60.00 £50.00 £50.00 £60.00 £60.00 £60.00
€26.41 €95.02 €81.82 €67.40 €58.76 €57.31 €74.02 €75.25 €74.31
Ecstasy 
(per tablet)
£3.00 £3.00 £3.00 £2.50 £2.50 £5.00 £3.00 £3.00 £5.00
€4.40 €4.39 €3.78 €2.81 €2.94 €5.73 €3.70 €3.76 €6.19
Heroin
£52.00 £48.00 £45.00 £45.00 £45.00 £40.00 £40.00 £50.00 £50.00
€76.28 €70.17 €56.65 €50.55 €52.88 €45.85 €49.35 €62.71 €61.93
LSD 
(per dose)
£3.00 £3.50 £3.00 £3.00 £3.00 - - £3.00 £3.00
€4.40 €5.12 €3.78 €3.37 €3.53 - - €3.76 €3.72
Mephedrone
£10.00 £20.00 £20.00 £15.00 -
€11.75 €22.92 €24.67 €18.81 -
Ketamine
£25.00 £25.00 £20.00 £20.00 £20.00
€29.38 €28.66 €24.67 €25.08 €24.78
* Before 2007 the cannabis values were based on the price per ounce. In 2007 this changed to being based on a usual street 
deal of 1/8oz and the price was converted to gram equivalent. In 2011 prices were reported on a gram basis.
† Crack cocaine prices before 2007 were provided per rock (0.2g) not per gram. Prices after 2007 cannot be compared to 
earlier prices.
Source: ST16
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Data on cannabis potency are not provided due to concerns about the representativeness of samples 
submitted for forensic analysis. A cannabis potency study was carried out in 2008 (Home Office, 2008). 
No further study has been carried out. Purity data are shown in Table 9.2 and commentary is provided 
by individual drug.
Amphetamines
The typical domestic resale purity of amphetamines continued to rise following a small rise in from five 
per cent in 2012 to seven per cent in 2013, and in 2014 reached 12%, a level higher than at any other time 
in the last decade. Almost all amphetamines seized are cut with caffeine, while other common diluting 
agents include lactose and glucose. 
Table 9.2: Domestic resale mean percentage purity of certain drugs seized by police in England and 
Wales, 2003 to 2014
DRUG 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Amphetamines 11 9 10 11 11 8 8 8 10 5 7 12
Cocaine powder 51 42 43 35 33 29 20 24 26 37 38 36
Crack cocaine 70 64 65 50 52 43 27 31 26 30 36 37
Ecstasy* 65 67 66 48 52 33 44 49 71 102 n/a 90
Heroin (brown) 33 40 47 44 50 43 44 35 18 20 29 36
*mg of MDMA base per tablet
Source: ST14
Cocaine
Cocaine entering the UK tends to be either adulterated or sold at premium prices as high quality. When 
adulterated, it is not unusual for (as an example) 80% pure to become 40% through a 1:1 ratio mix with 
the most common cutting agent, benzocaine. It is not unusual for a total reduction to take place down 
to about 20% for street level supply, with the adulteration not always occurring at a single stage of the 
supply chain.
The average purity of cocaine powder in the domestic market has fallen slightly for the first time in five 
years from 38% in 2013 to 36% in 2014. However, it still remains over one and half times higher than the 
level seen in 2009 (20%). Conversely, in the last year purity-adjusted price has risen for the first time in 
five years and is now more expensive when taking purity into account than in the indexed year (Table 
9.3). Levamisole is commonly detected in wholesale cocaine seizures (added at the point of production) 
while benzocaine is used to bulk out the product within the UK. Other adulterants detected by forensic 
agencies include caffeine and phenacetin.
Purity of crack cocaine followed a similar pattern to that of cocaine in powder form, reducing between 
2003 and 2009, although the purity of crack cocaine remained higher over this period. The increase in 
purity of crack cocaine since 2009 has been less pronounced than that of cocaine powder, having risen 
to 37% in 2014. 
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Table 9.3: Purity-adjusted price of heroin and cocaine per gram in the United Kingdom, 2003 to 2013: 
indexed to 2003
YEAR HEROIN COCAINE
2003 £62.00 £55.00
2004 £45.08 £61.58
2005 £37.97 £58.75
2006 £39.09 £72.70
2007 £31.52 £70.94
2008 £34.46 £71.11
2009 £33.11 £100.89
2010 £42.16 £86.05
2011 £74.32 £78.17
2012 £65.40  £55.65
2013 £49.55 £53.89
2014 £45.52 £56.89
Source: ST14 and ST16
Heroin
Paracetamol is the main cutting agent used for bulking heroin although it is also adulterated with caffeine. 
In most cases a blend of the two (cooked brown to mimic the colour) is used.
The quality of heroin imported to the UK tends to vary to a greater degree than cocaine. This generates a 
dynamic where those less informed of source, trafficker reputation and production quality are not aware 
of the domestic quality of heroin they have purchased. This results in domestic suppliers ‘doing what 
they do’ regarding adulteration, generating a lottery to street dealers and users alike concerning the 
strength of drug they supply and consume. Although retail prices remain stable, the purity of a £10 bag 
(0.1 gram) has the potential to range from five per cent to 50%. High strength drugs are potentially more 
dangerous than poor quality — particularly if a user has built a tolerance to heroin of a fairly consistent 
(lower) purity.
After a large decrease in the purity of street-level heroin between 2010 and 2011, which was largely 
sustained in 2012, the purity of this drug rose sharply to 29% in 2013, and continued to rise to 36% in 
2014 (Table 9.2). This possibly indicates a potential resurgence in the quantity of heroin arriving in the UK 
and the quality being targeted on UK markets. Despite the increase in the price per gram at street-level, 
the purity-adjusted price has fallen considerably from a peak around £74 per gram in 2011 to around £45 
in 2014 (Table 9.3) as a result of the increased quality of the substance typically being sold at street-level. 
However, in 2014, heroin remains more expensive than it had been for several years prior to 2010 when 
adjusting for purity.
Figure 9.1 shows that the purity-adjusted price of cocaine powder and heroin had been at a similar level 
in 2003, after which they took divergent paths with cocaine being the more expensive. They returned to 
similar levels between 2011 and 2013; however, in the last year the purity-adjusted price of heroin has 
continued to fall whilst that of cocaine has risen slightly. It is too early to say whether this is the beginning 
of a trend.
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Figure 9.1: Purity-adjusted price of cocaine powder and heroin per gram in the United Kingdom, 2003 
to 2014: indexed to 2003
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*Since 2008 data have been received from more forensic providers
Source: ST14 and ST16
9.4 Drug supply reduction activities
9.4.1 Key priorities of supply reduction
The UK Drug Strategy 2010, Reducing demand, restricting supply, building recovery: supporting 
people to live a drug free life (Her Majesty’s Government, 2010) was published in December 2010.
The strategy is divided into the three broad themes of reducing demand, restricting supply and building 
recovery, each with a number of objectives and proposed actions. The restricting supply strand aims to 
make the UK an unattractive destination for drug traffickers.
The strategy set out a number of objectives for reducing the supply of illicit substances including:
•	 law enforcements reforms, such as the introduction of Police and Crime Commissioners (PCCs) and 
the NCA; 
•	 integrated local enforcement;
•	 reducing drug supply in prisons;
•	 sharing intelligence to increase understanding of who is involved in organised crime;
•	 monitoring the NPS market through the development of a Forensic Early Warning System (FEWS) 
and restricting their supply through the introduction of TCDOs;
•	 reduce the trade of substances via UK websites in violation of the Misuse of Drugs Act 1971;
•	 increasing the number of money laundering prosecutions relating to drug-related offences and 
increasingly disrupting criminal finances;
•	 reducing the trade in cutting agents and precursor chemicals through new powers to seize supplies; and 
•	 strengthening relations with overseas partners to tackle the international drugs trade
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The UK Serious and Organised Crime Strategy (Her Majesty’s Government, 2013b) was published in 
October 2013 and coincided with the launch of the new NCA. It reflects the changes to the threats the 
UK faces, targeting national and international serious and organised crime with the aim to substantially 
reduce it. The strategy uses the framework developed for counter-terrorist work and has four components: 
prosecuting and disrupting people engaged in serious and organised crime (Pursue); preventing people 
from engaging in this activity (Prevent); increasing protection against serious and organised crime 
(Protect); and reducing the impact of this criminality where it takes place (Prepare). On illicit drugs, the 
strategy particularly focuses on restricting the supply to the UK, engaging International partners to help 
disrupt OCGs smuggling illicit drugs through UK borders and ensuring the retrieval of the proceeds and 
assets from the crimes these groups commit. 
9.4.2 Areas of activity of supply reduction
In the last year, progress towards restricting supply has included several pieces of new legislation: the 
Serious Crime Act 2015 (Her Majesty’s Government, 2015b) introduced powers for law enforcement to 
tackle the trade in cutting agents, driving up the cost and risk for organised criminals; the strengthening 
of the Proceeds of Crime Act ((Her Majesty’s Government, 2002) enabled assets to be frozen and 
recovered, and traffickers prosecuted more quickly; a number of NPS and prescription medicines were 
permanently controlled under the Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971); and 
a new drug-driving offence was enacted (see section 2.2.1). In addition, guidance documents were 
published for local authorities and the police to advise them of the powers available to them to reduce 
the supply of NPS through head shops (Home Office, 2015h) (see section 2.2.3). The Psychoactive 
Substances Bill has been introduced in Parliament and, subject to Parliamentary approval, this legislation 
will ban the sale, supply, production and distribution of psychoactive substances for human consumption. 
In order to restrict the supply of illicit drugs, future work will include: a crackdown on UK-based websites 
in violation of the Misuse of Drugs Act 1971; an evaluation of the five new Joint Border Intelligence Units 
and, if successful, the roll out of further units; and increased access to centralised data on drug testing 
on arrest to enable the identification of local trends.
9.4.3 Organisational structures/co-ordinating bodies
Home Office 
The Home Office is the department with lead responsibility for the co-ordination of the delivery of the 
Drug Strategy on behalf of the Government, and publishing annual reviews detailing the progress made 
towards the strategy’s objectives. 
Border Force
Based within the Home Office, Border Force secures the UK border by carrying out immigration and 
customs controls for people and goods entering the UK. This includes searching baggage, vehicles 
and cargo for illicit goods, patrolling the UK coastline and searching vessels, gathering intelligence and 
alerting the police and security services to people of interest. 
National Crime Agency
The NCA, formerly SOCA, became operational in October 2013. They are a non-ministerial government 
department, accountable to the Home Secretary. They work with the police, Border Force and international 
collaborators to lead the UK law enforcement’s fight to cut serious and organised crime. This includes 
restricting the supply of drugs trafficked into the UK. 
Police and Crime Commissioners 
Established under the Drug Strategy 2010, PCCs are elected officials with the responsibility of securing 
efficient and effective policing in their area. 
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9.5 Seizures
9.5.1 Drug seizures in the United Kingdom in 2013/14
The total number of seizures across the UK remained stable from 2012/13 to 2013/14, dropping 1.5% 
from 231,720 to 228,250. 
There was an increase in the number of seizures for all drugs, except cannabis and mephedrone (Table 
9.4). The number of ketamine seizures in the UK rose 18% from 2012/13 due to an increase in seizures 
in England and Wales. Over the same time period, the number of cocaine powder and crack cocaine 
seizures rose by 6.6% and 5.0% respectively.
Table 9.4: The number of seizures of individual drugs in the United Kingdom by country in 2013/14 and 
percentage change from 2012/13
DRUG
ENGLAND 
AND WALES
SCOTLAND
NORTHERN 
 IRELAND*
Uk
% CHANGE 
FROM 2012/13
Amphetamines 6,067 562 96 6,725 2.8
Cannabis – herbal 130,045 14,205 3,059 147,309 -0.9
Cannabis – resin 6,803 6,702 600 14,105 -18.8
Cannabis plants 14,501 998 245 15,744 -0.6
Cocaine powder 16,825 2,565 430 19,820 6.6
Crack cocaine 4,746 151 - 4,897 5.0
Ecstasy type substances 3,237 549 127 3,913 4.8
Heroin 8,579 2,302 32 10,913 2.5
Ketamine 1,621 26 3 1,650 15.8
Mephedrone* 2,882 61 135 3,078 -24.9
*Police seizures only
Source: ST13
As with previous years, cannabis was by far the most commonly seized drug (approximately 177,000 
seizures in total), involved in around nine times as many seizures as cocaine powder, the next most 
commonly seized drug. However, the number of seizures of all types of cannabis dropped in the last year 
(a decrease of almost 10%). The largest fall within types of cannabis was observed in cannabis resin; 
down 18.8% on the number of seizures in the previous year.
Unlike the numbers of seizures, the quantity of some drugs seized changed substantially between 
2012/13 and 2013/14 (Table 9.5). The largest decrease was seen for cannabis resin which fell steeply by 
91.6%, driven by a substantial decrease in the quantity seized in England and Wales. 
With a rise of 7.1%, the amount of cocaine powder seized increased almost in line with the number of 
seizures (6.6%). However, changes in one measure are not always reflected in the other. For example, 
despite the 0.9% reduction in numbers of herbal cannabis seizures, the quantity seized rose by 
41.2%. Inversely, despite the small increase in seizures of ecstasy-type substances, the quantity of 
tablets seized decreased by 10.1%. The quantity of ketamine seized saw the largest increase between 
2012/13 and 2013/14, rising 46.3%, which was again driven by changes to the amount seized in 
England and Wales. 
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Table 9.5: The quantity of individual drugs seized in the United Kingdom by country in 2013/14 and 
percentage change from 2012/13
DRUG UNIT
ENGLAND 
AND WALES
SCOTLAND
NORTHERN  
 IRELAND*
Uk
% CHANGE 
FROM 2012/13
Amphetamines Kg 1217.0 504.9 8.2 1730.1 16.1
Cannabis – herbal Kg 17,953.0 452.7 299.3 18,705 41.2
Cannabis – resin Kg 735.0 367.8 30.8 1,133.6 -91.6
Cannabis plants Plant 451,154.0 23,336.0 10,155.0 484,645.0 -12.8
Cocaine powder Kg 3,412.0 124.3 25.2 3,561.5 7.1
Crack cocaine Kg 48.0 2.3 - 50.3 8.2
Ecstasy type substances Tablet (000s) 399.0 15.7 8.3 423.0 -10.1
Heroin Kg 642.0 142.8 0.1 784.9 -5.6
Ketamine Kg 355.0 0.1 2.1 357.2 46.3
Mephedrone** Kg 84.0 66.8 3.6 154.4 -45.6
*Police seizures only
**Powder only
Source: ST13
9.5.2 Trends in drug seizures in England and Wales
As UK drug seizure data have not been available on a consistent basis in the past six years, data from 
England and Wales are used to comment on trends. Cannabis has remained the most commonly seized 
drug throughout this period (Home Office, 2014b). The number of seizures of herbal cannabis increased 
substantially between 2004 and 2008/09, while the quantity of herbal cannabis seized remained stable 
(Table 9.6; Table 9.7). Over this period there was also a large rise in recorded possession offences (see 
section 2.3.2). As quantities seized resulting from possession offences are typically small, the lack of a 
corresponding rise in quantity of herbal cannabis seized may indicate that the rise in numbers of seizures 
was primarily due to increased possession offences.
The quantity of heroin seized over the last decade has varied greatly year on year. Following a low in 
2010/11 (which may have been indicative of the reduction in the availability of heroin widely regarded to 
have affected the market during this period) (European Monitoring Centre for Drugs and Drug Addiction, 
2013) the quantity of heroin that was seized more than doubled in 2011/12. However, it has since fallen 
by more than 65% and in 2013/14 was at a level lower than that which had been seen in 2010/11. 
Seizures of ecstasy tablets, which similarly increased greatly in quantity from 2010/11 to 2011/12, have 
also returned to levels comparable to those reported in 2010/11. Such variation between years in the 
quantity of drugs seized may reflect varying law enforcement activity between years and should not be 
assumed to directly reflect the availability, or indeed use, of these substances. 
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Table 9.6: Number of seizures of drugs by police forces and Border Force in England and Wales, 2004 
to 2013/14
DRUG 2004 2005 2006/07* 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13† 2013/14†
Amphetamines 6,504 7,837 8,477 8,863 7,760 7,302 7,185 6,773 5,758 6,067
Cannabis – herbal 43,072 76,157 109,649 137,526 145,353 144,456 139,237 149,371 136,765 130,045
Cannabis – resin 35,219 41,454 32,590 30,870 35,795 24,339 18,312 14,207 8,234 6,803
Cannabis plants 2,930 4,327 5,805 8,539 9,380 12,920 14,423 16,590 14,597 14,501
Cocaine powder 8,279 12,512 16,917 21,346 24,659 21,377 17,710 17,596 16,664 16,825
Crack cocaine 5,164 6,705 6,955 7,578 6,623 5,081 5,385 4,985 4,581 4,746
Ecstasy 6,256 6,688 8,184 7,173 5,218 3,724 2,537 3,200 3,215 3,237
Heroin 11,668 14,072 13,942 14,186 13,302 12,836 10,821 9,182 8,485 8,579
Benzodiazepines‡ 830 1,747 2,261 2,815 4,038 2,957 2,489 2,695 1,997 2,032
Ketamine - - - - 1,269 1,612 1,793 1,543 1,518 1,621
Total§ 112,923 169,802 196,099 228,131 241,473 224,401 212,786 218,721 198,578 192,294
*in 2006/07 data moved to a financial year basis
†excludes Gwent Police
‡These figures relate only to police seizures, and do not include temazepam
§ As a seizure can involve more than one drug, figures for individual drugs and drug classes cannot be added together to 
produce totals
Source: (Home Office, 2014b)
Trends in seizures of cannabis plants over time fluctuate less year on year and reveal long-term trends 
which may be reflective of market activity. The quantity of plants seized rose steadily and steeply more 
than eightfold over a five year period from 2004. However, since then fewer plants have been seized 
in each year and the total quantity seized has fallen by 40% from the peak in 2009/10 to 2013/14. The 
initial rapid increase may reflect the burgeoning of domestic cannabis production on an industrial scale 
in the UK. The latter reduction in quantity of plants seized stands in contrast to the trend in the number 
of seizures of plants, which continued to rise steadily up to 2011/12 only dropping 13% over the last 
two years and remaining higher than any time prior to 2011/12. The divergence in these trends may be 
indicative of a shift in domestic production towards use of smaller cultivation sites. 
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Table 9.7: The quantity of individual drugs seized by police forces and Border Force in England and 
Wales, 2004 to 2013/14
DRUG UNIT 2004 2005 2006/07* 2007/08 2008/09 2009/10 2010/11 2011/ 12 2012/13† 2013/14†
Amphetamines Kg 1,257 2,091 1,390 1,811 2,939 1,326 711 1,062 1,434 1,217
Cannabis – herbal Kg 21,535 20,583 25,832 20,093 33,363 17,951 20,693 22,326 12,353 17,953
Cannabis – resin Kg 63,234 50,591 19,851 16,710 31,799 12,563 18,659 19,478 11,325 735
Cannabis plants Plant 93,469 220,019 363,679 535,888 643,510 758,943 729,584 639,227 507,438 451,154
Cocaine powder Kg 4,640 3,821 3,244 3,453 2,916 2,643 2,387 3,461 3,036 3,412
Crack cocaine Kg 140 51 60 37 33 59 50 35 42 48
Ecstasy
Tablet
(000s)
4,740 3,019 6,685 965 547 171 371 663 453 399
Heroin Kg 2,170 1,907 1,030 1,059 1,552 1,516 732 1,849 752 642
Ketamine Kg - - - - 27 293 802 81 244 355
*in 2006/07 seizures data moved to a financial year basis
†excludes Gwent Police
Source: (Home Office, 2014b)
9.5.3 Other seizures data
The Medicines and Healthcare Products Regulatory Agency (MHRA) announced in June 2015 that, 
as part of a global operation, £15.8 million worth of counterfeit and unlicensed medicines were seized 
in the UK during a series of raids over a one-week period; almost twice as much as the value of the 
substances seized in the same operation the previous year.139 The majority of the medicines seized in the 
UK originated from India, China, Hong Kong and Singapore. The operation was part of an international 
crackdown named Operation Pangea, which was coordinated through Interpol and targeted the illicit 
online medicine trade. Seizures of substances in the UK accounted for a third (30.6%) of the overall 
market value of the drugs seized internationally as part of the operation.
139 See: https://www.gov.uk/government/news/uk-leads-the-way-with-158-million-seizure-in-global-operation-targeting-
counterfeit-and-unlicensed-medicines-and-devices 
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